



Determinazione del Responsabile Ufficio Formazione n° 388 del 29 APR. 2015

Oggetto: Aggiornamento senza oneri, Dirigente Medico, Dott. Boi Alberto.

Pubblicata all'Albo Pretorio dell'Azienda Ospedaliera a partire dal 29 APR. 2015 per 15 giorni consecutivi e posta a disposizione per la consultazione.

Il Responsabile Ufficio Formazione

- Visto** il D. Lgs. n. 502/92 e successive modificazioni ed integrazioni;
- Viste** le Leggi Regionali n. 10/2006 e n. 05/2007;
- Vista** la Deliberazione n. 263 del 04.03.2015, con la quale il Commissario Straordinario ha autorizzato il Responsabile dell'Ufficio Formazione Dott. Andrea Corrias, a predisporre le Determinazioni;
- Vista** la comunicazione Prot. n° 8665 del 14.04.2015 con la quale la Ditta OIC Way S.r.l. si è resa disponibile ad invitare un Medico della S.C. Cardiologia al Congresso: "Euro PCR 2015" che si terrà a Parigi dal 19.05.2015 al 22.05.2015;
- Considerato** che il Direttore della S.C. Emodinamica ha autorizzato a partecipare al suddetto Congresso il Dott. Boi Alberto;
- Atteso** che il Responsabile dell'Ufficio Formazione ha espresso parere favorevole in merito;
- Ritenuto** di dover autorizzare la partecipazione del Dott. Boi Alberto al Congresso: "Euro PCR 2015" che si terrà a Parigi dal 19.05.2015 al 22.05.2015; di dover prendere atto che le spese di iscrizione, vitto, alloggio e trasporto saranno totalmente a carico della Ditta OIC Way S.r.l.

DETERMINA

Per i motivi esposti in premessa:




1. Autorizzare la partecipazione del Dott. Boi Alberto al Congresso: "Euro PCR 2015" che si terrà a Parigi dal 19.05.2015 al 22.05.2015.
2. Dare atto che le spese di iscrizione, vitto, alloggio e trasporto saranno totalmente a carico della Ditta OIC Way S.r.l.
3. Trasmettere la presente determinazione al Direttore della S.C. del Personale per gli adempimenti normativi di competenza.

Il Responsabile dell'Ufficio Formazione
Dott. Andrea Corrias

oic

way | travel
& events

Firenze, 13 aprile 2015



Spett.le
A.O. BROTTU
Piazzale Ricci, 1
09134 Cagliari

AO BROTTU

PG/2015/ 0008665 del 14/04/2015 ore 11,29

Mittente: OIC WAY SRL

Assegnatario: Ufficio Formazione

c.a. Direzione Sanitaria
c.c. Ufficio Formazione

Posta Prioritaria



Oggetto: Invito alla partecipazione al Congresso EuroPCR 2015

La O.I.C. Way Srl per conto di Abbott S.r.l. ha il piacere di invitare un Vostro dipendente appartenente al Reparto di Cardiologia, al Congresso in oggetto che si terrà dal 19 al 22 maggio 2015 presso il Palais des Congrès di Parigi in considerazione dell'alto contenuto scientifico e divulgativo degli argomenti trattati, nonché del sicuro interesse del dibattito e del confronto conseguenti.

La informiamo che la O.I.C. Way Srl provvederà direttamente all'iscrizione, vitto, alloggio e trasporto. Eventuali ulteriori spese sostenute dal Vostro dipendente per la partecipazione all'iniziativa (ossia per taxi, ovvero per rimborso chilometrico superiore ai 100 km e per pedaggio autostradale) - e che Abbott riterrà pertinenti - saranno rimborsate solo previa presentazione da parte Sua di idonea documentazione giustificativa.

Nel caso di Vostro accoglimento della nostra richiesta, Vi saremmo grati per la restituzione al seguente numero di fax 055-5528421 di copia della presente firmata per autorizzazione, con l'indicazione della persona da Voi autorizzata. Per le finalità relative al trattamento dei dati personali, Vi chiediamo cortesemente di restituirci al seguente numero di fax 055-5528421 la scheda invito allegata debitamente compilata e firmata dalla persona designata. Per ulteriori informazioni, potrete rivolgerVi alla Sig.ra Claudia Bisaccioni al seguente numero di telefono 055-5035250.

Cordiali saluti.

O.I.C. Way S.r.l.
Viale G. Matteotti, 7
50121 FIRENZE

Il sottoscritto Dott. BRUNO LOI (generalità e qualifica) autorizza il
Dott. ALBERTO BOI (generalità e qualifica) a partecipare all'iniziativa in
oggetto.

CA 14/9/15 Azienda Ospedaliera Brotzu
(data firma e timbro)
S.O. al Emodinamica
Direttore: Dott. Bruno Loi

OIC Way Srl
Viale G. Matteotti 7 - 50121 Firenze - Italia
Tel. +39 055 50351 - Fax +39 055 598156 - Email: info@oic.it
Capitale Sociale € 358.175,00 (i.v. - R.E.A. di Firenze 389921
Iscrizione Registro Imprese / C.F. / P.IVA 03790970481
www.oic.it

AZIENDA OSPEDALIERA G. BROTTU
UFFICIO FORMAZIONE



**IMPORTANTE: COMPIRE
TUTTI I CAMPI**

SCHEDA INVITO

FAX n.:

EVENTO: EUROPA

LUOGO: PARIGI

DATA: 19-22 MAGGIO 2011

Cognome: BOI

Nome: ABENI

Specializzazione: CAARDIOLOGIA

Tel.:

cell. 3290056020 e-mail abeni@abo.it

Cod. Fisc. BOURRT820038356V

Indirizzo Privato VIA BOUTEV 6

CAP 0114 Città BOLOGNA Prov. BO

Qualifica DIVULGATORE MEDICO e/o AO BOUTEV

Ente di appartenenza SSN

Ufficio di detto Ente al quale inviare copia dell'invito

UFFICIO CONFERENZE

Via RICERCA NUOVA

N° 1 Città CALCANO Prov. CA

STATUS

Professione Univ. RICERCATORE

☐ Tempo pieno

☐ Dipendente SSN

☐ Libero

☐ Tempo definito

☒ Intramurario

☐ Specializzando/

☐ Extramurario

☐ Paramedico

☐ Tecnico di laboratorio

☐ Altro (Specificare)

☐ Medico medicina Generale

☐ Pediatra di libera scelta

☐ In regime di convenzione con la USL/ASL n. 1 di 1

☐ Altro (Specificare)

IMPORTANTE PER L'OPERATORE SANTARIO: Firmando questa scheda, io sottoscritto operatore sanitario dichiaro che i costi di viaggio e l'ospitalità o ogni altra voce di sponsorizzazione offerta da Abbott, così come descritta nella Lettera di invito che Abbott mi invierà, costituiscono l'intera e unica sponsorizzazione che riceverò da Abbott in relazione alla mia partecipazione all'evento scientifico descritto sopra.

Il sottoscritto ai sensi dell'art. 47 del DPR 445/2000, con la sottoscrizione della presente, consapevole delle sanzioni penali richiamate dall'art. 76 del DPR 445/2000 in caso di dichiarazioni mendaci e della decadenza dei benefici eventualmente conseguenti al provvedimento emanato sulla base di dichiarazioni non veritiere di cui all'art. 75 del DPR 445/2000, ai sensi e per gli effetti dell'art. 47 del citato DPR 445/2000, sotto la propria responsabilità dichiara che non vi sono impedimenti da parte del proprio ente di appartenenza alla partecipazione all'evento di cui sopra e che ciò non è in conflitto con i propri doveri d'ufficio ed orari di lavoro. Abbott S.r.l. è da me interamente manlevata a detto riguardo.

Ai sensi dell'art. 13 del D.Lgs 196/2003, Abbott S.r.l. con sede legale in Campoverde di Apria (LT), SR 148 Pontina Km 52 snc, in qualità di Titolare del trattamento, La informo che tratterà i Suoi dati personali, con o senza strumenti automatizzati, per inviarle l'invito a partecipare a congressi, seminari e/o altri corsi organizzati o sponsorizzati da Abbott S.r.l. o per inviarle il relativo materiale informativo. Il conferimento è necessario e in sua mancanza Abbott non potrà inviarla a tali congressi, seminari e/o corsi. I Suoi dati potranno essere comunicati, per le finalità di cui sopra, a prestatori di servizi di cui Abbott si avvalga per la gestione e organizzazione di detti eventi ad altre società del gruppo Abbott in Europa o negli Stati Uniti d'America, così come a Farmindustria, se applicabile, e ad altri soggetti autorizzati per legge. Il Responsabile del trattamento è il responsabile della Direzione Commerciale di riferimento e l'elenco aggiornato degli altri responsabili sarà disponibile richiedendolo all'indirizzo email: abbott@pec.it. Lei potrà esercitare i diritti di cui all'art. 7 del D.Lgs 196/2003, ed in particolare potrà ottenere a titolo esemplificativo in qualsiasi momento l'aggiornamento, la rettifica o la cancellazione dei Suoi dati, rivolgendosi alla Abbott S.r.l., fax n. +39 06/820071695 o email abbott@pec.it.

Acquisite le informazioni di cui all'articolo 13 del D.Lgs 196/2003, ai sensi dell'articolo 23 di tale decreto presso il consenso al trattamento dei miei dati personali per ricevere inviti per le finalità sopra descritte.

Consenso al trattamento dei dati personali

Spedite alla Brozzi

Modificativa

NOTA: BOI

IS-FPS/RAM (nome e cognome)

DM/AM (nome e cognome)



PO 1.046A ALLA Rev. 1



way | travel
& events

<i>Da/From:</i>	Claudia Bisaccioni
<i>E mail:</i>	c.bisaccioni@oic.it
<i>Telefono/Telephone:</i>	+39 055 5035250
<i>Fax n.:</i>	+39 055 5528421
<i>Per/To:</i>	DIREZIONE SANITARIA
<i>Attenzione/Attention:</i>	
<i>Tel.:</i>	
<i>Fax:</i>	070/530814
<i>Pagine/Pages:</i>	3 - Inclusa la presente
<i>Data/Date:</i>	13 APRILE 2015


INVITO PARTECIPAZIONE A CONGRESSO

Egregi Signori,

Vi preghiamo di prendere visione di quanto allegato.

In attesa di Vostro riscontro salutiamo cordialmente.


Claudia Bisaccioni
MICE Department
OIC Way Srl
Viale G. Matteotti 7 - 50121 Firenze - Italia
Office +39 055 5035250 - Fax +39 055 5528421
c.bisaccioni@oic.it
www.oic.it



OIC Way Srl
Viale G. Matteotti 7 - 50121 Firenze - Italia
Tel. +39 055 50351 - Fax +39 055 588156 - Email: info@oic.it
Capitale Sociale € 358.176,00 i.v. - R.E.A. di Firenze 389921
Iscrizione Registro Imprese / C.F. / P.IVA 03790970481
www.oic.it



Programme update



Valid as of 19th March, 2015

Only Faculty who confirmed their attendance are listed in this programme.
For real-time updates, please consult the Interactive programme.



- 10:00 -

10:00-11:00 ■ Opening EuroPCR 2015
MAIN ARENA

Complex cardiovascular interventions and new techniques: LIVE demonstration from Kerckhoff Heart Center - Bad Nauheim, Germany

- 11:00 -

11:05-12:20 ■ 2015 Great Debate - Burning issues with dual antiplatelet therapy
MAIN ARENA
With an unrestricted educational grant from MEDTRONIC



Chairperson: A. Baumbach
Co-chairperson: M. Giffard
Panelists: A. Gerthoff, S. James, F.J. Neumann, M. Volkmann

- 12:00 -

12:00-13:30 ■ STEMI patient with multivessel disease - What about the non-culprit lesions?
THEATRE BLEU

Chairperson: F. Ribichini
Co-chairperson: L. Al Rashdan

Attend this session if you want:

- > To reflect on the existing evidence
- > To discuss clinical scenario guiding individualised decisions
- > To define a personal strategy for my daily clinical practice

Session objectives - L. Al Rashdan

- > How to select the best revascularisation strategy for STEMI patients with multivessel disease - F.J. Gerthoff
- > Time to React@PCR

LIVE demonstration from Instituto Dante Pazzanese de Cardiologia - São Paulo, Brazil

> Time to React@PCR

> Optimal timing for complete revascularisation in STEMI

T. Johnson

> Time to React@PCR

> Session evaluation and key learnings - F. Ribichini

12:00-13:30 ■ Imaging in TAMI
THEATRE
Co-chairperson: N. Van Mieghem

Panelists: F. Badier

Attend this session if you want:

- > To learn how to perform annulus stenting
- > To know how to assess the severity of aortic regurgitation
- > To understand the place of imaging during TAMI procedures

Session objectives

> What do you do before? - Time to React@PCR

> Imaging before TAMI - S. Von Bardeleben

LIVE demonstration from Kerckhoff Heart Center - Bad Nauheim, Germany

> What do you do during? - Time to React@PCR

> Imaging during TAMI

> What do you do after? - Time to React@PCR

> Imaging after TAMI

> Session evaluation and key learnings - N. Van Mieghem

12:00-13:30 ■ Endovascular treatment of complex aortic aortic disease
THEATRE
HALLWAY

Chairperson: H.A. Noor

Co-chairperson: M. Boers

Panelists: O. Gerthoff, S.T. Lim, E. Stobbe

Attend this session if you want:

- > To become familiar with advantages and challenges of endovascular and surgical approaches to aortic aortic occlusions
- > To learn about recanalisation techniques
- > To know the appropriate set of equipment

With continuous LIVE demonstration from Universitäts-Herzcentrum Freiburg - Bad Krozingen - Bad Krozingen, Germany

With continuous time to React@PCR

Session objectives - H.A. Noor

> Endovascular perspective - E. Stobbe

> Surgical perspective - Y. Gerthoff

> Session evaluation and key learnings - M. Boers

12:00-13:30 ■ The essentials: how to treat in-stent restenosis
ROOM 241
The essentials

Chairperson: A. Vahanian

Senior advisor: F. Alfonso Monterola

Facilitators: R. Byrne, J. Tan

Attend this session if you want:

- > To learn how and why in-stent restenosis occurs
- > To evaluate the pros and cons of different devices for in-stent restenosis treatment in selected scenarios
- > To discuss how to use drug-coated balloons for in-stent restenosis PCI

12:00-13:30 ■ Percutaneous aortic valve interventions in heart failure patients
ROOM 242AB

Chairperson: A. Vahanian

Panelists: M. Al Abdallah, P. Menon

Attend this session if you want:

- > To learn about appropriate diagnostic work-up of patients with low-flow output aortic stenosis and systolic heart failure
- > To understand procedural challenges
- > To share practical tips and tricks for percutaneous aortic valve interventions in systolic heart failure

Session objectives - A. Vahanian

> Case presentation: what would you do? - W. Wojakowski

> Discussion and audience interaction

> How to diagnose aortic stenosis in a heart failure patient

J.J. Box

> Discussion and audience interaction

> Percutaneous aortic valve interventions in heart failure: procedural challenges, tips and tricks - P. McCarthy

> Discussion and audience interaction


> Case presentation: what we did - W. Wojakowski

> Discussion and audience interaction

> Session evaluation and key learnings

Scientific programme

Tuesday 19th May, 2015



Valid as of 19th March, 2015

Only Faculty who confirmed their attendance are listed in this programme.
For real-time updates, please consult the interactive programme.



12:00-13:30 ■ Innovative stents and scaffolds: potential of new technologies for your cathlab

ROOM 352A

Innovation Hub

Chairperson: C.K. Nobber

Co-chairperson: R. Gao

Panelists: PW. Serruys

- Attend this session if you want:
- > To exchange about innovative technologies developed in the Asia-Pacific region
 - > To discuss specific indications of novel stents and scaffolds
 - > To learn about the potential of novel drug delivery systems

- 12:00 Session objectives - C.K. Nobber
- 12:05 Stent-eluting stent with abdominal groove-filled bioresorbable polymer (Micropore, China)
- 12:11 Questions and answers
- 12:14 Bioresorbable PLLA-based stent-eluting Neolus scaffold (Lapuo Medical, China)

- 12:20 Questions and answers
- 12:22 Coated chromium-based bioresorbable polymer stent-eluting stent (LM Medical Systems, China) - Y. Zhang
- 12:29 Questions and answers
- 12:32 Bioresorbable Polymer Target Release Rapamycin-eluting scaffold (Huaan Bioarch, China)

- 12:35 Questions and answers
- 12:41 A novel bioresorbable PLLA-based stent-eluting scaffold (Micropore, China) - R. Wimon
- 12:49 Questions and answers
- 12:50 Stent-eluting fully bioresorbable scaffold with mixed PLLA/PDLA (ART/Verum, France/Japan) - A. Lofort

- 12:56 Questions and answers
- 12:59 Fully bioresorbable PLLA-based stent-eluting Medes 100 scaffold (Medell Life Science, India)
- 13:05 Questions and answers
- 13:06 Nano-microsphere for drug elution (Envision Scientific and Concept Medical, India)

- 13:14 Questions and answers
- 13:17 Bioresorbable polymer stent-eluting stent with electro-grafting base layer (Siommed, China) - PM. Serruys
- 13:23 Questions and answers
- 13:26 Session evaluation and key learnings - R. Gao

12:00-13:30 ■ Macedonia and Switzerland share their most educational cases

ROOM 352A

How should I treat?

With the collaboration of the Working Group on Interventional Cardiology and ACS of the Swiss Society of Cardiology and the Working Group on Interventional Cardiology of the Macedonian Society of Cardiology

Chairpersons: S. Kedej, M. Hoff

Attend this session if you want:

- > To address variation in the utilization of bioresorbable scaffolds in Macedonia and Switzerland
- > To understand the potential advantages and limitations of currently available bioresorbable scaffolds in STEMI
- > To share the importance of imaging techniques (OCT/IVUS) for bioresorbable scaffolds

- 12:00 Session objectives - S. Kedej
- 12:05 Case 1 - Radial approach for bioresorbable scaffolds implantation in young patient with large anterior wall STEMI
- 12:10 How would I treat? - S. Cook
- 12:15 How would I treat? - S. Anov
- 12:20 How did I treat?
- 12:20 Discussion and audience interaction
- 12:40 Consensus - S. Kedej
- 12:45 Case 2 - Subacute bioresorbable scaffolds thrombosis following primary PCI
- 12:50 How would I treat? - S. Anov
- 12:55 How would I treat? - S. Cook
- 13:00 How did I treat?
- 13:10 Discussion and audience interaction
- 13:20 Consensus - M. Hoff
- 13:25 Session evaluation and key learnings - M. Hoff

12:00-13:30 ■ Portugal and Spain share their most educational cases

ROOM 352B

How should I treat?

With the collaboration of the Association of Interventional Cardiology of the Portuguese Society of Cardiology (APCI) and the Working Group on Interventional Cardiology of the Spanish Society of Cardiology

Chairpersons: M. Costa, R. Trillo Mouche

Attend this session if you want:

- > To reflect on unsolved issues of PCI in STEMI patient
- > To learn tips and tricks on how to use bioresorbable scaffolds and new DES in acute myocardial infarction setting
- > To discuss the role of short polymer absorption in STEMI

- 12:00 Session objectives - M. Costa
- 12:05 Case 1 - The role of bioresorbable scaffolds and new generation DES in STEMI - P. Carinho
- 12:10 How would I treat? - F. Hernandez
- 12:15 How would I treat? - H.C. Canabarro

- 12:20 How did I treat? - P. Carinho
- 12:29 Discussion and audience interaction
- 12:40 Consensus - M. Costa
- 12:45 Case 2 - Primary PCI in multivessel disease: what should we treat? - R. Ocazoma
- 12:50 How would I treat? - H.C. Canabarro
- 12:55 How did I treat? - F. Hernandez
- 13:00 Discussion and audience interaction
- 13:10 Consensus - R. Trillo Mouche
- 13:20 Session evaluation and key learnings - R. Trillo Mouche
- 13:25

12:00-13:30 ■ Learning FFR - iFR

ROOM 352A

Learning

How should I treat?

Facilitators: T. Cusset, N. Melkian, K. Niemela

Attend this session if you want:

- > To understand the principles behind intracoronary physiologic measurements
- > To review the potential pitfalls or limitations of each procedural step
- > To discuss together when FFR or iFR can be useful and impact on procedural strategy and outcomes

- 12:00 Session objectives - T. Cusset
- 12:05 Case 1 - The role of bioresorbable scaffolds and new generation DES in STEMI - P. Carinho
- 12:10 How would I treat? - F. Hernandez
- 12:15 How would I treat? - H.C. Canabarro

- 12:20 How did I treat? - P. Carinho
- 12:29 Discussion and audience interaction
- 12:40 Consensus - M. Costa
- 12:45 Case 2 - Primary PCI in multivessel disease: what should we treat? - R. Ocazoma
- 12:50 How would I treat? - H.C. Canabarro
- 12:55 How did I treat? - F. Hernandez
- 13:00 Discussion and audience interaction
- 13:10 Consensus - R. Trillo Mouche
- 13:20 Session evaluation and key learnings - R. Trillo Mouche
- 13:25

12:25-14:45 ■ Complex cardiovascular interventions

MAIN ARENA

With the collaboration of the Working Group on Interventional Cardiology and ACS of the Swiss Society of Cardiology and the Working Group on Interventional Cardiology of the Macedonian Society of Cardiology

Chairpersons: S. Kedej, M. Hoff

Attend this session if you want:

- > To address variation in the utilization of bioresorbable scaffolds in Macedonia and Switzerland
- > To understand the potential advantages and limitations of currently available bioresorbable scaffolds in STEMI
- > To share the importance of imaging techniques (OCT/IVUS) for bioresorbable scaffolds

- 13:00 -

13:40-15:10 ■ Percutaneous revascularisation for complex multivessel disease in stable coronary artery disease

THEATRE BLEU

Chairperson: R. Urban

Co-chairperson: F. Malik

Panelists: H. Amin, A. Banning, C. Berry

- Attend this session if you want:
- > To learn how to select and optimise the revascularisation strategy for multivessel disease in stable coronary artery disease
 - > To discuss the objectives of PCI in stable coronary artery disease

- 13:40 Session objectives - F. Malik
- 13:45 What can we achieve with PCI in stable coronary artery disease? - A. Korian
- 13:50 Time to Revascularisation - J. Müller-Eberhard
- 13:55 LVE demonstration from Kerckhoff Heart Center - Bad Nauheim, Germany
- 14:00 Time to Revascularisation
- 14:05 Role of coronary physiology measurement in the decision-making process of multivessel disease in stable coronary artery disease - N.E.L. West
- 14:10 Time to Revascularisation
- 14:15 Session evaluation and key learnings - R. Urban

13:40-15:10 ■ TAVI: how to prevent thromboembolic complications?

THEATRE BLEU

Chairperson: P. Wenaweser

Co-chairperson: K.H. Kuck

Panelists: K. Almer, M. Dalguth

- Attend this session if you want:
- > To understand neurological complications
 - > To learn the actual rate of these complications in contemporary series
 - > To develop clinical strategies to decrease these complications

- 13:40 Session objectives - P. Wenaweser
- 13:45 How to decrease the risk of stroke: devices, drugs or both?
- 13:50 Time to Revascularisation
- 13:55 LVE demonstration from St Thomas' Hospital - London, United Kingdom
- 14:00 Time to Revascularisation
- 14:05 How to diagnose and treat atrial fibrillation before and after TAVI - G. Schuler
- 14:10 Time to Revascularisation
- 14:15 Session evaluation and key learnings - K.H. Kuck

13:40-15:10 ■ Successful strategies for femoropopliteal interventions

THEATRE BLEU

Chairperson: F. Carrion

Co-chairperson: M. Sopot

Panelists: H. Amin, A. Banning, C. Berry

- Attend this session if you want:
- > To become familiar with the different therapeutic options
 - > To select the appropriate technology for the individual lesion/patient
 - > To be updated on the clinical evidence on device performance

- 13:40 With continuous LVE demonstration from Universitäts-Herzzentrum Freiburg Bad Krozingen - Bad Krozingen, Germany
- 13:45 With continuous time to Revascularisation
- 13:50 Session objectives
- 13:55 Setting the standard of care in drug-eluting therapy - A. Alcorn
- 14:00 Expanding treatment options: plaque excision and drug elution - F. Carrion
- 14:05 Session evaluation and key learnings - F. Carrion

13:40-15:10 ■ The essentials: how to correctly interpret OCT with the collaboration of the EAPCI New Initiatives for Young Interventionalists Committee

ROOM 241

Innovation Hub

Senior advisor: G. Gungl

Facilitators: T. Adriaenssens, F. Chahert, M. Radu

- Attend this session if you want:
- > To appreciate when OCT may be useful prior and after stent implantation
 - > To be able to recognise the most common OCT patterns
 - > To learn the most accepted OCT definitions

- 13:40 Session objectives - Why neuromodulation in heart failure is needed - A. Fotiadis
- 13:45 Renal denervation - F. Mohlrad
- 13:50 Discussion and audience interaction
- 14:00 Baroreceptor stimulation - J. Müller-Eberhard
- 14:05 Discussion and audience interaction
- 14:10 Vagus stimulation
- 14:15 Discussion and audience interaction
- 14:20 Session evaluation and key learnings - D. Burkhoff

- 14:25 Session objectives - Why neuromodulation in heart failure is needed - A. Fotiadis
- 14:30 Renal denervation - F. Mohlrad
- 14:35 Discussion and audience interaction
- 14:45 Baroreceptor stimulation - J. Müller-Eberhard
- 14:50 Discussion and audience interaction
- 14:55 Vagus stimulation
- 15:00 Session evaluation and key learnings - D. Burkhoff

- 15:05 Session objectives - Why neuromodulation in heart failure is needed - A. Fotiadis
- 15:10 Renal denervation - F. Mohlrad
- 15:15 Discussion and audience interaction
- 15:25 Baroreceptor stimulation - J. Müller-Eberhard
- 15:30 Discussion and audience interaction
- 15:35 Vagus stimulation
- 15:40 Session evaluation and key learnings - D. Burkhoff

- 15:45 Session objectives - Why neuromodulation in heart failure is needed - A. Fotiadis
- 15:50 Renal denervation - F. Mohlrad
- 15:55 Discussion and audience interaction
- 16:05 Baroreceptor stimulation - J. Müller-Eberhard
- 16:10 Discussion and audience interaction
- 16:15 Vagus stimulation
- 16:20 Session evaluation and key learnings - D. Burkhoff

- 16:25 Session objectives - Why neuromodulation in heart failure is needed - A. Fotiadis
- 16:30 Renal denervation - F. Mohlrad
- 16:35 Discussion and audience interaction
- 16:45 Baroreceptor stimulation - J. Müller-Eberhard
- 16:50 Discussion and audience interaction
- 16:55 Vagus stimulation
- 17:00 Session evaluation and key learnings - D. Burkhoff

13:40-15:10 ROOM 332A *Should treat?	Latvia and Russia share their most educational cases With the collaboration of the Working Group on Interventional Cardiology of the Latvian Society of Cardiology and the Russian Scientific Society of Interventional Cardiology (RSCA) Chairpersons: A. Erglis, D.G. Iosseliani Attend this session if you want: > To learn immediate and mid-term results of bioresorbable scaffolds > To understand the particularities of bioresorbable scaffolds implantation > To reflect on the indications for the use of bioresorbable scaffolds Session objectives - A. Erglis Case 1 - 2-year results of 2-stent technique combining bioresorbable scaffolds and DES with IVUS and OCT guidance in distal left main bifurcation lesion - D. Sordore > How would I treat? - D. Sordore > How would I treat? - I. Kumsars > How did I treat? - D. Sordore > Discussion and audience interaction Consensus - A. Erglis Case 2 - Multiple PCI with the use of bioresorbable scaffolds in a female with chronic coronary artery disease > How would I treat? - I. Kumsars > How would I treat? - D. Sordore > How did I treat? Discussion and audience interaction Consensus - D.G. Iosseliani Session evaluation and key learnings - D.G. Iosseliani
ROOM 332B H. Should treat?	Israel and Slovenia share their most educational cases With the collaboration of the Working Group on Interventional Cardiology of the Israel Heart Society and the Working Group on Interventional Cardiology of the Slovenian Society of Cardiology Chairpersons: M. Bunc, E. Lev Attend this session if you want: > To understand the identification, management and consequences of saphenous vein graft > To learn basic decision options and strategy of PCI in patients after CABG presenting with ACS > To learn basic technical tips and medical treatment for optimal saphenous vein graft PCI and complex PCI in post-CABG patients Session objectives - E. Lev Case 1 - High-risk PCI in post-CABG patients presenting with ACS - R. Rubinstein > How would I treat? - M. Noc > How would I treat? - G. Weisz > How did I treat? - R. Rubinstein > Discussion and audience interaction Consensus - E. Lev Case 2 - PCI in patients with ACS and previous CABG > How would I treat? - G. Weisz > How would I treat? - M. Noc > How did I treat? Discussion and audience interaction Consensus - M. Bunc Session evaluation and key learnings - M. Bunc

13:40-15:10 ROOM TENNESSEE	Will this trial change my practice? TOTAL: the randomised controlled trial to determine the value of thrombus aspiration during primary PCI Chairperson: A. Baumhach Co-chairperson: S. James 13:40 > Introduction: the trial headlines - A. Baumhach 13:45 > A case: how should I treat? - M. Haude 13:50 > Discussion: what is common practice? 14:00 > What was known before TOTAL - K.G. Oldroyd 14:15 > Trialist's review: methods, results, conclusion - A. Lomsky 14:30 > Discussion and audience interaction 14:45 > Case conclusion: how does this apply to my practice M. Haude 15:00 > Discussion and audience interaction 15:05 > Session evaluation and key learnings - S. James
15:20-16:50 THEATRE BLEU	Practical issues for FFR and iFR measurements Chairperson: J. Escaned Co-chairperson: H. Amin Attend this session if you want: > To learn how to select patients for FFR/iFR measurement > To learn practical tips and tricks for accurate FFR/iFR measurement Session objectives - J. Escaned LVE demonstration from St Thomas' Hospital - London, United Kingdom > Time to React@PCI > Key tips and tricks to avoid mistakes during FFR/iFR measurements - E. Borotko > Time to React@PCI > Limitations of FFR/iFR in 2015: clinical situations, practical issues - G. Tschichat > Time to React@PCI > Session evaluation and key learnings - H. Amin
15:20-16:50 THEATRE BONDEAUX	Challenging patient settings in TAVI Chairperson: P. McCarthy Co-chairperson: J. Scholer Attend this session if you want: > To understand the evolution of indications for TAVI > To understand who is not a good candidate for TAVI > To learn how to select the best candidates for TAVI Session objectives - P. McCarthy Patient assessment: beyond risk scores - A.P. Koppstein > Time to React@PCI > When the aortic stenosis severity is unclear - D. Hombert > Time to React@PCI > Role of TAVI in patients with associated mitral regurgitation - H. Bourgeois > Time to React@PCI > When is surgery the better choice? - T. Modine > Time to React@PCI > Session evaluation and key learnings - J. Scholer

- 15:00 -

15:20-16:50 THEATRE HMWANE	Merging evidence with experience: challenging revascularisation in critical limb ischaemia Chairperson: M. Bosters Co-chairperson: R. Ferrerai Panelists: I. Alhabadad, A. Cernone, Y. Gouffic, A. Milani Attend this session if you want: > To understand the role of revascularisation in the context of a multidisciplinary foot care unit > To be able to identify the revascularisation target in critical limb ischaemia > To become familiar with specific access options, equipment and techniques With continuous LIVE demonstration from Universitäts-Herzentrums Freiburg-Bad Krozingen - Bad Krozingen, Germany With continuous time to React@PCI Session objectives - R. Ferrerai State-of-the-art lecture: below-the-knee interventions for critical limb ischaemia - R. Ferrerai Session evaluation and key learnings - M. Bosters
15:20-16:50 ROOM 241 The essentials	The essentials: how to manage calcified and resistant coronary lesions With the collaboration of the EAPCI New Initiatives for Young Interventionalists Committee Senior advisor: A. Ong Facilitators: J. Daemen, D. Miliashovic Attend this session if you want: > To learn tips and tricks when balloon or stent are unable to cross the lesion > To understand when and how to use cutting / scoring devices > To learn how to properly use rotational atherectomy Session objectives - E. Grube Attend this session if you want: > To understand the limitations of the available TAVI technology > To gain insight into the new developments in the field > To appreciate the potential value of the upcoming technologies in the treatment of aortic pathology Session objectives - E. Grube Remaining limitations of current devices - N. Pozzo > Discussion and audience interaction Overview on upcoming TAVI devices - M.G. Leon > Discussion and audience interaction Overview on upcoming TAVI enabling technologies - N. Van Mieghem > Discussion and audience interaction Session evaluation and key learnings - G. Montalvan

15:20-16:50 ROOM 342AB	Thrombus aspiration in STEMI: from evidence to individual decisions Chairperson: S. James Co-chairperson: T. Johnson Attend this session if you want: > To exchange about the relevance of recent trial results on clinical practice > To understand in which patients thrombus aspiration may provide a clinical benefit Session objectives - S. James > Thrombus aspiration in STEMI patients: what do we know? H.A. Noor 15:30 > Discussion and audience interaction 15:35 > A STEMI case with thrombus aspiration - Q. Muller 15:40 > Discussion and audience interaction 15:45 > A STEMI case without thrombus aspiration - T. Adriaenssens 16:00 > Discussion and audience interaction 16:05 > What do IVS/E and TOTAL mean for my clinical practice? A. Baumhach 16:30 > Discussion and audience interaction 16:45 > Session evaluation and key learnings - T. Johnson
15:20-16:50 ROOM 332A How should treat?	Denmark and Sweden share their most educational cases With the collaboration of the Working Group on Interventional Cardiology of the Danish Society of Cardiology and the Working Group on Interventional Cardiology of the Swedish Society of Cardiology Chairperson: H.H. Thiele Attend this session if you want: > To understand the complexities of CTO-PCI > To learn how to cope with the different challenges occurring during CTO-PCI > To reflect on the various treatment options that evolves during CTO-PCI Session objectives - H.H. Thiele Case 1 - Second attempt on right coronary artery CTO: which strategy to choose? - L.O. Jensen > How would I treat? - E. Christensen > How did I treat? - L.O. Jensen > Discussion and audience interaction Consensus - H.H. Thiele Case 2 - PCI of CTO in left anterior descending artery with coronary rupture treated with use of retrograde technique > How would I treat? - E. Christensen > How did I treat? > Discussion and audience interaction Consensus > Session evaluation and key learnings

3:40-15:10 Learning bifurcation PCI

ROOM LEARNING	Facilitators: B. Farah, F. Heilig, G. Stankovic Attend this session if you want: > To discuss together the best indications for different stenting strategies > To review in detail specific procedural technique using one stent or two stents
---------------	--

17:20-16:50 ■ Italy and Turkey share their most educational cases

ROOM 3328
 16:50-17:00 ■ *With the collaboration of the Association of Percutaneous Cardiovascular Interventions of the Turkish Society of Cardiology and the Italian Society of Invasive Cardiology (SISE) Chairpersons: S. Berti, E. Bozkurt*

- Attend this session if you want:
- > To learn how to diagnose and treat a patient with cardiological shock and concomitant aortic valve and left main stenosis
 - > To understand percutaneous treatment of degenerated bioprosthetic valve associated with severe paravalvular leak
 - > To share different treatment options for these two particular patients

15:20 Session objectives - S. Berti

- > Case 1 - Cardiological shock after palliative balloon aortic valvuloplasty in a patient with an untreated left main stenosis, diagnostic challenges and therapeutic solutions
- > How would I treat? - D. Kaya
- > How would I treat? - E. Piccaluga
- > How did I treat?
- > Discussion and audience interaction

15:40 Consensus - S. Berti

- > Case 2 - Percutaneous valve-in-valve transcatheter aortic valve replacement with simultaneous paravalvular leak closure in a patient with refractory right heart failure
- > How would I treat? - E. Piccaluga
- > How would I treat? - D. Kaya
- > How did I treat?
- > Discussion and audience interaction

16:40 Consensus - F. Bozkurt

- > Session evaluation and key learnings - E. Bozkurt

17:20-16:50 ■ Learning TAVI

ROOM 3328
 16:50-17:00 ■ *Facilitators: D. Mylotte, T. Schmitz*
 Attend this session if you want:
 > To learn how to improve your technical skills in percutaneous transcatheter TAVI
 > To learn how to prevent per-procedural complications

17:20-16:50 ■ Will this trial change my practice? ABSORB II: 12-month report after implantation of bioresorbable scaffolds versus DES

ROOM 3328
 16:50-17:00 ■ *Chairperson: I. Al Rashdan*

- > Introduction: the trial headlines
- > A case: how should I treat? - R.J. Van Geuns
- > Discussion: what is common practice?
- > What was known before ABSORB II? - T. Pilgrim
- > Trialist's review: methods, results, conclusion
- > Discussion and audience interaction
- > Case conclusion: how does this apply to my practice
- > Session evaluation and key learnings - I. Al Rashdan

- 16:00 -

17:00-16:55 ■ Complex cardiovascular interventions and new techniques: LIVE demonstration from Montreal Heart Institute - Montreal, Canada

- 17:00 -

17:00-19:00 ■ Lesion and patient tailored DES choice: solution for CTO and diabetic patients
 THEATRE BLEU
 17:00-19:00 ■ *With an unrestricted educational grant from ALIUMEDICA*
 17:00-19:00 ■ *Medical, Technologists*

Chairperson: R. Mehan
 Co-chairperson: M.C. Morice
 Panelists: O. Goktekin, R. Mohd Ali

- Attend this session if you want:
- > To understand how to improve PCI success in coronary CTOs ensuring persistence of recanalisation by using absorbable polymer DES technology (Coraco)
 - > To learn the added efficacy and safety value provided by the polymer-free DES technology (Ces8) in the setting of diabetic patients
 - > To share practical knowledge on the use of Ces8 and Coraco in these patient subsets through transmitted LIVE cases

17:00-18:30 ■ Session objectives - R. Mehan

- > How to ensure procedural safety and good long-term results in complex coronary CTO procedures - A. Khoshdel
- > LIVE demonstration from Institut Cardiovasculaire Paris Sud - Massy, France
- > Time to React@PCR
- > The latest available data on polymer-free DES technology in diabetic patients - G. Sordella
- > LIVE demonstration from Institut Cardiovasculaire Paris Sud - Massy, France
- > Time to React@PCR
- > Session evaluation and key learnings - M.C. Morice

17:00-18:30 ■ Simplicity for a complex world: introducing ACURATE neo TF TAVI

ROOM 3328
 17:00-18:30 ■ *With an unrestricted educational grant from SYMETIS SA*
 Chairperson: U. Scheller
 Co-chairperson: B. Kroll
 Panelists: S. Badier, C. Hengstenberg, H. Tzeede

- Attend this session if you want:
- > To learn about the ACURATE neo TAVI and Symetis' innovative portfolio
 - > To limit procedural risks such as vascular access complication, paravalvular leak, and new pacemaker implant post-TAVI
 - > To review ACURATE neo case examples and outcomes

17:00-18:30 ■ Session objectives - U. Scheller

- > Technology for straightforward implantation and stable, predictable valve release - C. Hengstenberg
- > LIVE demonstration from Kerckhoff Heart Center - Bad Nauheim, Germany
- > Time to React@PCR
- > Low paravalvular leak and new pacemaker implantation rates - T. Rudolph
- > Delivering reproducible results via real-world use and in clinical studies - S. Badier
- > Enhancing the safety of apical access with new generation innovation - H. Tzeede
- > Session evaluation and key learnings - B. Kroll

17:00-18:30 ■ Transforming PCI with the DESolve novolimus-eluting scaffold platforms

ROOM 3328
 17:00-18:30 ■ *With an unrestricted educational grant from ELIUM MEDICAL*
 Chairpersons: S. Verhage
 Co-chairperson: M.B. Leon
 Panelists: R. Mei, J. Omission

- Attend this session if you want:
- > To gain insight on the optimal implantation techniques for the DESolve bioresorbable scaffold platform(s)
 - > To gain insight on the DESolve scaffold platform(s) unique characteristics, engineering science and long-term clinical trial data
 - > To discuss Elium Medical's DESolve bioresorbable scaffold next generation platforms and future clinical studies

17:00-18:30 ■ Session objectives - M.B. Leon

- > LIVE demonstration from Instituto Dante Pazzanese de Cardiologia - São Paulo, Brazil
- > Time to React@PCR
- > DESolve engineering science - J. Omission
- > DESolve scaffold optimal implantation techniques - H. Mei
- > DESolve NX clinical trial data and next generation platforms - S. Verhage
- > Session evaluation and key learnings - M.B. Leon

17:00-18:30 ■ How to optimise complex PCI: cases and discussions

ROOM 3328
 17:00-18:30 ■ *With an unrestricted educational grant from TERUMO*
 Chairperson: T. Cusset
 Co-chairperson: M. Roffi

- Attend this session if you want:
- > To learn about remaining challenges in complex coronary interventions
 - > To obtain an update on technical choices in complex PCI
 - > To discuss the role of contemporary DES versus bioresorbable scaffold in daily practice

17:00-18:30 ■ Session objectives - T. Cusset

- > Challenging case 1 - Left main and bifurcation - J. Mehilli
- > Is there an alternative strategy? - A. Colombo
- > Discussion and audience interaction
- > Challenging case 2 - STEMI patient - M. Volonghi
- > Is there an alternative strategy? - T. Johnson
- > Discussion and audience interaction
- > Challenging case 3 - Multivessel disease - M. Lesiak
- > Is there an alternative strategy? - J.R. Ramirez
- > Discussion and audience interaction
- > Session evaluation and key learnings - M. Roffi

17:00-18:00 ■ The prognostic value of FFR: linking physiologic severity to clinical outcomes

ROOM 241
 17:00-18:00 ■ *With an unrestricted educational grant from ST. JUDE MEDICAL*
 Chairperson: N.H. Pijls
 Co-chairperson: S. James

- Attend this session if you want:
- > To learn the latest clinical evidence to use FFR in the cathlab as a prognostic tool pre- and post- PCI
 - > To discover how to perform FFR fast and easily without compromising accuracy
 - > To understand the value of FFR in guiding full revascularisation in NSTEMI patients

17:00-18:00 ■ Session objectives - N.H. Pijls

- > FFR-guided PCI: evidence has never been stronger
- > Discussion and audience interaction
- > How to bring the ESC guidelines recommendations for FFR in your daily practice - B. De Bruyne
- > Discussion and audience interaction
- > Non-culprit lesion in NSTEMI: the value of FFR-guided full revascularisation - C. Berry
- > Discussion and audience interaction
- > Session evaluation and key learnings - S. James

17:00-18:30 ■ Latest evidence on unique self-expanding technology: long-term results with CoreValve and initial results with CoreValve Evolut R

ROOM 242AB
 17:00-18:30 ■ *With an unrestricted educational grant from MEDTRONIC*
 Chairperson: A. Vahanian
 Co-chairperson: R. Komorowski
 Panelists: S.J.D. Breckler, G. Manoharan, N. Piazza, J.J. Popma

- Attend this session if you want:
- > To assess the long-term performance of self-expanding CoreValve platform with the CoreValve ADVANCE study
 - > To gain insights into the latest long-term outcomes from world's largest TAVI prospective randomised clinical trial - The CoreValve US Pivotal study
 - > To attend the first presentation worldwide of the 6-month outcomes of Evolut R CE-marked study

17:00-18:30 ■ Session objectives - A. Vahanian

- > The CoreValve ADVANCE study - 3-year results - S.J.D. Breckler
- > Discussion and audience interaction
- > Latest insights on the CoreValve US Pivotal High Risk 2-year data - J.J. Popma
- > Discussion and audience interaction
- > How technology translates into clinical advancement: the Evolut R platform - N. Piazza
- > Discussion and audience interaction
- > Evolut R 26 and 29 CE study - 6-month results
- > Discussion and audience interaction
- > Session evaluation and key learnings - R. Komorowski

17:00-18:30 ■ From bioresorbable polymer DES to fully absorbable metallic scaffolds: optimising patient care

ROOM 241
 17:00-18:30 ■ *With an unrestricted educational grant from BIOTRONIK*
 Chairperson: S. Windecker
 Co-chairperson: M. Jorier

- Attend this session if you want:
- > To learn how bioresorbable polymer and ultrathin stent design impact healing
 - > To understand the current evidence supporting the Orsiro DES and what benefit such a device can bring in certain subgroups
 - > To understand the properties of an absorbable metallic scaffold and explore what we can expect from such a device

17:00-18:30 ■ Session objectives - S. Windecker

- > How strut thickness, flow and polymer affect healing
- > Discussion and audience interaction
- > How the Orsiro DES performs in high risk subgroups
- > Discussion and audience interaction
- > When do we stand with DAPT for bioresorbable polymer DES? - T. Pilgrim
- > Discussion and audience interaction
- > The absorbable magnesium scaffold: DREAMS - M. Haude
- > Discussion and audience interaction
- > Session evaluation and key learnings - M. Jorier

17:00-18:30 ■ Latest evidence on unique self-expanding technology: long-term results with CoreValve and initial results with CoreValve Evolut R

ROOM 242AB
 17:00-18:30 ■ *With an unrestricted educational grant from MEDTRONIC*
 Chairperson: A. Vahanian
 Co-chairperson: R. Komorowski
 Panelists: S.J.D. Breckler, G. Manoharan, N. Piazza, J.J. Popma

- Attend this session if you want:
- > To assess the long-term performance of self-expanding CoreValve platform with the CoreValve ADVANCE study
 - > To gain insights into the latest long-term outcomes from world's largest TAVI prospective randomised clinical trial - The CoreValve US Pivotal study
 - > To attend the first presentation worldwide of the 6-month outcomes of Evolut R CE-marked study

17:00-18:30 ■ Session objectives - A. Vahanian

- > The CoreValve ADVANCE study - 3-year results - S.J.D. Breckler
- > Discussion and audience interaction
- > Latest insights on the CoreValve US Pivotal High Risk 2-year data - J.J. Popma
- > Discussion and audience interaction
- > How technology translates into clinical advancement: the Evolut R platform - N. Piazza
- > Discussion and audience interaction
- > Evolut R 26 and 29 CE study - 6-month results
- > Discussion and audience interaction
- > Session evaluation and key learnings - R. Komorowski

17:00-18:30 ■ From bioresorbable polymer DES to fully absorbable metallic scaffolds: optimising patient care

ROOM 241
 17:00-18:30 ■ *With an unrestricted educational grant from BIOTRONIK*
 Chairperson: S. Windecker
 Co-chairperson: M. Jorier

- Attend this session if you want:
- > To learn how bioresorbable polymer and ultrathin stent design impact healing
 - > To understand the current evidence supporting the Orsiro DES and what benefit such a device can bring in certain subgroups
 - > To understand the properties of an absorbable metallic scaffold and explore what we can expect from such a device

17:00-18:30 ■ Session objectives - S. Windecker

- > How strut thickness, flow and polymer affect healing
- > Discussion and audience interaction
- > How the Orsiro DES performs in high risk subgroups
- > Discussion and audience interaction
- > When do we stand with DAPT for bioresorbable polymer DES? - T. Pilgrim
- > Discussion and audience interaction
- > The absorbable magnesium scaffold: DREAMS - M. Haude
- > Discussion and audience interaction
- > Session evaluation and key learnings - M. Jorier

7:00-18:30 ■ Fully bioresorbable vascular scaffolds in everyday practice - Case-based approach
ROOM 342AB
Symposium

With an unrestricted educational grant from ABBOTT VASCULAR
Chairpersons: J. Fogaret
Co-chairpersons: A. Serra
Attend this session if you want:
> To understand the possibilities of using fully bioresorbable vascular scaffolds in complex lesions
> To learn more on how to obtain optimal outcomes in treating complex lesions with fully bioresorbable vascular scaffolds

17:00 > Session objectives - A. Serra

Use of fully bioresorbable vascular scaffolds in long diffuse lesions in a diabetic patient

17:05 > Case presentation and result - J. Diaz Fernandez
17:15 > Key point highlighted by the Chairpersons - A. Serra
17:16 > Discussion and audience interaction

Use of fully bioresorbable vascular scaffolds in young ACS patients

17:25 > Case presentation and result - A. Al Noorani
17:35 > Key point highlighted by the Chairpersons - A. Serra
17:36 > Discussion and audience interaction

Use of fully bioresorbable vascular scaffolds in bifurcations, using the provisional approach

17:45 > Case presentation and result - T. Sorrento
17:55 > Key point highlighted by the Chairpersons - J. Fogaret
17:56 > Discussion and audience interaction

Use of fully bioresorbable vascular scaffolds in calcified coronary CTO lesions

18:05 > Case presentation and result - A. Serra
18:15 > Key point highlighted by the Chairpersons - J. Fogaret
18:16 > Discussion and audience interaction
18:25 > Session evaluation and key learnings - J. Fogaret

7:00-18:30 ■ All you need to know about uncontrolled hypertension
ROOM 351
With the collaboration of FHC-IRENDS 2015

Chairperson: F. Mohlrad
Co-chairpersons: M. Lobo

Attend this session if you want:
> To review a comprehensive and clinically relevant update on this field
> To identify the current evidence base and existing guidelines
> To recognise the open questions that need addressing in the near future

17:00 > Session objectives - M. Lobo
17:05 > Definitions and therapeutic options - A. Parvaz
17:15 > Clinical data: update on treatment results 2015
17:16 *F. Mohlrad*

17:25 > Guidelines and recommendations
17:35 > Unresolved issues and outlook - M. Lobo
17:45 > Questions and answers
17:55 > Session evaluation and key learnings - F. Mohlrad

17:00-18:30 ■ Transcatheter valve interventions: new indications, new valves and how to treat complications - The best of the Warsaw Course on Cardiovascular Interventions (WCCI) 2015
ROOM 352A
With the collaboration of Warsaw Course on Cardiovascular Interventions

Chairpersons: R.J. Gil, A. Witkowski
Panelists: A. Ozada

Attend this session if you want:
> To learn about the use of currently available transcatheter valve technologies in different clinical scenarios
> To understand how to avoid and treat transcatheter valve intervention complications
> To share with presenters, panelists and audience your own experience on TAVI and transcatheter mitral valve repair

17:00 > EuroPCR welcomes WCCI - A. Baumhach
17:05 > Session objectives - R.J. Gil

> First-in-man transcatheter mitral valve implantation for mitral regurgitation with the Mitra device - A. Cheung
> Discussion and audience interaction
> First-in-man simultaneous transcatheter aortic and mitral valve replacement to treat severe native aortic and mitral valve stenoses - M. Dobrowolski
> Discussion and audience interaction

> The appropriate amount of preparation for access site may reduce complications in TAVI procedures - R. Bilenker
> Discussion and audience interaction
> A complex TAVI procedure in a frail patient deferred from a surgical aortic valve replacement due to an extremely high surgical risk - K. Wilczek
> Discussion and audience interaction

18:15 > Session evaluation and key learnings - A. Witkowski

17:00-18:30 ■ Learning from complications and nightmares
ROOM 352B
With the collaboration of National Interventional Council of the Cardiological Society of India (NIC)

Chairpersons: A. Banerjee, P. Chandra

Attend this session if you want:
> To understand how to recognise complication at an early stage
> To learn how to treat new methods on specific complication

17:00 > EuroPCR welcomes NIC
17:05 > Session objectives - A. Banerjee
17:10 > Left main complication during routine PCI
17:15 > Discussion and audience interaction
17:20 > Acute haemodynamic collapse during a simple discussion
17:25 *R. Bhargava*

> Discussion and audience interaction
> Complication occurring during CTO PCI
> Discussion and audience interaction
> Severe aortic regurgitation after TAVI - P. Chandra
17:34 > Discussion and audience interaction
17:39 > A story of vanishing stent - M.P. Gribb
18:07 > Discussion and audience interaction
18:12 > PCI in acute myocardial infarction with late presentation leading to unexplained mortality - D. Kohli
18:20 > Discussion and audience interaction

18:25 > Session evaluation and key learnings - P. Chandra

17:00-19:00 ■ Learning left main PCI

Facilitators: I. Al Rashidan, A. Banning, J. Tan

Attend this session if you want:
> To understand the specifics of left main PCI
> To review the role of periprocedural imaging
> To share tips and tricks to improve your technical skills

17:00-18:30 ■ Understanding TAVI complications with the TAVI Valve Atlas
ROOM TERNES 1
Participants: R.W. Serruys, S. Stortrecky, N. Van Mieghem

Attend this session if you want:
> To understand how to use the PCR Valve Atlas
> To understand how the PCR Valve Atlas can complement your TAVI practice
> To dissect complications using the PCR Valve Atlas

17:00 > Session objectives

17:05 > Case 1
17:20 > Case 2
18:00 > Case 3
18:25 > Session evaluation and key learnings

18:35-19:38 ■ EAPC General Assembly

ROOM 253

18:35 > Welcome - S. Windecker

18:37 > EAPC Membership - A. Baumhach
18:40 > Eurointervention - P. Camm
18:44 > ESC eLearning platform (ESL Cell) - R. Taha Nouch
18:48 > EAPC website - E. Stabile
18:52 > EAPC Fellowship programme - A. Witkowski
18:56 > Databases and Registries - F. Weidinger
19:00 > EAPC@ESC Congress 2015 - J.P. Collet
19:04 > Stent for Life Initiative - Z. Kolosova
19:08 > EAPC Budget - J. Escaned

19:11 > EuroPCR - S. Windecker
19:14 > Resistant Hypertension Course - F. Mohlrad
19:17 > PCR London Valves - M. Houde
19:20 > New initiatives for young interventionalists - D. Copodanno
19:23 > EAPC Women Committee - J. Mehili
19:26 > Nurses & Technicians Committee - L. Knapstad
19:29 > Relations with international societies - M. Gilard
19:32 > EAPC Elections 2016 - J. Fogaret
19:35 > Adjourning - S. Windecker

- 08:00 -

08:15-12:00 ■ **Complex cardiovascular interventions and new techniques: LIVE demonstrations from University Hospital Brno - Brno, Czech Republic; from King Fahd Armed Forces Hospital - Jeddah, Saudi Arabia; and from Ferrarotto Hospital, University of Catania - Catania, Italy**

08:15-10:15 ■ **How to integrate the currently available bioresorbable scaffolds in daily practice?**
Chairperson: J. Fogdler

Co-chairperson: T. Mognol

Attend this session if you want:

- > To discuss the proper selection of patients and lesions suitable for bioresorbable scaffold use
- > To learn practical tips and tricks for adequate implantation of bioresorbable scaffolds
- > To evaluate current scientific evidence about bioresorbable scaffolds in different clinical settings

08:15 Session objectives - *T. Mognol*

08:19 Update on bioresorbable scaffolds in 2015 - *J. Omission*

08:29 Time to React@PCR

08:47 LIVE demonstration from Conflita Heart and Vascular Center - Essen, Germany

09:22 Time to React@PCR

09:37 Key points for an optimal bioresorbable scaffold implantation - *S. Cook*

09:45 Time to React@PCR

09:55 Do we need specific DAPT for bioresorbable scaffolds? *G. Cayla*

10:09 Time to React@PCR

10:11 Session evaluation and key learnings - *J. Fogdler*

08:15-10:15 ■ **Pericardaneous edge-to-edge mitral valve repair (Mitralclip) in heart failure: potentials and limitations**
Chairperson: J. Hausleiter

Co-chairperson: T. Feldman

Attend this session if you want:

- > To understand the relevance of functional mitral regurgitation in progression of heart failure
- > To review the available evidence of treating functional mitral regurgitation with pericardaneous edge-to-edge repair in heart failure patients
- > To learn about patient-tailored periprocedural planning and challenges related to pericardaneous edge-to-edge repair

08:15 Session objectives - *J. Hausleiter*

08:21 Heart failure patient with functional mitral regurgitation: prognosis and therapeutic options

08:27 Percardaneous Mitralclip interventions in heart failure: selection and pre-procedural planning - *S. Böhm*

08:33 Time to React@PCR

08:41 LIVE demonstration from Ferrarotto Hospital, University of Catania - Catania, Italy

09:38 Time to React@PCR

09:53 The role of Mitralclip in the scope of heart failure management including cardiac resynchronization therapy, assist devices and heart transplantation - *J. Van Der Heyden*

09:59 Time to React@PCR

10:09 Session evaluation and key learnings - *T. Feldman*

08:15-10:15 ■ **A comprehensive approach to femoropopliteal occlusive disease**
Chairperson: A. Micari

Co-chairperson: Y. Gouffie

Panelists: J. Alhabed, R. Ferrero, J. Tan

Attend this session if you want:

- > To select the appropriate technology for the individual lesion/patient
- > To master a step-by-step approach
- > To avoid and manage complications

With continuous LIVE demonstration from Clinique Pasteur - Toulouse, France
With continuous time to React@PCR

08:15 Session objectives - *Y. Gouffie*

08:26 Tips and tricks for a successful recanalisation - *A. Micari*

08:36 Session evaluation and key learnings - *A. Micari*

08:15-10:15 ■ **Catheter-based renal sympathetic denervation: a comprehensive update in 2015**
With the collaboration of RHC-CHENDS 2015
Facilitators: F. Mahfoud, A. Pathak, R. Schneider, K. Tiofais

Attend this session if you want:

- > To assess a comprehensive update on this field, actively share your experience and get answers to your questions
- > To identify and discuss the current evidence base and its impact for daily clinical practice
- > To recognise the open questions that need addressing in the near future

08:15 Session objectives - *F. Mahfoud*

08:26 Different hypertension phenotypes: how to diagnose and treat - *R. Schneider*

08:36 Case 1 - Best candidate for renal denervation - *F. Sharif*

08:46 Renal sympathetic nerves: recent clinical and pre-clinical findings: changed my procedural performance - *F. Mahfoud*

08:56 Discussion and audience interaction

09:06 What have we learned from recent clinical trials and what to do now? - *A. Pathak*

09:16 Discussion and audience interaction

09:26 Case 2 - A patient with uncontrolled hypertension and comorbidities - *H. Siewert*

09:36 Where to go from here? - *C. Ukena*

09:46 Discussion and audience interaction

09:56 Session evaluation and key learnings - *R. Schneider*

10:06 Session evaluation and key learnings - *T. Van Hecke*

08:15-10:15 ■ **Training and education for European Nurses and Technicians today and tomorrow**
Chairperson: T. Van Hecke

Co-chairperson: J. Laub

Attend this session if you want:

- > To share the current situation in different countries
- > To discuss the future of the EAPC training and education programme
- > To know how to use social networks in our community

08:15 Session objectives - *J. Laub*

08:26 Italy - *M. Longoni*

08:36 Discussion and audience interaction

08:46 Denmark - *M. Mogard Weierdoff*

08:56 Discussion and audience interaction

09:06 United Kingdom - *F. Gudge*

09:16 Discussion and audience interaction

09:26 Spain - *V. Rodriguez Garcia-Abad*

09:36 Discussion and audience interaction

09:46 The USA current model - *R. Dele*

09:56 Discussion and audience interaction

10:06 EAPC education programme and how to "Linkin"

10:16 Discussion and audience interaction

10:26 The learning platform of the future - *ESCI - M. Solerme*


10:36 Discussion and audience interaction

10:46 Session evaluation and key learnings - *T. Van Hecke*

euro PCR

Scientific programme

Wednesday 20th May, 2015



Valid as of 19th March, 2015

Only Faculty who confirmed their attendance are listed in this programme.
For real-time update, please consult the interactive programme.



8:15-09:15 ■ Planned and ongoing clinical trials: a status update from genese

ROOM 332A
Introduction HMDChairperson: *B. Segers*

Attend this session if you want:

- > to be updated on planned or ongoing clinical trials that may change our future practice
- > to gain in-depth understanding of trial design and execution
- > to learn about upcoming milestones for trial recruitment, analysis and presentation plan

08:15

> Session objectives - *B. Segers*

> Left atrial decompression using the VMware shunt

> Discussion and audience interaction

> REFLECT: evaluation of the TriGuard embolic deflection device during TAVI

> Discussion and audience interaction

> PAME: a compares FFR-guided PCI with CAG in triple vessel disease - *W. Tezcan*

> Discussion and audience interaction

> ILLUMINATE clinical programme

> Discussion and audience interaction

> DESolve: novolimus-eluting scaffold and fully bioreabsorbable - *S. Verheyne*

> Discussion and audience interaction

> Session evaluation and key learnings

09:10

8:15-10:15 ■ Decision-making in true bifurcation lesions: case-based approach

ROOM 342AB

Chairperson: *M. Lesiak*Co-chairperson: *O. Darmonot*Panelists: *A. Erglis, J.F. Lassen*

Attend this session if you want:

- > to exchange about the relevant factors influencing decision-making in treating bifurcation lesions
- > to experience the relevance of planning ahead for procedural outcome
- > to learn practical tips and tricks to prevent and solve complications

08:15

> Session objectives - *O. Darmonot*> Looks complex? Keep it simple: a one-stent strategy *F. Ribichini*

> Discussion and audience interaction

> Two-stent strategy? Which one to choose? First case example - *A. Erglis*

> Discussion and audience interaction

> Two-stent strategy? Which one to choose? Second case example - *J.F. Lassen*

> Discussion and audience interaction

> Expect the unexpected - *G. Stankovic*

> Discussion and audience interaction

> Session evaluation and key learnings - *M. Lesiak*

09:15

> Session objectives - *G. Stankovic*> Expect the unexpected - *G. Stankovic*

> Discussion and audience interaction

> Session evaluation and key learnings - *M. Lesiak*> Session objectives - *G. Stankovic*> Expect the unexpected - *G. Stankovic*

> Discussion and audience interaction

> Session evaluation and key learnings - *M. Lesiak*> Session objectives - *G. Stankovic*> Expect the unexpected - *G. Stankovic*

> Discussion and audience interaction

> Session evaluation and key learnings - *M. Lesiak*> Session objectives - *G. Stankovic*> Expect the unexpected - *G. Stankovic*

> Discussion and audience interaction

> Session evaluation and key learnings - *M. Lesiak*> Session objectives - *G. Stankovic*> Expect the unexpected - *G. Stankovic*

> Discussion and audience interaction

> Session evaluation and key learnings - *M. Lesiak*> Session objectives - *G. Stankovic*> Expect the unexpected - *G. Stankovic*

> Discussion and audience interaction

> Session evaluation and key learnings - *M. Lesiak*> Session objectives - *G. Stankovic*> Expect the unexpected - *G. Stankovic*

> Discussion and audience interaction

> Session evaluation and key learnings - *M. Lesiak*> Session objectives - *G. Stankovic*> Expect the unexpected - *G. Stankovic*

> Discussion and audience interaction

08:15-09:15 ■ Ireland and South Africa share their most educational cases

ROOM 332A
ComplicationsChairperson: *D. Kerites*

Attend this session if you want:

- > to understand and identify major causes of complex complications during CTO
- > to learn how to prevent this complication
- > to share effective techniques that can be lifesaving when common complications occur

08:15

> Session objectives

> Case 1 - Antegrade CTO: when is it time to inflate the balloon?

> Discussion and audience interaction

> Case 2 - Guidewire exits and perforations during CTO PCI: how far to push the envelope and how to avoid tamponade - *D. Mylotte*

> Discussion and audience interaction

> Case 3 - Calcium is brittle covered stent rescue - *G. Cassel*

> Discussion and audience interaction

> Case 4 - Occlusive left main dissection during CTO PCI to proximal left anterior descending artery: strategies to treat and especially to avoid

> Discussion and audience interaction

> Key learnings session evaluation - *D. Kerites*

> Session evaluation and key learnings

09:15

> Session objectives

> Case 1 - Antegrade CTO: when is it time to inflate the balloon?

> Discussion and audience interaction

> Case 2 - Guidewire exits and perforations during CTO PCI: how far to push the envelope and how to avoid tamponade - *D. Mylotte*

> Discussion and audience interaction

> Case 3 - Calcium is brittle covered stent rescue - *G. Cassel*

> Discussion and audience interaction

> Case 4 - Occlusive left main dissection during CTO PCI to proximal left anterior descending artery: strategies to treat and especially to avoid

> Discussion and audience interaction

> Key learnings session evaluation - *D. Kerites*

> Session evaluation and key learnings

09:15

> Session objectives

> Case 1 - Antegrade CTO: when is it time to inflate the balloon?

> Discussion and audience interaction

> Case 2 - Guidewire exits and perforations during CTO PCI: how far to push the envelope and how to avoid tamponade - *D. Mylotte*

> Discussion and audience interaction

> Case 3 - Calcium is brittle covered stent rescue - *G. Cassel*

> Discussion and audience interaction

> Case 4 - Occlusive left main dissection during CTO PCI to proximal left anterior descending artery: strategies to treat and especially to avoid

> Discussion and audience interaction

> Key learnings session evaluation - *D. Kerites*

> Session evaluation and key learnings

09:15

> Session objectives

> Case 1 - Antegrade CTO: when is it time to inflate the balloon?

> Discussion and audience interaction

> Case 2 - Guidewire exits and perforations during CTO PCI: how far to push the envelope and how to avoid tamponade - *D. Mylotte*

> Discussion and audience interaction

> Case 3 - Calcium is brittle covered stent rescue - *G. Cassel*

> Discussion and audience interaction

> Case 4 - Occlusive left main dissection during CTO PCI to proximal left anterior descending artery: strategies to treat and especially to avoid

> Discussion and audience interaction

> Key learnings session evaluation - *D. Kerites*

> Session evaluation and key learnings

09:15

> Session objectives

> Case 1 - Antegrade CTO: when is it time to inflate the balloon?

> Discussion and audience interaction

> Case 2 - Guidewire exits and perforations during CTO PCI: how far to push the envelope and how to avoid tamponade - *D. Mylotte*

> Discussion and audience interaction

> Case 3 - Calcium is brittle covered stent rescue - *G. Cassel*

> Discussion and audience interaction

> Case 4 - Occlusive left main dissection during CTO PCI to proximal left anterior descending artery: strategies to treat and especially to avoid

> Discussion and audience interaction

> Key learnings session evaluation - *D. Kerites*

> Session evaluation and key learnings

09:15

> Session objectives

> Case 1 - Antegrade CTO: when is it time to inflate the balloon?

> Discussion and audience interaction

> Case 2 - Guidewire exits and perforations during CTO PCI: how far to push the envelope and how to avoid tamponade - *D. Mylotte*

> Discussion and audience interaction

> Case 3 - Calcium is brittle covered stent rescue - *G. Cassel*

> Discussion and audience interaction

> Case 4 - Occlusive left main dissection during CTO PCI to proximal left anterior descending artery: strategies to treat and especially to avoid

> Discussion and audience interaction

> Key learnings session evaluation - *D. Kerites*

> Session evaluation and key learnings

09:20-10:20 ■ Planned and ongoing clinical trials: a status update from Cardiolysis and the European Cardiovascular Research Institute (ECRI)

ROOM 332A
Introduction HMDChairperson: *P.W. Serruys, G.A. Van Es*

Attend this session if you want:

- > to be updated on planned or ongoing clinical trials that may change our future practice
- > to gain in-depth understanding of trial design and execution
- > to learn about upcoming milestones for trial recruitment, analysis and presentation plan

09:20

> Session objectives - *G.A. Van Es*> ECRI 1 to ECRI 5: current status of investigator-initiated studies - *P.W. Serruys*

> Discussion and audience interaction

> Need for multimodally imaging to assess bioreabsorbable scaffolds: Absorb, Aorta, Bioguide - *H.M. Garcia-Garcia*

> Discussion and audience interaction

> Chinese technology tested in Europe: Pioneet, Nano Plus

> Discussion and audience interaction

> RESOUND: lessons learned from VASC 2

> Discussion and audience interaction

> DART, PEGASUS, GLOBAL LEADERS: implications for clinical (trial) practice

> Discussion and audience interaction

> Session evaluation and key learnings - *P.W. Serruys*> Session objectives - *G.A. Van Es*> ECRI 1 to ECRI 5: current status of investigator-initiated studies - *P.W. Serruys*

> Discussion and audience interaction

> Need for multimodally imaging to assess bioreabsorbable scaffolds: Absorb, Aorta, Bioguide - *H.M. Garcia-Garcia*

> Discussion and audience interaction

> Chinese technology tested in Europe: Pioneet, Nano Plus

> Discussion and audience interaction

> RESOUND: lessons learned from VASC 2

> Discussion and audience interaction

> DART, PEGASUS, GLOBAL LEADERS: implications for clinical (trial) practice

> Discussion and audience interaction

> Session evaluation and key learnings - *P.W. Serruys*> Session objectives - *G.A. Van Es*> ECRI 1 to ECRI 5: current status of investigator-initiated studies - *P.W. Serruys*

> Discussion and audience interaction

> Need for multimodally imaging to assess bioreabsorbable scaffolds: Absorb, Aorta, Bioguide - *H.M. Garcia-Garcia*

> Discussion and audience interaction

> Chinese technology tested in Europe: Pioneet, Nano Plus

> Discussion and audience interaction

> RESOUND: lessons learned from VASC 2

> Discussion and audience interaction

> DART, PEGASUS, GLOBAL LEADERS: implications for clinical (trial) practice

> Discussion and audience interaction

> Session evaluation and key learnings - *P.W. Serruys*> Session objectives - *G.A. Van Es*> ECRI 1 to ECRI 5: current status of investigator-initiated studies - *P.W. Serruys*

> Discussion and audience interaction

> Need for multimodally imaging to assess bioreabsorbable scaffolds: Absorb, Aorta, Bioguide - *H.M. Garcia-Garcia*

> Discussion and audience interaction

> Chinese technology tested in Europe: Pioneet, Nano Plus

> Discussion and audience interaction

> RESOUND: lessons learned from VASC 2

> Discussion and audience interaction

> DART, PEGASUS, GLOBAL LEADERS: implications for clinical (trial) practice

> Discussion and audience interaction

> Session evaluation and key learnings - *P.W. Serruys*> Session objectives - *G.A. Van Es*> ECRI 1 to ECRI 5: current status of investigator-initiated studies - *P.W. Serruys*

> Discussion and audience interaction

> Need for multimodally imaging to assess bioreabsorbable scaffolds: Absorb, Aorta, Bioguide - *H.M. Garcia-Garcia*

> Discussion and audience interaction

> Chinese technology tested in Europe: Pioneet, Nano Plus

> Discussion and audience interaction

> RESOUND: lessons learned from VASC 2

> Discussion and audience interaction

> DART, PEGASUS, GLOBAL LEADERS: implications for clinical (trial) practice

> Discussion and audience interaction

> Session evaluation and key learnings - *P.W. Serruys*> Session objectives - *G.A. Van Es*> ECRI 1 to ECRI 5: current status of investigator-initiated studies - *P.W. Serruys*

> Discussion and audience interaction

> Need for multimodally imaging to assess bioreabsorbable scaffolds: Absorb, Aorta, Bioguide - *H.M. Garcia-Garcia*

> Discussion and audience interaction

> Chinese technology tested in Europe: Pioneet, Nano Plus

> Discussion and audience interaction

> RESOUND: lessons learned from VASC 2

> Discussion and audience interaction

> DART, PEGASUS, GLOBAL LEADERS: implications for clinical (trial) practice

> Discussion and audience interaction

09:20-10:20 ■ Bulgaria and Greece share their most educational cases

ROOM 332A
ComplicationsChairperson: *V. Galey, G. Stanos*

Attend this session if you want:

- > to understand the clinical, anatomical, pharmacological parameters/predictors associated with left main PCI complications
- > to learn how to prevent and effectively treat left main complications

09:20

> Session objectives - *V. Galey*> Case 1 - Dissection-thrombosis during left main PCI *G. Bonanno*

> Discussion and audience interaction

> Case 2 - Left main dissection during left anterior descending artery PCI with rosiablation

> Discussion and audience interaction

> Case 3 - Left main occlusion during retrograde recanalisation of a right coronary artery CTO - *K. Tziouzas*

> Discussion and audience interaction

> Case 3 - Left main coronary artery dissection during an attempt for occlusion of aortofemoral malformation between left main coronary artery and pulmonary artery

> Discussion and audience interaction

> Session evaluation and key learnings - *G. Stanos*> Session objectives - *V. Galey*> Case 1 - Dissection-thrombosis during left main PCI *G. Bonanno*

> Discussion and audience interaction

> Case 2 - Left main dissection during left anterior descending artery PCI with rosiablation

> Discussion and audience interaction

> Case 3 - Left main occlusion during retrograde recanalisation of a right coronary artery CTO - *K. Tziouzas*

> Discussion and audience interaction

> Case 3 - Left main coronary artery dissection during an attempt for occlusion of aortofemoral malformation between left main coronary artery and pulmonary artery

> Discussion and audience interaction

> Session evaluation and key learnings - *G. Stanos*> Session objectives - *V. Galey*> Case 1 - Dissection-thrombosis during left main PCI *G. Bonanno*

> Discussion and audience interaction

> Case 2 - Left main dissection during left anterior descending artery PCI with rosiablation

> Discussion and audience interaction

> Case 3 - Left main occlusion during retrograde recanalisation of a right coronary artery CTO - *K. Tziouzas*

> Discussion and audience interaction

> Case 3 - Left main coronary artery dissection during an attempt for occlusion of aortofemoral malformation between left main coronary artery and pulmonary artery

> Discussion and audience interaction

> Session evaluation and key learnings - *G. Stanos*> Session objectives - *V. Galey*> Case 1 - Dissection-thrombosis during left main PCI *G. Bonanno*

> Discussion and audience interaction

> Case 2 - Left main dissection during left anterior descending artery PCI with rosiablation

> Discussion and audience interaction

> Case 3 - Left main occlusion during retrograde recanalisation of a right coronary artery CTO - *K. Tziouzas*

> Discussion and audience interaction

> Case 3 - Left main coronary artery dissection during an attempt for occlusion of aortofemoral malformation between left main coronary artery and pulmonary artery

> Discussion and audience interaction

> Session evaluation and key learnings - *G. Stanos*> Session objectives - *V. Galey*> Case 1 - Dissection-thrombosis during left main PCI *G. Bonanno*

> Discussion and audience interaction

> Case 2 - Left main dissection during left anterior descending artery PCI with

- 10:00 -

1:30-12:00 ■ Innovative solutions in complex PCI in a complex milieu: the case of diabetics

T: ENTRE BLEU

Chairperson: A. Mehra
Panelists: U. Kaul, A. Seif

- Attend this session if you want:
- > To understand how diabetics differ in complexity of the coronary artery disease process and their PCI outcomes
 - > To evaluate how newer technologies can influence the results of complex PCI in diabetics
 - > To review how newer technologies and strategies on the horizon can influence outcomes in complex multivessel intervention

10:30 10:35 10:40 11:00 11:15 11:25 11:35 11:45 11:50 11:55

10:30-12:00 ■ How to optimise outcomes: access management when using large-size sheaths

THEATRE HAVANE

Chairperson: M. Roffi
Co-chairperson: C. Seacci
Panelists: A. Alkhatib, F. Carrara, O. Gokkeli

- Attend this session if you want:
- > To become familiar with strategies and dedicated devices for large-size sheath management
 - > To be prepared to solve life-threatening complications
- Session objectives: - M. Roffi
- > How to prevent complications? - P. Wenaweser
 - > Case demonstration - P. Wenaweser
 - > Time to React@PCR
 - > How to treat complications? - F. Carrara
 - > Case demonstration from Maria Cecilia Hospital - Colipolo, Italy - F. Carrara
 - > Time to React@PCR
 - > Session evaluation and key learnings - C. Seacci

10:30 10:35 10:40 11:00 11:15 11:25 11:35 11:45 11:50 11:55

1:30-12:00 ■ Devices for advanced heart failure: what device, what patient? Update for Interventionalists

THEATRE BONDEAUX

Chairperson: J. Bartunek
Panelists: F. Feldman, A. Ince, J. Van Der Heyden

- Attend this session if you want:
- > To understand the role of device-based interventions in the current multidisciplinary management of heart failure
 - > To become familiar with the therapeutic potential of devices promoting cardiac remodeling and ventricular remodeling
 - > To understand when and for which patient a device-based approach may be considered

10:30 10:35 10:40 11:00 11:15 11:25 11:35 11:45 11:50 11:55

10:30-12:00 ■ The Heart Team@Work: difficult decisions in patients with left main and multivessel coronary artery disease

ROOM 241

Organized by: Università degli Studi di Napoli Federico II, Naples, Italy - Course Directors: R. Trimarco, G. Esposito
Chairpersons: G. Angelini, A. Bouniech

- Attend this session if you want:
- > To exchange about indications for CABG and PCI in complex patients
 - > To discuss the relevance on the clinical outcome for the individual patient
 - > To learn that a true Heart Team approach provides real benefit for the patient
- Session objectives
- > Case 1 - Multivessel disease in a patient with stable coronary artery disease - T. Wallner
 - > How would I treat? - E. Barbato
 - > Discussion and audience interaction
 - > Conclusion of the case and take-home message from the Heart Team - A. Bouniech
 - > Case 2 - Left main disease - E. Barbato
 - > How would I treat? - T. Wallner
 - > Discussion and audience interaction
 - > Conclusion of the case and take-home message from the Heart Team - G. Angelini
 - > Case 3 - Complex coronary artery disease in a diabetic patient - T. Wallner
 - > How would I treat? - M. Bolognini
 - > Discussion and audience interaction
 - > Conclusion of the case and take-home message from the Heart Team
 - > Session evaluation and key learnings - E. Barbato

10:30 10:35 10:40 11:00 11:15 11:25 11:35 11:45 11:50 11:55


10:30-12:00 ■ Treating hypertensive patients at risk

ROOM 242AB

With the collaboration of HRC-FREEDS 2015
Chairperson: R. Schnieder
Co-chairperson: K. Tzioufis
Panelists: M. Kundi, S.T. Lim, F. Mahfoud

- Attend this session if you want:
- > To learn how to identify and diagnose hypertensive patients with end-organ damage with the use of dedicated checklists
 - > To appreciate the best personalised approach to treat hypertensive patients at risk
- Session objectives: - R. Schnieder
- > A hypertensive patient with shortness of breath - K. Tzioufis
 - > How to systematically diagnose and treat left ventricular hypertrophy and heart failure with preserved ejection fraction? - A. Prazak
 - > Discussion and audience interaction
 - > A hypertensive patient with palpitation and fatigue - S. Ewen
 - > How to systematically diagnose and treat atrial fibrillation in hypertensive patients? - C. Ullrich
 - > Discussion and audience interaction
 - > An asymptomatic hypertensive patient with renal impairment - S. Gadoor
 - > How to systematically diagnose and treat albuminuria and worsening of renal function? - L. Rullope
 - > Discussion and audience interaction
 - > Session evaluation and key learnings - K. Tzioufis

10:30 10:35 10:40 11:00 11:15 11:25 11:35 11:45 11:50 11:55



In this session, discover the 3 hypertensive patient phenotypes

10:30-12:00 ■ Treatment options for superficial femoral artery

ROOM 243

With the collaboration of the ESC Working Group on Peripheral circulation
Chairperson: M. Brodmann
Co-chairperson: A. Cernone
Panelists: M. Kundi, S.T. Lim, F. Mahfoud

- Attend this session if you want:
- > To discuss the appropriate treatment strategy for patients with superficial femoral artery disease
 - > To learn about the use of dedicated advanced technologies
 - > To understand the role of surgical versus endovascular treatment
- Session objectives: - A. Cernone
- > Medical/Conservative treatment of superficial femoral artery disease
 - > Discussion and audience interaction
 - > Treatment algorithm for superficial femoral artery disease in 2015 - M. De Carlo
 - > Discussion and audience interaction
 - > Drug-coated balloons in superficial femoral artery disease - E. Sforzella
 - > Discussion and audience interaction
 - > Stents in superficial femoral artery disease - A. Micali
 - > Discussion and audience interaction
 - > Still a place for surgical repair?
 - > Discussion and audience interaction
 - > Session evaluation and key learnings - M. Brodmann

10:30 10:35 10:40 11:00 11:15 11:25 11:35 11:45 11:50 11:55

10:30-12:00 ■ ACS patients - Putting guidelines into practice

ROOM 251

Chairperson: S. Grigolo
Co-chairperson: R. Estevens
Facilitators: S. Carson, H. Follot
Panelists: M. Kundi, S.T. Lim, F. Mahfoud

- Attend this session if you want:
- > To update your knowledge about the treatment of ACS
 - > To understand how to deliver the best patient care according to the current guidelines
- Session objectives: - R. Estevens
- > Guidelines: what happens to the patient before entering the cathlab - M. Soler
 - > Discussion and audience interaction
 - > Inside the cathlab how do guidelines influence practice? - J. Marques
 - > Discussion and audience interaction
 - > Current approach to patients presenting with STEMI/NSTEMI - E. Perrin
 - > Discussion and audience interaction
 - > What happens next? Life after the cathlab - V. Ortolano
 - > Discussion and audience interaction
 - > Session evaluation and key learnings - S. Grigolo

10:30 10:35 10:40 11:00 11:15 11:25 11:35 11:45 11:50 11:55

10:30-12:00 ■ Innovations in Cardiovascular Interventions

ROOM 252A

With the collaboration of Innovations in Cardiovascular Interventions (ICI)
Chairpersons: R. Beyar, C. Lalon

- Attend this session if you want:
- > To obtain an update on cardiovascular innovations as presented at ICI 2014
 - > To recognise unique examples of cardiovascular innovations
 - > To acknowledge unmet needs in the cardiovascular interventions
- Session objectives: - R. Beyar
- > The ICI mission and the ICI forum "Innovation of the year" - C. Lalon
 - > TIA medical's EverLink system - Winner of the 2014 ICI Innovation of the year award
 - > Discussion and audience interaction
 - > Lev EL technology - Merge award winner
 - > Discussion and audience interaction
 - > Cardiovascular innovations in Israel: the "Start-up nation" phenomenon - R. Kornowski
 - > Discussion and audience interaction
 - > Pangenin endovascular simulators
 - > Discussion and audience interaction
 - > HealthWatch Master: Caution
 - > Discussion and audience interaction
 - > Medtronic's active
 - > Discussion and audience interaction
 - > Panel discussion: future clinical needs in cardiovascular interventions
 - > Session evaluation and key learnings - C. Lalon

10:30 10:35 10:40 11:00 11:15 11:25 11:35 11:45 11:50 11:55

11:30-12:00 ■ EuroIntervention / EHI Joint session: the year in Intervention

ROOM 341

With the collaboration of EuroIntervention and the European Heart Journal

Chairpersons: P. Cammings, P. De Feyter, T.F. Lüscher, P.M. Seuring

- Attend this session if you want:
- > To discover publications reporting on innovations within the interventional field
 - > To reflect on the impact of these publications in your daily practice
 - > To appreciate these publications in the form of robust, solid summaries by key opinion leader

- 10:30-12:00 ■ Session objectives - P.M. Seuring
- 10:35 ▶ Percutaneous valvular intervention and TAVI - A. Vahanian
- 10:39 ▶ Discussion and audience interaction
- 11:00 ▶ Coronary intervention in ACS and STEM - U. Landmesser
- 11:13 ▶ Discussion and audience interaction
- 11:25 ▶ Coronary intervention in stable coronary artery disease - P.M. Seuring
- 11:40 ▶ Discussion and audience interaction
- 11:50 ▶ Session evaluation and key learnings - T.F. Lüscher

11:30-12:00 ■ Registries and imaging in TAVI and PCI: a Latin American perspective

ROOM 342AB

With the collaboration of the Sociedad Latinoamericana de Cardiología Intervencionista (SOLACI)

Chairpersons: R. Liberos, J.A. Sosa, Panelists: J.A.G. Alvarez, J.L. Leiva Pons

Attend this session if you want:

- > To share the latest results of registries on interventions in Latin America
- > To understand the use of imaging in interventional procedures
- > To discuss complex PCI and TAVI

- 10:30 ▶ EuroCR welcomes SOLACI - J. Escaned
- 10:32 ▶ Session objectives - R. Liberos
- 10:37 ▶ Latin American registries in STEMI - How to improve it? - J. Becerra
- 10:45 ▶ Discussion and audience interaction
- 10:50 ▶ TAVI registries in Latin America - Where are we? - F. Sandoz/De Rivo
- 10:58 ▶ Discussion and audience interaction
- 11:03 ▶ Rational use of imaging methods in interventional cardiology: which, when and how? - P. Lenos
- 11:11 ▶ Discussion and audience interaction
- 11:16 ▶ What should we know to better approaching left main percutaneously? - C. Di Mario
- 11:23 ▶ Discussion and audience interaction
- 11:29 ▶ Unusual case of coronary angioplasty - That is the best option - A. Mendil
- 11:37 ▶ Discussion and audience interaction
- 11:42 ▶ Unusual case of TAVI - Yes we can! - A. Doger
- 11:50 ▶ Discussion and audience interaction
- 11:55 ▶ Session evaluation and key learnings - J.A. Sosa

10:30-12:00 ■ Challenges of antithrombotic therapy in TAVI

ROOM 343

Chairperson: J.P. Collet

Co-Chairperson: S. Windecker

Attend this session if you want:

- > To identify the risk of per-procedural and long-term thromboembolic complications in patients with valvular heart disease
- > To learn about per-procedural strategies of antithrombotic therapy in TAVI
- > To learn about long-term strategies of antithrombotic therapy in TAVI

- 10:30 ▶ Session objectives - J.P. Collet
- 10:35 ▶ What is the risk of thromboembolic complications during and after TAVI - M. Glicad
- 10:45 ▶ Antithrombotic therapy before and during TAVI - P. Vranckx
- 10:55 ▶ Discussion and audience interaction
- 11:00 ▶ What is the risk of early and late bleeding complications
- 11:10 ▶ Long-term antithrombotic therapy after TAVI: antiplatelet or anticoagulant therapy - G.S. Stefanini
- 11:20 ▶ Discussion and audience interaction
- 11:35 ▶ Session evaluation and key learnings - S. Windecker

10:30-12:00 ■ All you need to know about treatment of STEMI

ROOM 351

Chairperson: G. Durcrocq

Co-Chairperson: P. Widimsky

Attend this session if you want:

- > To review a comprehensive and clinically relevant update on this field
- > To identify the current evidence base and existing guidelines
- > To recognise the open questions that need addressing in the near future

- 10:30 ▶ Session objectives - G. Durcrocq
- 10:35 ▶ Background and clinical data - P. Widimsky
- 10:55 ▶ Clinical issues: drug regimens - M. Volkmann
- 11:15 ▶ Guidelines - G. Durcrocq
- 11:25 ▶ Unresolved issues and outlook - S. James
- 11:45 ▶ Questions and answers
- 11:55 ▶ Session evaluation and key learnings - G. Durcrocq

10:30-12:00 ■ Finland and Norway share their most educational

ROOM 352A

Chairperson: J. Trowik

Co-Chairperson: M. Niemela

Attend this session if you want:

- > To understand the difference between quality of initial angiographic result and long-term outcome
- > To reflect on different ways to treat stenosis in bifurcation lesions
- > To understand how to evaluate left main bifurcation lesions by OCT

- 10:30 ▶ Session objectives - M. Niemela
- 10:35 ▶ Case 1 - Left main distal lesion after endocarditis - K. Keränen
- 10:45 ▶ How would I treat? - P. Karijabinen
- 10:55 ▶ How did I treat? - K. Keränen
- 11:05 ▶ Discussion and audience interaction
- 11:15 ▶ Consensus - M. Niemela
- 11:25 ▶ Case 2 - Challenging double bifurcation in in-stent restenosis - A. Alkahi
- 11:35 ▶ How would I treat? - P. Karijabinen
- 11:45 ▶ How did I treat? - A. Alkahi
- 11:50 ▶ Discussion and audience interaction
- 11:55 ▶ Consensus - T. Trowik
- 11:55 ▶ Session evaluation and key learnings - T. Trowik

10:30-12:00 ■ Austria and Hungary share their most

ROOM 352B

Chairperson: J. Trowik

Co-Chairperson: M. Niemela

Attend this session if you want:

- > To discuss indications for multivessel PCI in STEMI
- > To reflect on antithrombotic strategies in patients with STEMI, suboptimal TIMI flow and prior stroke
- > To show the technique of transcatheter coil embolisation in LMA dysfunction due to stent phenomenon

- 10:30 ▶ Session objectives - F. Weidinger
- 10:35 ▶ Case 1 - STEMI with right bundle branch and anterior STEIs: complications by inpatient cardiogenic shock in a patient with prior stroke - H. Almer
- 10:40 ▶ How would I treat? - I. Ungl
- 10:45 ▶ How did I treat? - H. Almer
- 10:50 ▶ How did I treat? - I. Ungl
- 11:00 ▶ Discussion and audience interaction
- 11:10 ▶ Consensus - F. Weidinger
- 11:15 ▶ Case 2 - Acute and long-term treatment of a spontaneous left main dissection in STEMI - Z. Ruzsa
- 11:20 ▶ How would I treat?
- 11:25 ▶ How did I treat? - Z. Ruzsa
- 11:30 ▶ Discussion and audience interaction
- 11:40 ▶ Consensus - B. Merkely
- 11:55 ▶ Session evaluation and key learnings - B. Merkely

10:30-12:00 ■ Learning bifurcation PCI

ROOM 352C

Chairpersons: B. Faruqi, J.F. Lassen, G. Sionkovic

Attend this session if you want:

- > To discuss together the best indications for different stenting strategies
- > To review in detail specific procedural technique using one stent or two stents

- 10:30 ▶ Session objectives - B. Faruqi
- 10:35 ▶ Background and clinical data - G. Sionkovic
- 10:55 ▶ Clinical issues: drug regimens - M. Volkmann
- 11:15 ▶ Guidelines - G. Durcrocq
- 11:25 ▶ Unresolved issues and outlook - S. James
- 11:45 ▶ Questions and answers
- 11:55 ▶ Session evaluation and key learnings - G. Durcrocq

- 12:00 -

12:30-14:30 ■ Realising the full potential of TAVI

THEATRE BORDEAUX

Chairperson: B. Penedagost

Co-Chairperson: H. Reichenspurner

Attend this session if you want:

- > To learn how the features of Sapien 3 bring benefits to TAVI patients
- > To understand how Sapien 3 is simplifying the TAVI procedure and the patient management
- > To discover the latest clinical results of the Sapien 3 platform

- 12:30 ▶ Session objectives - H. Reichenspurner
- 12:35 ▶ LIVE demonstration from Ferreroto Hospital, University of Calabria - Calabria, Italy
- 13:15 ▶ Time to React@PCR
- 13:30 ▶ TAVI procedural optimisation - J. Mellili
- 13:45 ▶ TAVI latest data summary - A. Vahanian
- 13:55 ▶ LIVE demonstration from Ferreroto Hospital, University of Calabria - Calabria, Italy
- 14:15 ▶ Time to React@PCR
- 14:30 ▶ Session evaluation and key learnings - B. Penedagost

12:30-14:30 ■ Acute stroke - The new frontier for interventional

THEATRE HANAU

Chairpersons: N. Hopkins, P. Widimsky

Co-Chairpersons: A. Bonaldi, A. Cernone

Attend this session if you want:

- > To understand how to start or to improve performing acute stroke interventions in your institution
- > To learn whether acute stroke interventions could follow the success story of acute myocardial infarction interventions
- > To learn about the new evidence from randomised trials in acute stroke finally favouring catheter-based strategies

- 12:30 ▶ Session objectives - N. Hopkins
- 12:35 ▶ Stroke intervention for cardiology: why and how to get into the game
- 12:40 ▶ Neurovascular anatomy: computed tomographic angiography, magnetic resonance angiography and invasive angiography
- 12:45 ▶ Patient selection and indication for endovascular treatment - N. Hopkins
- 12:50 ▶ Time to React@PCR
- 12:55 ▶ Getting access to the target vessel and dealing with the occlusion: equipment and techniques
- 13:00 ▶ Periprocedural antithrombotic treatment - P. Widimsky
- 13:05 ▶ Time to React@PCR
- 13:10 ▶ Case demonstration - A. Bonaldi
- 13:15 ▶ Time to React@PCR

- 13:20 ▶ New evidence in recent stroke trials
- 13:25 ▶ Recent negative New England Journal of Medicine trials: What did we learn?
- 13:30 ▶ Five new randomised, placebo-controlled efficacy trials all positive - What are the implications?
- 13:35 ▶ Evolution and future of stroke treatment and trials
- 13:40 ▶ Time to React@PCR
- 13:45 ▶ Session evaluation and key learnings - P. Widimsky

- 12:30-14:30 ■ Left main and complex bifurcation stenting
- THEATRE BLEU
- Chairperson: M.C. Morice
- Co-Chairperson: R. Kornowski
- Panelists: M. Al Muehri, J. Diaz Fernandez, D. Hildick-Smith, H.H. Ho, H. Mishi
- Attend this session if you want:
- > To discuss how to select the optimal treatment option for the patients presenting with left main or complex bifurcations
 - > To acknowledge Ultrashear DES results in complex patients population
 - > To understand the value of optical frequency domain imaging in complex PCI

- 12:30 ▶ Session objectives - M.C. Morice
- 12:35 ▶ LIVE demonstration from Institut Cardiovasculaire Paris Sud - Massy, France
- 12:40 ▶ Time to React@PCR
- 12:45 ▶ Discover Ultrashear with optical frequency domain imaging - D. Hildick-Smith
- 12:50 ▶ LIVE demonstration from Institut Cardiovasculaire Paris Sud - Massy, France
- 12:55 ▶ Time to React@PCR
- 13:00 ▶ Session evaluation and key learnings - R. Kornowski

12:00-14:00 ■ Optimal healing and DAPT duration in today's complex PCI: the Synergy stent

ROOM 241
MALLOT
With an unrestricted educational grant from BOSTON SCIENTIFIC

Chairperson: I. Meredith
Co-chairperson: K.G. Oldroyd
Panelists: S. Cook, T. Cusset, J.M. De La Torre Hernandez, S. Wirth

- Attend this session if you want:
- > To learn how the synergy stent is being used in complex patient subsets
 - > To learn how durable and biobasorbable polymers and stent design impact both early and late healing
 - > To understand the current evidence when assessing ischaemic, bleeding and thrombotic risks for specific patient subsets

- 12:30
12:35
12:42
12:55
13:03
13:15
13:21
13:35
13:43
13:55
- > Session objectives - I. Meredith
 - > PCI in elderly patients: device and pharmacotherapy considerations in next generation DES - T. Cusset
 - > Discussion and audience interaction
 - > Early healing with Synergy in real-world patients
 - > Discussion and audience interaction
 - > Optimal revascularisation in multivessel disease and coronary CTO: the Belfast experience - S. Wirth
 - > Discussion and audience interaction
 - > Synergy in an all-comers population: the SWEET registry S. Cook
 - > Discussion and audience interaction
 - > Session evaluation and key learnings - K.G. Oldroyd

12:30-13:30 ■ Redefining bioabsorbable DES with MISTent: drug elution beyond polymer presence

ROOM 241
Symposium
With an unrestricted educational grant from STENTIS

Chairpersons: P.M. Serruys, W. Wijns

- Attend this session if you want:
- > To learn how persistence of drug elution after polymer absorption coupled with stent design impacts both early and late healing
 - > To understand how the novel MISTent design allows for drug elution to continue beyond polymer absorption
 - > To understand the current and future clinical studies examining the role of the MISTent coronary stent

- 12:30
12:35
12:42
12:49
12:52
13:03
13:09
13:21
13:26
- > Session objectives - P.M. Serruys
 - > Technical overview and design intent - J. Orniston
 - > Discussion and audience interaction
 - > Clinical programme overview: DESOLVE II and III W. Wijns
 - > Discussion and audience interaction
 - > Case study - C. Di Mario
 - > Discussion and audience interaction
 - > Session evaluation and key learnings - P.M. Serruys

12:30-14:00 ■ Renal denervation for uncontrolled hypertension using the Symplicity Sympyl System: a pivotal moment

ROOM 242A
Symposium
With an unrestricted educational grant from MEDTRONIC

Chairperson: F. Mohr
Co-chairperson: K. Hoch-Singh
Panelists: D. Kandzari, R. Schneider

- Attend this session if you want:
- > To understand new histological insights into the anatomical distribution of the renal nerves and how this information can be leveraged to maximise procedural safety and efficacy
 - > To realise the impact of variable and dynamic adherence to complex drug therapy regimens on clinical trial outcome and how trial design features such as drug adherence monitoring may minimise this confounding factor
 - > To appreciate the relationship between absolute pressure drop and cardiovascular risk reduction across the spectrum of comorbidities within the uncontrolled hypertensive population

- 12:30
12:35
12:42
12:55
13:03
13:09
13:20
13:30
- > Session objectives - F. Mohr
 - > Anatomical optimisation of renal denervation with Symplicity Sympyl: have we found the "sweet spot"? D. Kandzari
 - > Discussion and audience interaction
 - > Addressing the confounding effect of dynamic drug therapy adherence in clinical trial design - R. Schneider
 - > Discussion and audience interaction
 - > Understanding the optimal target population for renal denervation: how does blood pressure reduction translate to cardiovascular risk reduction?
 - > Discussion and audience interaction
 - > Session evaluation and key learnings - K. Hoch-Singh

12:30-13:30 ■ Prevention of atherothrombotic events: can we do better?

ROOM 251
Symposium
With an unrestricted educational grant from MSD

Co-Chairperson: J.P. Collet

- Attend this session if you want:
- > To discuss that patients with a history of myocardial infarction and/or peripheral artery disease are at high short- and long-term risk for atherothrombotic events despite standard therapy
 - > To educate on the multiple pathways involved in the activation of platelets
 - > To appreciate the PAF-1 pathway as a key platelet activation pathway that is critical for thrombosis

- 12:30
12:35
12:47
12:52
12:54
12:56
13:04
13:09
13:21
13:26
- > Session objectives
 - > Atherothrombotic disease: risk stratification in clinical practice
 - > Discussion and audience interaction
 - > PAF-1: a key platelet activation pathway - K. Huber
 - > Discussion and audience interaction
 - > Antiplatelet therapies: benefits beyond standard of care
 - > Discussion and audience interaction
 - > Session evaluation and key learnings

12:30-13:30 ■ Planned and ongoing clinical trials: a status update from Medialinum Cardiovascular Research (MCRI)

ROOM 352A
Innovation Hub
With the collaboration of Medialinum Cardiovascular Research (MCRI)

Chairpersons: A. Colombo, M.C.J. Jorl
Attend this session if you want:

- > To be updated on planned or ongoing clinical trials that may change our future practice
- > To gain in-depth understanding of trial design and execution
- > To learn about upcoming milestones for trial recruitment, analysis and presentation plan

- 12:30
12:35
12:42
12:45
12:52
12:55
13:02
13:05
13:12
13:15
13:22
13:26
- > Session objectives - M.C.J. Jorl
 - > PARTICIPATE: Prove Abtinal Reservoir Technology: clinical benefit in all-comers? PATIENTS: a multicentre, multinational trial in a large cohort of patients comparable to the everyday clinical practice with a specific focus on diabetic subjects - A. Colombo
 - > Discussion and audience interaction
 - > The ELDERLY ACS 2 study: a comparison of reduced-dose prasugrel and clopidogrel in elderly patients with ACS undergoing early PCI - S. Sonvito
 - > Discussion and audience interaction
 - > The LADIES ACS study: age at menopause and severity of coronary artery disease among post-menopausal women with ACS - S. Sonvito
 - > Discussion and audience interaction
 - > The Surgery After Stenting (SAS) registry: a multicentre registry of consecutive patients undergoing cardiac and non-cardiac surgery or operative endoscopic/endovascular procedures after implantation of a coronary stent - R. Kossini
 - > Discussion and audience interaction
 - > The DEB SFA-LONG study: safety and efficacy of the Drug Eluting Balloon for the treatment of the Superficial Femoral Artery ischaemic vascular disease in symptomatic patients presenting with long lesions: a pilot study A. Micot
 - > Discussion and audience interaction
 - > Session evaluation and key learnings - A. Colombo

12:30-14:00 ■ The optimal timing of initiation and duration of DAPT: recent findings and their impact on future patient care

ROOM 342AB
EBAC
Accreditation has been applied for
ASTRAZENCA

Chairperson: P.G. Steg

Co-Chairperson: R. Mehran

- Attend this session if you want:
- > To appreciate roles of DAPT in reducing ongoing cardiovascular disease risk and in-stent protection in patients with ACS
 - > To review the recent clinical data exploring the optimal time of initiation and duration of DAPT in patients with coronary artery disease undergoing PCI
 - > To explore how DAPT can be tailored to the patient to improve outcomes

- 12:30
12:40
12:50
12:59
13:09
13:20
13:30
13:35
- > Session objectives - P.G. Steg
 - > What is the optimal time for DAPT initiation: P2Y12 inhibitor administration in the ambulance, emergency room or cathlab? - M. Mackel
 - > Discussion and audience interaction
 - > What is the optimal DAPT duration for patients with coronary artery disease undergoing PCI? - M.P. Bonaca
 - > Discussion and audience interaction
 - > Tailoring DAPT to the benefit: risk profile of the patient (e.g. stable coronary artery disease versus ACS, type of ACS, management strategy, bleeding risk) - M. Vologin
 - > Discussion and audience interaction
 - > Session evaluation and key learnings - R. Mehran

12:30-13:30 ■ Polymer bioresorbable scaffolds: to routine practice in PCI

ROOM 351
Symposium
With an unrestricted educational grant from AIRT

Chairperson: S. Sano
Co-Chairperson: A. Lofort

- Attend this session if you want:
- > To improve your understanding of the relation between clinical basics and polymer fundamentals
 - > To assess the potential clinical benefits of new bioresorbable scaffolds
 - > To explore the future of bioresorbable scaffolds in routine PCI practice

- 12:30
12:35
12:42
12:47
12:55
13:01
13:11
13:16
- > Session objectives - S. Sano
 - > Polymer fundamentals related to PCI efficacy and safety M. Verj
 - > Pre-clinical bioresorbable scaffolds data - A. Lofort
 - > Bioresorbable scaffolds in clinical practice - J. Fogador
 - > Discussion and audience interaction
 - > Session evaluation and key learnings - A. Lofort

12:30-13:30 ■ United Kingdom and Ukraine share their most educational cases

ROOM 352A
Complications
With the collaboration of the Association of Interventional Cardiologists of Ukraine (UAIC) and the British Cardiovascular Intervention Society (BCIS)

Chairpersons: M. Curzen, M. Sotolov

- Attend this session if you want:
- > To understand the prompt recognition of potential left main complications
 - > To discuss various management strategies
 - > To share collective experience

- 12:30
12:35
12:42
12:47
12:55
13:01
13:11
13:16
13:22
13:26
13:30
13:35
13:42
13:46
13:54
13:56
13:59
14:06
14:12
14:16
14:22
14:26
14:30
14:35
14:42
14:46
14:52
14:56
15:02
15:06
15:12
15:16
15:22
15:26
15:30
15:35
15:42
15:46
15:52
15:56
16:02
16:06
16:12
16:16
16:22
16:26
16:30
16:35
16:42
16:46
16:52
16:56
17:02
17:06
17:12
17:16
17:22
17:26
17:30
17:35
17:42
17:46
17:52
17:56
18:02
18:06
18:12
18:16
18:22
18:26
18:30
18:35
18:42
18:46
18:52
18:56
19:02
19:06
19:12
19:16
19:22
19:26
19:30
19:35
19:42
19:46
19:52
19:56
20:02
20:06
20:12
20:16
20:22
20:26
20:30
20:35
20:42
20:46
20:52
20:56
21:02
21:06
21:12
21:16
21:22
21:26
21:30
21:35
21:42
21:46
21:52
21:56
22:02
22:06
22:12
22:16
22:22
22:26
22:30
22:35
22:42
22:46
22:52
22:56
23:02
23:06
23:12
23:16
23:22
23:26
23:30
23:35
23:42
23:46
23:52
23:56
24:02
24:06
24:12
24:16
24:22
24:26
24:30
24:35
24:42
24:46
24:52
24:56
25:02
25:06
25:12
25:16
25:22
25:26
25:30
25:35
25:42
25:46
25:52
25:56
26:02
26:06
26:12
26:16
26:22
26:26
26:30
26:35
26:42
26:46
26:52
26:56
27:02
27:06
27:12
27:16
27:22
27:26
27:30
27:35
27:42
27:46
27:52
27:56
28:02
28:06
28:12
28:16
28:22
28:26
28:30
28:35
28:42
28:46
28:52
28:56
29:02
29:06
29:12
29:16
29:22
29:26
29:30
29:35
29:42
29:46
29:52
29:56
30:02
30:06
30:12
30:16
30:22
30:26
30:30
30:35
30:42
30:46
30:52
30:56
31:02
31:06
31:12
31:16
31:22
31:26
31:30
31:35
31:42
31:46
31:52
31:56
32:02
32:06
32:12
32:16
32:22
32:26
32:30
32:35
32:42
32:46
32:52
32:56
33:02
33:06
33:12
33:16
33:22
33:26
33:30
33:35
33:42
33:46
33:52
33:56
34:02
34:06
34:12
34:16
34:22
34:26
34:30
34:35
34:42
34:46
34:52
34:56
35:02
35:06
35:12
35:16
35:22
35:26
35:30
35:35
35:42
35:46
35:52
35:56
36:02
36:06
36:12
36:16
36:22
36:26
36:30
36:35
36:42
36:46
36:52
36:56
37:02
37:06
37:12
37:16
37:22
37:26
37:30
37:35
37:42
37:46
37:52
37:56
38:02
38:06
38:12
38:16
38:22
38:26
38:30
38:35
38:42
38:46
38:52
38:56
39:02
39:06
39:12
39:16
39:22
39:26
39:30
39:35
39:42
39:46
39:52
39:56
40:02
40:06
40:12
40:16
40:22
40:26
40:30
40:35
40:42
40:46
40:52
40:56
41:02
41:06
41:12
41:16
41:22
41:26
41:30
41:35
41:42
41:46
41:52
41:56
42:02
42:06
42:12
42:16
42:22
42:26
42:30
42:35
42:42
42:46
42:52
42:56
43:02
43:06
43:12
43:16
43:22
43:26
43:30
43:35
43:42
43:46
43:52
43:56
44:02
44:06
44:12
44:16
44:22
44:26
44:30
44:35
44:42
44:46
44:52
44:56
45:02
45:06
45:12
45:16
45:22
45:26
45:30
45:35
45:42
45:46
45:52
45:56
46:02
46:06
46:12
46:16
46:22
46:26
46:30
46:35
46:42
46:46
46:52
46:56
47:02
47:06
47:12
47:16
47:22
47:26
47:30
47:35
47:42
47:46
47:52
47:56
48:02
48:06
48:12
48:16
48:22
48:26
48:30
48:35
48:42
48:46
48:52
48:56
49:02
49:06
49:12
49:16
49:22
49:26
49:30
49:35
49:42
49:46
49:52
49:56
50:02
50:06
50:12
50:16
50:22
50:26
50:30
50:35
50:42
50:46
50:52
50:56
51:02
51:06
51:12
51:16
51:22
51:26
51:30
51:35
51:42
51:46
51:52
51:56
52:02
52:06
52:12
52:16
52:22
52:26
52:30
52:35
52:42
52:46
52:52
52:56
53:02
53:06
53:12
53:16
53:22
53:26
53:30
53:35
53:42
53:46
53:52
53:56
54:02
54:06
54:12
54:16
54:22
54:26
54:30
54:35
54:42
54:46
54:52
54:56
55:02
55:06
55:12
55:16
55:22
55:26
55:30
55:35
55:42
55:46
55:52
55:56
56:02
56:06
56:12
56:16
56:22
56:26
56:30
56:35
56:42
56:46
56:52
56:56
57:02
57:06
57:12
57:16
57:22
57:26
57:30
57:35
57:42
57:46
57:52
57:56
58:02
58:06
58:12
58:16
58:22
58:26
58:30
58:35
58:42
58:46
58:52
58:56
59:02
59:06
59:12
59:16
59:22
59:26
59:30
59:35
59:42
59:46
59:52
59:56
60:02
60:06
60:12
60:16
60:22
60:26
60:30
60:35
60:42
60:46
60:52
60:56
61:02
61:06
61:12
61:16
61:22
61:26
61:30
61:35
61:42
61:46
61:52
61:56
62:02
62:06
62:12
62:16
62:22
62:26
62:30
62:35
62:42
62:46
62:52
62:56
63:02
63:06
63:12
63:16
63:22
63:26
63:30
63:35
63:42
63:46
63:52
63:56
64:02
64:06
64:12
64:16
64:22
64:26
64:30
64:35
64:42
64:46
64:52
64:56
65:02
65:06
65:12
65:16
65:22
65:26
65:30
65:35
65:42
65:46
65:52
65:56
66:02
66:06
66:12
66:16
66:22
66:26
66:30
66:35
66:42
66:46
66:52
66:56
67:02
67:06
67:12
67:16
67:22
67:26
67:30
67:35
67:42
67:46
67:52
67:56
68:02
68:06
68:12
68:16
68:22
68:26
68:30
68:35
68:42
68:46
68:52
68:56
69:02
69:06
69:12
69:16
69:22
69:26
69:30
69:35
69:42
69:46
69:52
69:56
70:02
70:06
70:12
70:16
70:22
70:26
70:30
70:35
70:42
70:46
70:52
70:56
71:02
71:06
71:12
71:16
71:22
71:26
71:30
71:35
71:42
71:46
71:52
71:56
72:02
72:06
72:12
72:16
72:22
72:26
72:30
72:35
72:42
72:46
72:52
72:56
73:02
73:06
73:12
73:16
73:22
73:26
73:30
73:35
73:42
73:46
73:52
73:56
74:02
74:06
74:12
74:16
74:22
74:26
74:30
74:35
74:42
74:46
74:52
74:56
75:02
75:06
75:12
75:16
75:22
75:26
75:30
75:35
75:42
75:46
75:52
75:56
76:02
76:06
76:12
76:16
76:22
76:26
76:30
76:35
76:42
76:46
76:52
76:56
77:02
77:06
77:12
77:16
77:22
77:26
77:30
77:35
77:42
77:46
77:52
77:56
78:02
78:06
78:12
78:16
78:22
78:26
78:30
78:35
78:42
78:46
78:52
78:56
79:02
79:06
79:12
79:16
79:22
79:26
79:30
79:35
79:42
79:46
79:52
79:56
80:02
80:06
80:12
80:16
80:22
80:26
80:30
80:35
80:42
80:46
80:52
80:56
81:02
81:06
81:12
81:16
81:22
81:26
81:30
81:35
81:42
81:46
81:52
81:56
82:02
82:06
82:12
82:16
82:22
82:26
82:30
82:35
82:42
82:46
82:52
82:56
83:02
83:06
83:12
83:16
83:22
83:26
83:30
83:35
83:42
83:46
83:52
83:56
84:02
84:06
84:12
84:16
84:22
84:26
84:30
84:35
84:42
84:46
84:52
84:56
85:02
85:06
85:12
85:16
85:22
85:26
85:30
85:35
85:42
85:46
85:52
85:56
86:02
86:06
86:12
86:16
86:22
86:26
86:30
86:35
86:42
86:46
86:52
86:56
87:02
87:06
87:12
87:16
87:22
87:26
87:30
87:35
87:42
87:46
87:52
87:56
88:02
88:06
88:12
88:16
88:22
88:26
88:30
88:35
88:42
88:46
88:52
88:56
89:02
89:06
89:12
89:16
89:22
89:26
89:30
89:35
89:42
89:46
89:52
89:56
90:02
90:06
90:12
90:16
90:22
90:26
90:30
90:35
90:42
90:46
90:52
90:56
91:02
91:06
91:12
91:16
91:22
91:26
91:30
91:35
91:42
91:46
91:52
91:56
92:02
92:06
92:12
92:16
92:22
92:26
92:30
92:35
92:42
92:46
92:52
92:56
93:02
93:06
93:12
93:16
93:22
93:26
93:30
93:35
93:42
93:46
93:52
93:56
94:02
94:06
94:12
94:16
94:22
94:26
94:30
94:35
94:42
94:46
94:52
94:56
95:02
95:06
95:12
95:16
95:22
95:26
95:30
95:35
95:42
95:46
95:52
95:56
96:02
96:06
96:12
96:16
96:22
96:26
96:30
96:35
96:42
96:46
96:52
96:56
97:02
97:06
97:12
97:16
97:22
97:26
97:30
97:35
97:42
97:46
97:52
97:56
98:02
98:06
98:12
98:16
98:22
98:26
98:30
98:35
98:42
98:46
98:52
98:56
99:02
99:06
99:12
99:16
99:22
99:26
99:30
99:35
99:42
99:46
99:52
99:56
100:02
100:06
100:12
100:16
100:22
100:26
100:30
100:35
100:42
100:46
100:52
100:56
101:02
101:06
101:12
101:16
101:22
101:26
101:30
101:35
101:42
101:46
101:52
101:56
102:02
102:06
102:12
102:16
102:22
102:26
102:30
102:35
102:42
102:46
102:52
102:56
103:02
103:06
103:12

12:30-13:30 ■ Hybrid transcatheter treatment of ischaemic heart failure: left ventricular volume reduction, Revent System and reshaping using the Enhancement (LIVE)

13:35-14:35 ■ TAVI: current and future perspectives for conjunctive pharmacological therapy with an unrestricted educational grant from BAYER HEALTHCARE PHARMACEUTICALS

14:40-16:40 ■ Complex cardiovascular interventions and new techniques: LIVE demonstrations from King Fahd Armed Forces Hospital - Jeddah, Saudi Arabia and from University Hospital Brno - Brno, Czech Republic

14:40-16:40 ■ Endovascular abdominal aortic aneurysm repair: fully percutaneous endografting and new devices

Chairperson: J. Bartunek
Co-Chairperson: C. Munereto

Attend this session if you want:

- > To learn about the indications, imaging requirements and implantation techniques for the LIVE procedure for ischaemic heart failure patients
- > To hear updated 2-year clinical outcomes for Revent surgical and Revent transcatheter patients
- > To understand the added benefit the LIVE procedure has on ischaemic mitral valve regurgitation

Attend this session if you want:

- > To understand TAVI patient population characteristics, approved devices and expected clinical outcomes
- > To evaluate current and future antithrombotic therapy options around TAVI
- > To understand future perspectives and upcoming studies

14:40-16:40 ■ Appropriate use of coronary CTO interventions in 2015

14:40-16:40 ■ Transcatheter mitral valve replacement: new valves and experiences

Chairperson: J. Bartunek
Co-Chairperson: C. Munereto

Attend this session if you want:

- > To learn about the indications, imaging requirements and implantation techniques for the LIVE procedure for ischaemic heart failure patients
- > To hear updated 2-year clinical outcomes for Revent surgical and Revent transcatheter patients
- > To understand the added benefit the LIVE procedure has on ischaemic mitral valve regurgitation

Attend this session if you want:

- > To understand TAVI patient population characteristics, approved devices and expected clinical outcomes
- > To evaluate current and future antithrombotic therapy options around TAVI
- > To understand future perspectives and upcoming studies

Chairperson: G. Werner
Panellists: A. Senio

Attend this session if you want:

- > To reflect on the potential clinical benefit of CTO interventions
- > To learn practical tips and tricks for optimal CTO treatment

Chairperson: Z. Kogler
Co-Chairperson: C. Seacat
Panellists: M. Bosters, A. Grommes, Y. Gourelle

Attend this session if you want:

- > To discuss the selection of appropriate candidates for percutaneous endovascular aneurysm repair
- > To become familiar with low-profile endografts
- > To learn a comprehensive step-by-step approach

Chairperson: J. Bartunek
Co-Chairperson: C. Munereto

Attend this session if you want:

- > To learn about the indications, imaging requirements and implantation techniques for the LIVE procedure for ischaemic heart failure patients
- > To hear updated 2-year clinical outcomes for Revent surgical and Revent transcatheter patients
- > To understand the added benefit the LIVE procedure has on ischaemic mitral valve regurgitation

Attend this session if you want:

- > To understand TAVI patient population characteristics, approved devices and expected clinical outcomes
- > To evaluate current and future antithrombotic therapy options around TAVI
- > To understand future perspectives and upcoming studies

Chairperson: J. Strange
Co-Chairperson: N. Moot
Panellists: F. Bostel

Attend this session if you want:

- > To learn how to define intermediate risk in TAVI patients
- > To review the available evidence
- > To understand the current limitations of TAVI in this patient group

Chairperson: S. Winderet
Co-Chairperson: C. Ruiz

Attend this session if you want:

- > To review the latest data on new catheter-based mitral valves
- > To understand the current investigational status of novel mitral valves
- > To recognise the first-in-human clinical experiences and impending trials

Chairperson: R. Byrne
Co-Chairperson: M. Wolstein

Attend this session if you want:

- > To better understand the concept of drug-coated balloons and how it works
- > To learn practical tips for using drug-coated balloons

Attend this session if you want:

- > To discuss the risk of sudden cardiac death in the low ejection fraction, acute myocardial infarction patient undergoing PCI/percutaneous transluminal coronary angioplasty, including clinical evidence
- > To discuss the role of interventional cardiologists to screen patients for sudden cardiac death risk and establishing an appropriate care path, including optimal medical therapy and consideration of wearable cardioverter defibrillators, while long-term sudden cardiac death risk is determined

Chairperson: J. Hauke
Co-Chairperson: N. Moot
Panellists: F. Bostel

Attend this session if you want:

- > To learn how to define intermediate risk in TAVI patients
- > To review the available evidence
- > To understand the current limitations of TAVI in this patient group

Chairperson: S. Winderet
Co-Chairperson: C. Ruiz

Attend this session if you want:

- > To review the latest data on new catheter-based mitral valves
- > To understand the current investigational status of novel mitral valves
- > To recognise the first-in-human clinical experiences and impending trials

Chairperson: R. Byrne
Co-Chairperson: M. Wolstein

Attend this session if you want:

- > To better understand the concept of drug-coated balloons and how it works
- > To learn practical tips for using drug-coated balloons

Attend this session if you want:

- > To discuss the risk of sudden cardiac death in the low ejection fraction, acute myocardial infarction patient undergoing PCI/percutaneous transluminal coronary angioplasty, including clinical evidence
- > To discuss the role of interventional cardiologists to screen patients for sudden cardiac death risk and establishing an appropriate care path, including optimal medical therapy and consideration of wearable cardioverter defibrillators, while long-term sudden cardiac death risk is determined

Chairperson: J. Hauke
Co-Chairperson: N. Moot
Panellists: F. Bostel

Attend this session if you want:

- > To learn how to define intermediate risk in TAVI patients
- > To review the available evidence
- > To understand the current limitations of TAVI in this patient group

Chairperson: S. Winderet
Co-Chairperson: C. Ruiz

Attend this session if you want:

- > To review the latest data on new catheter-based mitral valves
- > To understand the current investigational status of novel mitral valves
- > To recognise the first-in-human clinical experiences and impending trials

- 13:00 -

13:55-14:35 ■ Real-life scenario where a drug-coated balloon could help you in daily practice

13:55-14:35 ■ The PCI was successful - But, now what?

Chairperson: R. Byrne
Co-Chairperson: M. Wolstein

Attend this session if you want:

- > To better understand the concept of drug-coated balloons and how it works
- > To learn practical tips for using drug-coated balloons

Attend this session if you want:

- > To discuss the risk of sudden cardiac death in the low ejection fraction, acute myocardial infarction patient undergoing PCI/percutaneous transluminal coronary angioplasty, including clinical evidence
- > To discuss the role of interventional cardiologists to screen patients for sudden cardiac death risk and establishing an appropriate care path, including optimal medical therapy and consideration of wearable cardioverter defibrillators, while long-term sudden cardiac death risk is determined

Chairperson: J. Hauke
Co-Chairperson: N. Moot
Panellists: F. Bostel

Attend this session if you want:

- > To learn how to define intermediate risk in TAVI patients
- > To review the available evidence
- > To understand the current limitations of TAVI in this patient group

Chairperson: S. Winderet
Co-Chairperson: C. Ruiz

Attend this session if you want:

- > To review the latest data on new catheter-based mitral valves
- > To understand the current investigational status of novel mitral valves
- > To recognise the first-in-human clinical experiences and impending trials

Chairperson: R. Byrne
Co-Chairperson: M. Wolstein

Attend this session if you want:

- > To better understand the concept of drug-coated balloons and how it works
- > To learn practical tips for using drug-coated balloons

Attend this session if you want:

- > To discuss the risk of sudden cardiac death in the low ejection fraction, acute myocardial infarction patient undergoing PCI/percutaneous transluminal coronary angioplasty, including clinical evidence
- > To discuss the role of interventional cardiologists to screen patients for sudden cardiac death risk and establishing an appropriate care path, including optimal medical therapy and consideration of wearable cardioverter defibrillators, while long-term sudden cardiac death risk is determined

Chairperson: J. Hauke
Co-Chairperson: N. Moot
Panellists: F. Bostel

Attend this session if you want:

- > To learn how to define intermediate risk in TAVI patients
- > To review the available evidence
- > To understand the current limitations of TAVI in this patient group

Chairperson: S. Winderet
Co-Chairperson: C. Ruiz

Attend this session if you want:

- > To review the latest data on new catheter-based mitral valves
- > To understand the current investigational status of novel mitral valves
- > To recognise the first-in-human clinical experiences and impending trials

Chairperson: R. Byrne
Co-Chairperson: M. Wolstein

Attend this session if you want:

- > To better understand the concept of drug-coated balloons and how it works
- > To learn practical tips for using drug-coated balloons

Attend this session if you want:

- > To discuss the risk of sudden cardiac death in the low ejection fraction, acute myocardial infarction patient undergoing PCI/percutaneous transluminal coronary angioplasty, including clinical evidence
- > To discuss the role of interventional cardiologists to screen patients for sudden cardiac death risk and establishing an appropriate care path, including optimal medical therapy and consideration of wearable cardioverter defibrillators, while long-term sudden cardiac death risk is determined

Chairperson: J. Hauke
Co-Chairperson: N. Moot
Panellists: F. Bostel

Attend this session if you want:

- > To learn how to define intermediate risk in TAVI patients
- > To review the available evidence
- > To understand the current limitations of TAVI in this patient group

Chairperson: S. Winderet
Co-Chairperson: C. Ruiz

Attend this session if you want:

- > To review the latest data on new catheter-based mitral valves
- > To understand the current investigational status of novel mitral valves
- > To recognise the first-in-human clinical experiences and impending trials

Chairperson: R. Byrne
Co-Chairperson: M. Wolstein

Attend this session if you want:

- > To better understand the concept of drug-coated balloons and how it works
- > To learn practical tips for using drug-coated balloons

Attend this session if you want:

- > To discuss the risk of sudden cardiac death in the low ejection fraction, acute myocardial infarction patient undergoing PCI/percutaneous transluminal coronary angioplasty, including clinical evidence
- > To discuss the role of interventional cardiologists to screen patients for sudden cardiac death risk and establishing an appropriate care path, including optimal medical therapy and consideration of wearable cardioverter defibrillators, while long-term sudden cardiac death risk is determined

Chairperson: J. Hauke
Co-Chairperson: N. Moot
Panellists: F. Bostel

Attend this session if you want:

- > To learn how to define intermediate risk in TAVI patients
- > To review the available evidence
- > To understand the current limitations of TAVI in this patient group

Chairperson: S. Winderet
Co-Chairperson: C. Ruiz

Attend this session if you want:

- > To review the latest data on new catheter-based mitral valves
- > To understand the current investigational status of novel mitral valves
- > To recognise the first-in-human clinical experiences and impending trials

Chairperson: R. Byrne
Co-Chairperson: M. Wolstein

Attend this session if you want:

- > To better understand the concept of drug-coated balloons and how it works
- > To learn practical tips for using drug-coated balloons

Attend this session if you want:

- > To discuss the risk of sudden cardiac death in the low ejection fraction, acute myocardial infarction patient undergoing PCI/percutaneous transluminal coronary angioplasty, including clinical evidence
- > To discuss the role of interventional cardiologists to screen patients for sudden cardiac death risk and establishing an appropriate care path, including optimal medical therapy and consideration of wearable cardioverter defibrillators, while long-term sudden cardiac death risk is determined

Chairperson: J. Hauke
Co-Chairperson: N. Moot
Panellists: F. Bostel

Attend this session if you want:

- > To learn how to define intermediate risk in TAVI patients
- > To review the available evidence
- > To understand the current limitations of TAVI in this patient group

Chairperson: S. Winderet
Co-Chairperson: C. Ruiz

Attend this session if you want:

- > To review the latest data on new catheter-based mitral valves
- > To understand the current investigational status of novel mitral valves
- > To recognise the first-in-human clinical experiences and impending trials

4:40-16:40 ■ Interventional hypertension treatment - Moving forward

ROOM 3428
CCC - RDN

With the collaboration of the Clinical Consensus Conference on Renal Denervation (CCC-RDN)

Attend this session if you want:

- > To exchange on the appropriate scientific evaluation of renal denervation in hypertensive patients
- > To be updated on the design of new clinical studies that will be launched soon
- > To discuss the current unmet needs in the field

- 14:40 > Session objectives
- 14:43 > Renal denervation in 2015: where do we stand?
- 14:53 > Discussion and audience interaction

New from the Clinical Consensus Conference on Renal Denervation (CCC-RDN)

- 14:56 > Considerations and consensus on treatment recommendations
- 15:08 > Discussion and audience interaction
- 15:13 > Considerations and consensus on patient population
- 15:23 > Discussion and audience interaction
- 15:28 > Considerations and consensus on methodology and clinical endpoints

Update on clinical trial programmes

- 15:38 > Medicron's trial programme
- 15:43 > Discussion and audience interaction
- 15:48 > St. Jude's trial programme
- 15:53 > Discussion and audience interaction
- 15:58 > Boston Scientific's trial programme
- 16:03 > Discussion and audience interaction
- 16:08 > Recor's trial programme
- 16:13 > Discussion and audience interaction
- 16:18 > Korak's trial programme
- 16:23 > Discussion and audience interaction
- 16:28 > Rok trial programme
- 16:33 > Discussion and audience interaction
- 16:38 > Session evaluation and key learnings

4:40-16:40 ■ Learning how to manage cathlab complications

ROOM 351
Panelist: *M. Oberhoff*

Attend this session if you want:

- > To be able to reduce patient complications by pre-procedural patient checks
- > To develop your skills in recognition and management of complications
- > To develop confidence to take action during a patient-related emergency in the cathlab

14:40-15:40 ■ Planned and ongoing clinical trials: a status update from the Cardiovascular European Research Center (ERC)

ROOM 352A
Innovation Hub

With the collaboration of the Cardiovascular European Research Center (ERC)

Chairpersons: *M.C. Morice, P. Smits*

Attend this session if you want:

- > To be updated on planned or ongoing clinical trials that may change our future practice
- > To gain in-depth understanding of trial design and execution
- > To learn about upcoming milestones for trial recruitment, analysis and presentation plan

- 14:40 > Session objectives - *P. Smits*
- 14:45 > SENIOR (very short DAPT after Synergy stent in elderly patients) - *O. Joverne*
- 14:52 > Discussion and audience interaction
- 14:55 > ILLUMINA (Nides stent, a stentless auto-expandable stent in superficial femoral artery and popliteal arteries)

- 15:02 > Discussion and audience interaction
- 15:07 > BIVAL (bore bivalvudin reduce the size of myocardial infarction assessed by magnetic resonance imaging)
- 15:12 > J. Gao*
- 15:15 > Discussion and audience interaction
- 15:17 > VIVA (Coronary in valve) - *D. Tschiché*
- 15:22 > Discussion and audience interaction

- 15:25 > COMPARTE ABSORB (BVS versus Xience in complex lesions and patients subsets) - *P. Smits*
- 15:32 > Discussion and audience interaction
- 15:35 > Session evaluation and key learnings - *M.C. Morice*

14:40-15:40 ■ All you need to know about metallic DES technology and clinical results

ROOM 351
Chairperson: *R. Byrne*
Co-chairperson: *T. Fligman*
Panelist: *M. Byrne*

Attend this session if you want:

- > To review a comprehensive and clinically relevant update on this field
- > To identify the current evidence base and existing guidelines
- > To recognise the open questions that need addressing in the near future

- 14:40 > Session objectives - *T. Fligman*
- 14:45 > Background: stents, polymers and drugs - *M. Joner*
- 14:55 > Clinical data - *T. Fligman*
- 15:05 > Clinical guidelines and market approval: what it needs to bring a new stent to the cathlab - *R. Byrne*
- 15:15 > Outlook: technology pipeline - *G.G. Stefanini*
- 15:25 > Questions and answers
- 15:35 > Session evaluation and key learnings - *R. Byrne*

14:40-15:40 ■ Overcoming radiation burden in complex PCI: it's time to protect ourselves

ROOM 352A

With the collaboration of the EAPCI Women Committee

Chairperson: *P. Ludman*

Co-chairperson: *A. Roguin*

Panelist: *F. Mauri*

Attend this session if you want:

- > To know more about the risk of radiation exposure
- > To learn how to reduce radiation exposure at work
- 14:40 > Session objectives - *A. Roguin*
- 14:44 > Occupational risks of chronic low-dose radiation exposure in the cathlab - *E. Piccolupo*
- 14:51 > Discussion and audience interaction
- 15:01 > Radiation burden and results of the WOMEN-EAPCI survey
- 15:06 > Discussion and audience interaction
- 15:16 > New measures to increase protection during complex procedures
- 15:25 > Discussion and audience interaction
- 15:35 > Session evaluation and key learnings - *P. Ludman*

14:40-16:40 ■ Belgium, Luxembourg and the Netherlands share their most educational cases

ROOM 352B
How should I treat?

With the collaboration of the Belgian Working Group on Interventional Cardiology of the Belgian Society of Cardiology (BWSIC), the Luxembourg Society of Cardiology (SLC) and the Working Group on Interventional Cardiology of the Dutch Society of Cardiology (WIC)

Chairpersons: *J. Beetsel, W. Denier, R. Van Der Schoof*

Attend this session if you want:

- > To understand the problems of imaging bioresorbable scaffolds stenting during and after PCI of CTO
- > To learn about the utilisation of OCT imaging to identify culprit lesion
- > To share our experience in bioresorbable scaffolds stenting and coronary imaging

- 14:40 > Session objectives - *W. Denier*
- 14:44 > Case 1 - OCT in search of the culprit lesion - *N. Hiltrop*
- 14:49 > How would I treat? - *O. Gach*
- 14:54 > How would I treat? - *N. Hiltrop*
- 14:59 > How did I treat? - *N. Hiltrop*
- 15:03 > Discussion and audience interaction
- 15:16 > Consensus - *W. Denier, R. Van Der Schoof*
- 15:20 > Case 2 - Bioresorbable scaffolds in CTO - *B. Pereira*
- 15:25 > How would I treat? - *O. Gach*
- 15:30 > How would I treat? - *D. Wagner*
- 15:35 > How did I treat? - *B. Pereira*
- 15:42 > Discussion and audience interaction
- 15:46 > Consensus - *J. Beetsel, W. Denier*
- 15:56 > Case 3 - A case of a complex primary PCI
- 16:01 > How would I treat? - *D. Wagner*
- 16:06 > How did I treat? - *J.J. Flek*
- 16:11 > How would I treat? - *J.J. Flek*
- 16:16 > Discussion and audience interaction
- 16:21 > Consensus - *J. Beetsel, R. Van Der Schoof*
- 16:26 > Session evaluation and key learnings - *J. Beetsel, R. Van Der Schoof*

14:40-16:40 ■ Learning left main PCI

ROOM 351
Panelist: *T. Majumdar*

Attend this session if you want:

- > To understand the specific of left main PCI
- > To review the role of periprocedural imaging
- > To share tips and tricks to improve your technical skills

- 15:00 -

15:45-16:45 ■ Planned and ongoing clinical trials: a status update from Cardiovascular Imaging Core Laboratories

ROOM 352A
Innovation Hub

With the collaboration of Cardiovascular Imaging Core Laboratories

Attend this session if you want:

- > To be updated on planned or ongoing clinical trials that may change our future practice
- > To gain in-depth understanding of trial design and execution
- > To learn about upcoming milestones for trial recruitment, analysis and presentation plan

15:45-16:45 ■ All you need to know about patent foramen ovale

ROOM 351
Chairperson: *P. Meier*
Co-chairperson: *P. Prebiero*
Panelist: *M. Meier*

Attend this session if you want:

- > To review a comprehensive and clinically relevant update on this field
- > To identify the current evidence base and existing guidelines
- > To recognise the open questions that need addressing in the near future

- 15:45 > Session objectives - *P. Prebiero*
- 15:50 > Background and clinical data - *P. Meier*
- 15:55 > Technical aspects - *D. Hillock-Smith*
- 16:00 > Guidelines and recommendations - *E. Eckhout*
- 16:05 > Unresolved issues - *P. Prebiero*
- 16:10 > Questions and answers
- 16:20 > Session evaluation and key learnings - *P. Meier*
- 16:40

15:45-16:45 ■ Jordan and Saudi Arabia share their most educational cases

ROOM 352A
Chairpersons

With the collaboration of the Jordan Group on Interventional Cardiology (JSGC) and the Saudi Arabian Cardiac Interventional Society of the Saudi Heart Association (SASIS)

Chairpersons: *I. Alhabdada, K. Al Faradi*

Attend this session if you want:

- > To understand potential challenges and complications of PCI of complex bifurcational lesion
- > To learn different strategies in solving serious complications
- > To share your knowledge and experience during interactive discussions

- 15:45 > Session objectives - *I. Alhabdada*
- 15:47 > Case 1 - My stent is stuck and the stent broke! - *M. Almarog*
- 15:52 > Discussion and audience interaction
- 16:01 > Case 2 - Unplanned bifurcation culprit technique: not an enjoyable experience - *H. Abu Hamrah*
- 16:07 > Discussion and audience interaction
- 16:15 > Case 3 - Multiple bifurcation left anterior descending artery treated with PCI: is this the right decision and right technique? - *M. Al Syehri*
- 16:21 > Discussion and audience interaction
- 16:27 > Case 4 - Facing the reality of stent thrombosis after bifurcations PCI: what to do - *M. Albolki*
- 16:35 > Discussion and audience interaction
- 16:43 > Session evaluation and key learnings - *K. Al Faradi*

- 16:00 -

6:50-18:20 ■ **Bleeding versus stent thrombosis: can short DAPT be safe in complex lesions?**
HEARTS BLEU
Sabbir Techniques
 (117)

INTERVENTIONAL
Chairperson: P. Urban
Co-chairperson: A. Abizaid
Panelists: D. Tresaked
 Attend this session if you want:
 > To discuss changes in DAPT guidelines and their application in daily practice
 > To identify the patient populations that suffer from bleeding complications and cannot tolerate DAPT duration according to guidelines
 > To understand how selection of a polymer-free stent can support optimising treatment of patients

16:56 > Session objectives - A. Abizaid
 16:55 > Evidence of DAPT duration with stents is inconclusive
 17:01 *A. Iniguez-Romo*
 LIVE demonstration from Conilla Heart and Vascular Center - Essen, Germany
 17:46 > Time to React@PCR
 18:02 > Are polymer-free drug-coated stents the solution for short DAPT? - T. Kinnaird
 18:07 > Clinical evidence on the horizon - G. Sardella
 18:15 > Session evaluation and key learnings - P. Urban

6:50-18:20 ■ **How to start treating coronary CTO using the J-CTO score?**
THEATRE
BOMBEAUX
Sabbir Techniques
 (117)

Chairperson: G. Werner
Co-chairperson: M. Yamane
 Attend this session if you want:
 > To start basic coronary CTO treatment
 > To learn about the J-CTO score
 > To broaden your knowledge of coronary CTO treatment techniques

16:50 > Session objectives - G. Werner
 16:55 > How to choose the right case - R. Garbo
 17:02 > Smart device selection - A. Gdali
 17:09 > Realistic benefits with J-CTO score - J. Ders
 17:16 > Session evaluation and key learnings - M. Yamane

16:50-18:20 ■ **How could fully bioresorbable vascular scaffolds improve PCI outcomes?**
THEATRE
HAWAII
Symposium

With an unrestricted educational grant from ABBOTT VASCULAR
Chairperson: P.W. Serruys
Panelists: J. Escaned, G.W. Stone, N.E.J. West
 Attend this session if you want:
 > To understand how PCI results could be further improved with fully bioresorbable vascular scaffolds
 > To learn more about all possible additional benefits of bioresorbable vascular scaffolds
 > To obtain a better understanding on the frequency of post-PCI angina and how fully bioresorbable vascular scaffolds could further decrease it

16:50 > Session objectives - T.F. Lüscher
 16:55 > The inner clinical need in PCI - G.W. Stone
 17:07 > Time to React@CR
 17:15 > The additional benefits of fully bioresorbable vascular scaffolds - An overview - P.W. Serruys
 17:27 > Time to React@CR
 17:35 > Post-PCI angina overview on the available data
 17:47 *J. Escaned*
 > Time to React@PCR
 17:55 > Could bioresorbable vascular scaffolds lead to a reduction in ischaemia post PCI: an hypothesis - N.E.J. West
 18:07 > Time to React@PCR
 18:15 > Session evaluation and key learnings - P.W. Serruys

16:50-17:50 ■ **The Lotus valve: advancing treatment options for patients with challenging anatomies**
ROOM
MALLOT
Care-in-point

With an unrestricted educational grant from BOSTON SCIENTIFIC
Chairperson: T. Feldman
Co-chairpersons: R. Lange, J. Meredith
Panelists: V. Bapat, U. Gerckens, M. Göbbel
 Attend this session if you want:
 > To recognize key features and procedural aspects of the Lotus valve
 > To learn how paravalvular leak can be minimised despite anatomical complexities
 > To understand the current evidence and latest available clinical data

16:50 > Session objectives - T. Feldman
 16:55 > Horizontal aorta - U. Gerckens
 17:02 > Discussion and audience interaction
 17:12 > Calcified annulus - M. Göbbel
 17:19 > Discussion and audience interaction
 17:27 > An alternative option for a patient without peripheral access - The direct aortic approach - V. Bapat
 17:36 > Discussion and audience interaction
 17:46 > Session evaluation and key learnings - J. Meredith

16:50-18:20 ■ **The role of prasugrel in the treatment of ACS-PCI patients**
ROOM
241
Symposium

With an unrestricted educational grant from DAIICHI SANKYO and ELI LILLY
Chairperson: J.W. Jukema
Co-chairperson: G. Montalescot
 Attend this session if you want:
 > To learn about the challenges and solutions for the optimal treatment for ACS patients undergoing PCI
 > To learn about protocol implementation, therapeutic and strategic options
 > To learn about the latest real-world evidence in ACS-PCI

16:50 > Session objectives - J.W. Jukema
 17:00 Evidence-based medicine in STEMi guidelines and implications - G. DeLuca
 17:15 > Case presentation - STEMi - A. Zamari
 17:20 Discussion and audience interaction
 17:27 > New evidence: how to decide on treatment strategy in NSTEMI-ACS - G. Montalescot
 17:32 > Case presentation - NSTEMI-ACS - H. Alker
 17:47 > Discussion and audience interaction
 18:15 > Session evaluation and key learnings - G. Montalescot

16:50-18:20 ■ **The Direct Flow TAVI system - Experiences from the real world**
ROOM
242AB
Symposium

With an unrestricted educational grant from DIRECT FLOW MEDICAL
Chairperson: D. Tchélicé
Co-chairperson: M. Tuzcu
 Attend this session if you want:
 > To learn how the Direct Flow Medical valve can improve patient outcomes
 > To understand the key learnings from the real-world experience with Direct Flow Medical
 > To review the newest clinical and technological developments

16:50 > Session objectives - M. Tuzcu
 16:55 > TAVI today - Are we missing anything?
 17:05 Discussion and audience interaction
 17:10 > Left ventricular outflow tract calcification - J. Scholer
 17:17 > Discussion and audience interaction
 17:25 > The Berlin experience - H. Ince
 17:32 > Discussion and audience interaction
 17:40 > Initial experience, contrast-free - M. Glaid
 17:47 > Discussion and audience interaction
 17:55 > On a surgeon's hands - H. Büning
 18:02 > Discussion and audience interaction
 18:10 > Clinical and technology outlook - A. Labib
 18:15 > Session evaluation and key learnings - D. Tchélicé

16:50-17:50 ■ **Practical approach to left main PCI: new stent technology for an old problem**
ROOM
342AB
Care-in-point

With an unrestricted educational grant from MEDTRONIC
Chairperson: D. Hildick-Smith
Co-chairperson: H.C. Gwon
 Attend this session if you want:
 > To learn what the treatment alternatives are for patients with these challenging lesions
 > To learn on relevance of conventional PCI bifurcation technique applied to left main bifurcations
 > To discuss the potential relevance of new stent technology for left main stenting

16:50 > Session objectives - H.C. Gwon
 16:55 > Treatment options for left main disease - A. Mitrino-Royne
 17:02 > Discussion and audience interaction
 17:12 > Distal left main bifurcation disease: complex lesions when two stents are required - A. Labib
 17:19 > Discussion and audience interaction
 17:20 > Distal left main bifurcation disease: complex lesions when the choice is not obvious - G. Stanekovic
 17:26 > Discussion and audience interaction
 17:46 > Session evaluation and key learnings - D. Hildick-Smith

16:50-18:20 ■ **Counterpulsation therapy - Should we continue to use IT?**
ROOM
351
Care-in-point

With an unrestricted educational grant from MAQUET Cardiovascular GENICE GROUP
Chairperson: S. Redwood
Co-chairperson: G. Leurent
 Attend this session if you want:
 > To understand the science of mechanical support in the complex coronary patient
 > To identify which patients are responders to intra-aortic balloon counterpulsation therapy
 > To discuss real-world experience and outcomes in treating complex PCI procedures

16:50 > Session objectives - G. Leurent
 16:55 > Intra-aortic balloon counterpulsation effect with exhausted autoregulation - D. Perrot
 17:03 > Discussion and audience interaction
 17:15 > Larger volume intra-aortic balloon counterpulsation effect on left ventricular unloading - M. Cohen
 17:23 > Discussion and audience interaction
 17:35 > Intra-aortic balloon counterpulsation in the multivessel complex coronary patient - A. Colombo
 17:43 > Discussion and audience interaction
 17:55 > Intra-aortic balloon counterpulsation in patients with persistent tachycardia - M.H. Pijls
 18:03 > Discussion and audience interaction
 18:15 > Session evaluation and key learnings - S. Redwood

6:50-18:20 ■ Germany and Scotland share their most educational cases
ROOM 352A
We should treat?

With the collaboration of the Scottish Cardiac Society (SCS) and the Working Group on Cardiovascular Interventions of the German Society of Cardiology (DGCI)

Chairpersons: H. Eteiba, H. Thiele

Attend this session if you want:

- > To share treatment option of a no-reflow for PCI for anterior STEMI
- > To learn prioritising management steps/strategy of haemodynamically compromised patient
- > To reflect on contemporary literature and practical tips and tricks to complete revascularisation in primary PCI

16:50 > Session objectives - H. Eteiba
16:55 > Case 1 - Management of a no-reflow for PCI with no STEMI T. Schuetz

17:00 > How would I treat? - N. Caden

17:05 > How would I treat? - H. Modlmann

17:10 > How did I treat? - T. Schuetz

17:20 > Discussion and audience interaction

17:30 > Consensus - H. Eteiba

17:35 > Case 2 - 56-year-old male patient, 5 days post-myocardial infarction, severe mitral regurgitation, severe aortic valve replacement - M. Lindqvist

17:40 > How would I treat? - H. Modlmann

17:45 > How would I treat? - N. Caden

17:50 > How did I treat? - M. Lindqvist

18:00 > Discussion and audience interaction

18:10 > Consensus - H. Thiele

18:15 > Session evaluation and key learnings - H. Thiele

16:50-18:20 ■ Learning primary PCI for STEMI

ROOM 352A
Facilitators: M. Belton, G. Coyla

LEARNING
Attend this session if you want:

- > To discuss the best management of both culprit and non-culprit vessels
- > To review pros and cons of using different stents for primary PCI
- > To share ways to prevent and treat common complications in this setting

16:50-18:20 ■ Will this trial change my practice? DAPT trial: 30 months of DAPT after implantation of DES
ROOM 352B
Chairperson: T. Cuisset
Co-Chairperson: J.F. Tangiay

TECHNICAL

16:50 > Introduction: the trial headlines - T. Cuisset

16:55 > A case: how should I treat? - A. Baumgartner

17:00 > Discussion: what is common practice?

17:15 > What was known before: evidence before DAPT

17:25 > Trialist's review: methods, results, conclusion - A. Lenky

17:40 > Discussion and audience interaction

18:00 > Case conclusion: how does this apply to my practice A. Baumgartner

18:10 > Outlook: more evidence on the horizon? - T. Cuisset

18:15 > Session evaluation and key learnings - J.F. Tangiay

6:50-18:20 ■ Left main coronary artery disease and ST-elevation myocardial infarction: a complex challenging situation

With the collaboration of the Groupe de Hélixion sur l'Cardiologie Interventionnelle (GRCI)

Chairpersons: P. Aubry, J. Montégny

Panelists: J.F. Collet, A. Py

Attend this session if you want:

- > To underline the difficulties in STEMI presenters with left main coronary artery disease
- > To define the place of PCI cardiac assist device and coronary artery bypass surgery
- > To share tips and tricks for left main PCI

16:50 > EuroPCR welcomes GRCI - E. Fechetour

16:55 > Session objectives - P. Aubry

16:55 > Are there specific features of STEMI with left main coronary artery disease? - M. Godin

17:00 > Discussion and audience interaction

17:15 > How to optimise PCI technique when left main coronary artery lesion is the culprit?

17:20 > Discussion and audience interaction

17:25 > When should you call the surgeon?

17:30 > Discussion and audience interaction

17:35 > How to manage left main coronary artery lesion when non-culprit?


17:40 > Discussion and audience interaction

17:45 > Session evaluation and key learnings - J. Montégny

18:15 > Session evaluation and key learnings - J. Montégny

europcr

Scientific programme
Thursday 21st May, 2015



Valid as of 19th March, 2015
Only Faculty who confirmed their attendance are listed in this programme.
For real-time updates, please consult the interactive programme.



- 08:00 -

8:15-12:00 ■ Complex cardiovascular interventions and new techniques: LIVE demonstrations from Bern

University: HEP, Bern, Switzerland;
from Clinique Pasteur - Toulouse, France;
and from Nanjing First Hospital, Nanjing Medical University - Nanjing, China

8:15-10:15 ■ China@EuroPCR - How to successfully perform PCI for complex left main stenosis?

With the collaboration of China Interventional Therapeutics (CIT) and the left Main & Coronary Bifurcation Summit (CBS)

Chairperson: R. Gao

Co-chairpersons: M.C. Morice, B. Xu

Panelists: J. Serrano, G. Stanekovic, Y. Yang

Attend this session if you want:
> To learn how to select patients and lesions for PCI in left main stenosis
> To learn practical tips and tricks for optimal left main stenosis treatment

08:15 ■ EuroPCR welcomes China - M.C. Morice

08:17 ■ Session objectives - R. Gao

08:20 ■ Key tips and tricks for optimal left main PCI - G. Stanekovic

08:30 ■ Time to React@PCR

Medical University - Nanjing, China

08:35 ■ Long-term follow-up after left main PCI - B. Xu

08:55 ■ Time to React@PCR

> Session evaluation and key learnings - M.C. Morice

8:15-10:15 ■ Is paravalvular aortic regurgitation a problem of the past?

Chairperson: A. Chibier

Panelists: M. M. Abdullah

Attend this session if you want:

> To learn the state-of-the-art 3D imaging for annulus sizing
> To understand how new device design reduces aortic regurgitation
> To appreciate the impact of post-TAVI paravalvular aortic regurgitation

08:15 ■ Session objectives - A. Chibier

08:18 ■ Prognostic impact of aortic regurgitation - The latest data of the impact of aortic regurgitation on survival - T. Lefèvre

08:28 ■ Time to React@PCR

LVE demonstration from Clinique Pasteur - Toulouse, France

08:35 ■ Time to React@PCR

> It's all about stenting - 3D imaging to select the right

08:40 ■ Prostheses - M. Piazza

08:48 ■ Time to React@PCR

> Have the new devices lived up to their expectations?

08:55 ■ U. Gerckens

> Time to React@PCR

> Session evaluation and key learnings

08:15-10:15 ■ Changing paradigms and future concepts in carotid artery stenting

Chairperson: A. Cammeri

Co-chairperson: O. Göktelek

Panelists: N. Hopkins, P. Montori, M. Hoff, A. Sauguet

Attend this session if you want:
> To know more about the double layer stent technology
> To learn about the use of advanced intravascular imaging in carotid interventions
> To become familiar with radial approach for carotid artery stenting

With continuous LIVE demonstration from Maria Cecilia Hospital - Cotigüela, Italy

With continuous time to React@PCR

08:15 ■ Session objectives - O. Göktelek

08:20 ■ Double layer mesh stents: facts or fiction - G.G. Secro

08:32 ■ Towards alternative strategies: radial approach - P. Montori

10:10 ■ Session evaluation and key learnings - A. Cammeri

08:15-10:15 ■ Transcatheter mitral valve therapies: new rings, anchors and techniques

Innovation Hub

Chairperson: R. Komrowik

Co-chairperson: K.H. Kuck

Attend this session if you want:

> To obtain an update upon new catheter-based mitral valve devices and techniques
> To understand the current research and development and investigational status of novel mitral procedures
> To recognise pre-clinical and/or clinical experiences of the new mitral devices

08:15 ■ Session objectives - R. Komrowik

08:18 ■ Overview: mitral insufficiency treated using catheters: the rationale for transcatheter repair - A. Vahanian

08:30 ■ Valtech / Cardioband - F. Mediano

08:34 ■ Valscare

08:42 ■ Mitralign - G. Ntergig

08:50 ■ Discussion and audience interaction

09:06 ■ MValve

09:14 ■ Necchord - A. Coll

09:22 ■ Mitralix / Mistral

09:30 ■ Discussion and audience interaction

09:38 ■ Cephea

09:46 ■ MVRK - A. Egloff

09:54 ■ MIRAASST - C. Ruiz

10:02 ■ Discussion and audience interaction

10:10 ■ Session evaluation and key learnings - K.H. Kuck

Thursday 21st May, 2015 - Programme update

08:15-10:15 ■ Catheter-based renal sympathetic denervation
Procedural aspects: time to revise treatment
recommendations?
CCC - RDN

With the collaboration of the Clinical Consensus Conference on Renal Denervation (CCC-RDN)

Chairperson: T. Zeller

Co-chairperson: R. Yimani

Panelists: E. Edelmann, F. Mohr, H. Sievert

Attend this session if you want:
> To appreciate the different characteristics of the available renal denervation systems
> To understand the clinical relevance of the most recent findings and their impact on procedural performance

> Session objectives - T. Zeller

08:20 ■ Human anatomy: Nerve distribution, sweet spots, the osium, the branches - F. Mohr

08:33 ■ Discussion and audience interaction

08:41 ■ How deep do we get? Review of preclinical and human data - M. Jone

08:54 ■ Discussion and audience interaction

09:02 ■ How much circumferential ablation is needed? - Review HTN3 pre-clinical data - H. Sievert

09:15 ■ Discussion and audience interaction

09:23 ■ Go distal and into the branches! Potential risks and benefits - T. Zeller

09:36 ■ Discussion and audience interaction

09:44 ■ Procedural parameters of successful ablation - Anything on the horizon? - E. Edelmann

09:57 ■ Discussion and audience interaction

10:05 ■ Consensus on treatment recommendations - K. Tsoulfas

10:10 ■ Session evaluation and key learnings - R. Yimani

08:15-10:15 ■ TAVI - Care and cure

Chairperson: M. De Ronde

Co-chairperson: P. Lütjke Thomassen

Panelists: M. Gland, M. Oberhoff, D. Zugnif

Attend this session if you want:
> To understand the pathophysiology of aortic valve disease
> To understand the role of Nurses and technicians as a member of the TAVI team
> To understand the challenge of nursing care in the TAVI patient

08:15 ■ Session objectives - M. De Ronde, M. Oberhoff

08:21 ■ The role of the TAVI nurse in patient selection: how, who and why - B. Wulff

08:33 ■ Discussion and audience interaction

08:41 ■ Pathophysiology and haemodynamics in TAVI - K. Wilson

08:51 ■ Discussion and audience interaction

08:57 ■ TAVI - Interactive case - M. De Ronde, D. Zugnif

09:09 ■ Discussion and audience interaction

09:15 ■ Complication management - P. Almeida

09:27 ■ Discussion and audience interaction

09:33 ■ Nurses and allied professionals care during TAVI

09:41 ■ Discussion and audience interaction

09:51 ■ Nursing care after TAVI - M. De Ronde

10:03 ■ Discussion and audience interaction

10:09 ■ Session evaluation and key learnings - M. Gland, P. Lütjke Thomassen

08:15-10:15 ■ Planned and ongoing clinical trials: a status update from the Cardiovascular Research Foundation (ICRF)

Innovation Hub

With the collaboration of the Cardiovascular Research Foundation (ICRF)

Chairperson: O. Ben-Yehuda

Attend this session if you want:

> To be updated on planned or ongoing clinical trials that may change our future practice
> To gain in-depth understanding of trial design and execution
> To learn about upcoming milestones for trial recruitment, analysis and presentation plan

08:15 ■ Session objectives - O. Ben-Yehuda

08:20 ■ RIVER-PCI (Rivaroxaban in incomplete Vessel Revascularisation)-PCI - G. Weisz

08:27 ■ Discussion and audience interaction

08:31 ■ ILLUMEN III - Optimize PCI - G.W. Stone

08:38 ■ Discussion and audience interaction

08:42 ■ PARTNER II TAVR - M.B. Leon

08:49 ■ Discussion and audience interaction

08:56 ■ Early feasibility studies for novel valves and indications

09:10 ■ Session evaluation and key learnings - O. Ben-Yehuda

09:16 ■ Discussion and audience interaction

09:23 ■ Session evaluation and key learnings - O. Ben-Yehuda

09:30 ■ Discussion and audience interaction

09:37 ■ Session evaluation and key learnings - O. Ben-Yehuda

Chairperson: J. Escand

Co-chairperson: S.T. Lim

Attend this session if you want:

> To exchange about factors influencing decision-making in treating a coronary CTO antegradely
> To experience the relevance of planning ahead for procedural outcome
> To learn practical tips and tricks to prevent and solve complications

08:15 ■ Session objectives - J. Escand

08:20 ■ The ideal case to get started - M. Yomane

08:32 ■ Discussion and audience interaction

08:47 ■ An advanced case using standard techniques - A. Zeng

09:00 ■ Discussion and audience interaction

09:15 ■ An advanced case using dedicated devices - S. Wadh

09:26 ■ Discussion and audience interaction

09:41 ■ When to stop? - M. Lesiak

09:55 ■ Discussion and audience interaction

10:10 ■ Session evaluation and key learnings - S.T. Lim

08:15-09:15 ■ Are bioresorbable scaffolds a tool to improve angina and overall performance of PCI?

With the collaboration of the EAPCI Women Committee

Chairperson: F. Marini

Co-chairperson: P.W. Serruys

Attend this session if you want:

> To discuss the selection of patients who will benefit from bioresorbable scaffolds
> To evaluate criteria for decision-making between metallic stents and bioresorbable scaffolds

08:15 ■ Session objectives - F. Marini

08:20 ■ Impact of patients age and comorbidity - P. Capranzano

08:27 ■ Discussion and audience interaction

08:37 ■ Impact of clinical presentation: stable disease, NSTEMI, STEMI - J. Wyckowski

08:44 ■ Discussion and audience interaction

08:54 ■ Impact of lesion subsets and angiographic features

09:03 ■ Discussion and audience interaction

09:10 ■ Session evaluation and key learnings - P.W. Serruys

01:5-09:15 ■ Spain and Turkey share their most educational cases
ROOM 3528
Completion

With the collaboration of the Association of Percutaneous Cardiovascular Intervention of the Turkish Society of Cardiology and the Working Group on Interventional Cardiology of the Spanish Society of Cardiology
Chairpersons: B. Eymen, J.R. Rumoroso

Attend this session if you want:

- > To appreciate the risk of acute complication during PCI for CTO
- > To learn how to manage major acute complication during PCI for CTO
- > To share different treatment options of acute complication during PCI for CTO

08:15 > Session objectives - *J.R. Rumoroso*
08:17 > Case 1 - Multiple complications during PCI of a CTO of the left anterior descending artery - *A. Tuncel*
08:23 > Discussion and audience interaction
08:31 > Case 2 - Where we prepared for this? - *L. Teruel*
08:37 > Discussion and audience interaction
08:45 > Case 3 - I never think that I would have a looped wire in a retrograde CTO case
08:51 > Discussion and audience interaction
08:59 > Case 4 - How far should we optimize a CTO result? - *A. Guillemez*
09:05 > Discussion and audience interaction
09:13 > Session evaluation and key learnings - *B. Eymen*

09:15-10:15 ■ Learning anterograde approach in coronary CTO
ROOM 3528
Completion

Facilitators: E. Barba, O. Gampell, J. Strange

Attend this session if you want:

- > To review the techniques needed for anterograde approach
- > To better understand the most appropriate equipment selection
- > To find out how to overcome or manage the most frequent issues

- 09:00 -

09:20-10:20 ■ All you need to know about adjunctive pharmacology
ROOM 351
Completion

Chairperson: M. Volginigil
Co-chairperson: A. Baumbach

Attend this session if you want:

- > To review a comprehensive and clinically relevant update on this field
- > To identify the current evidence base and existing guidelines
- > To recognise the open questions that need addressing in the near future

09:20 > Session objectives - *M. Volginigil*
09:25 > Background and clinical data update - *D. Angiolillo*
09:35 > DAPT - *T. Cuisset*
09:45 > Guidelines - *A. Baumbach*
09:55 > Outlook: new drugs for clinical practice - *M. Volginigil*
10:05 > Questions and answers
10:15 > Session evaluation and key learnings - *A. Baumbach*

09:20-10:20 ■ Morocco and Tunisia share their most educational cases
ROOM 352A
Completion

With the collaboration of the Working Group on Interventional Cardiology of the Moroccan Society of Cardiology (SMC) and the Working Group on Interventional Cardiology of the Tunisian Society of Cardiology and Cardiovascular Surgery (GTCC)
Chairpersons: N. Elhadadi, H. Gama

Attend this session if you want:

- > To share experiences on unusual complications of bifurcations PCI in diabetics
- > To understand the potential mechanisms and causes of these complications
- > To learn how to manage and to prevent these complications

09:20-10:20 ■ Argentina and France share their most educational cases
ROOM 352B
Completion

With the collaboration of the Argentinian College of Interventional Cardiologists (CCIC) and the Argentine Coronary and Interventional Cardiology Group of the French Society of Cardiology (GSCF)
Chairpersons: A. Fernandez Muga, R. Koning

Attend this session if you want:

- > To understand how to identify acute complication during TAVI procedure
- > To understand acute potential complication during PCI procedure
- > To share how to solve the TAVI and PCI procedural complication

09:20 > Session objectives - *A. Fernandez Muga*
09:22 > Case 1 - CTO still to treat an occlusive coronary dissection complication of a simple angioplasty - *H. Benamer*
09:28 > Discussion and audience interaction
09:36 > Case 2 - Aortic dissection after percutaneous aortic valve implant without complications - *A. Scuteri*
09:42 > Discussion and audience interaction
09:50 > Case 3 - When a left main stenosis angioplasty begins easily and becomes complicated - *H. Le Breton*
09:56 > Discussion and audience interaction
10:04 > Case 4 - The worst complication of a percutaneous valve implant - *A. Chiero*
10:10 > Discussion and audience interaction
10:18 > Session evaluation and key learnings - *R. Koning*

10:30-12:00 ■ Difficult clinical decisions in antithrombotic therapy for coronary interventions
THEATRE BLEU
Completion

Chairperson: T. Cuisset
Co-chairperson: R. Byrne

Attend this session if you want:

- > To integrate new scientific evidence about antithrombotic therapy in daily practice
- > To tailor my choice of drugs to each individual patient
- > To provide the best efficacy/safety balance to each patient

With continuous time to React@PCR

10:30 > Session objectives - *T. Cuisset*
10:35 > Case 1 - NSTEMI case treated with new generation DES - *A. Bellemain-Apoux*
11:00 > Case 2 - Complex PCI in stable coronary artery disease with new generation DES - *D. Angiolillo*
11:25 > Case 3 - Coronary intervention in an atrial fibrillation patient requiring oral anticoagulation: specific issues
11:50 > Session evaluation and key learnings - *R. Byrne*

10:30-12:00 ■ Valve-in-valve interventions: now the 'gold standard' treatment for bioprosthetic failure?
THEATRE ROUGE
Completion

Co-chairperson: A. Chibber
Panelists: P. Kolh, T. Modine

Attend this session if you want:

- > To explore treatment options in this patient group
- > To learn the most up-to-date outcome data on valve-in-valve procedures
- > To understand appropriate case selection according to the surgical bioprosthes type

10:30 > Session objectives - *N. Moat*
10:35 > Valve-in-valve procedures: the current evidence - *G. Nickenig*
10:43 > Time to React@PCR
10:49 > LIVE demonstration from Bern University Hospital - Bern, Switzerland
11:29 > Time to React@PCR
11:41 > Technical considerations depending on surgical valve type - *V. Bogert*
11:49 > Session evaluation and key learnings - *A. Chibber*

10:30-12:00 ■ Expanding treatment options: stroke complicating interventional procedures
THEATRE HAUWE
Completion

Chairpersons: O. Goktekin, F. Ribichini, P. Widimsky
Panelists: O. Goktekin, H. Hopkins, H. Sievert

Attend this session if you want:

- > To discuss the appropriate work-up and time-window treatment in patients with periprocedural neurological events
- > To become familiar with endovascular equipment and techniques
- > To learn about periprocedural antithrombotic therapy

10:30 > Session objectives - *H. Sievert*
10:35 > Case demonstration - *O. Goktekin*
10:45 > Time to React@PCR
10:55 > Antithrombotic strategy for periprocedural stroke - Case demonstration from Maria Cecilia Hospital - Cotognola (Italy) - *A. Cernone*
11:15 > Time to React@PCR
11:25 > Session evaluation and key learnings - *N. Hopkins*

10:30-12:00 ■ Novel bioresorbable scaffold technology for the future
ROOM MALLOT
Innovation Hub

Chairperson: P.M. Serruys
Co-chairperson: A. Abizaid

Attend this session if you want:

- > To learn the principles of biodegradation and vascular response to bioresorbable scaffolds
- > To gain insights into bench testing and pre-clinical data of bioresorbable scaffolds

10:30 > Session objectives - *P.M. Serruys*
10:35 > Bench testing: what should be assessed and how? - *J. Ormiston*
10:43 > Pre-clinical evaluation: what should be assessed and how? - *M. Jander*
10:51 > Bench testing and pre-clinical evaluation of a novel intraluminal scaffold - *S. Verhage*
10:57 > Questions and answers
10:59 > Bench testing and pre-clinical evaluation of a bioresorbable scaffold with a racemic mixture of L- and D-lactides - *A. Ladori*
11:05 > Questions and answers
11:07 > Bench testing and pre-clinical evaluation of the Amaranth PLLA scaffold - *J. Granada*
11:13 > Questions and answers
11:15 > Bench testing and pre-clinical evaluation of drug-eluting CD34 antibody-coated bioresorbable scaffold made of a mixed polymer
11:21 > Questions and answers
11:23 > Bench testing and pre-clinical evaluation of poly(lactic acid) biodegradable scaffold during a new intrus drug with a hybrid scaffold design - *R.L. Van Gaens*
11:29 > Questions and answers
11:31 > Bench testing and pre-clinical evaluation of a stentless-eluting scaffold
11:37 > Questions and answers
11:39 > Bench testing and pre-clinical evaluation of magnesium stents - *M. Houde*
11:45 > Questions and answers
11:47 > Bench testing and pre-clinical evaluation of iron stent
11:53 > Questions and answers
11:55 > Session evaluation and key learnings - *A. Abizaid*

10:30-12:00 ■ The essentials: how to treat left main disease
ROOM 241
The essentials

With the collaboration of the EAPCI New Initiatives For Young Interventionalists Committee
Senior advisor: J. Marco
Facilitators: K. Horiguchi, A. Wolf

Attend this session if you want:

- > To discuss how to properly identify the patient for PCI
- > To discuss the best strategies for bifurcation PCI
- > To learn how to use WUS and FFR in patients undergoing left main PCI

10:30-12:00 ■ Transcatheter therapy for mitral regurgitation: emerging techniques
ROOM 242AB
Completion

Chairperson: H. Moellmann
Co-chairperson: M. Burchinder

Attend this session if you want:

- > To learn about alternatives to edge-to-edge repair
- > To explore novel surgical techniques which may compete with catheter therapy

10:30 > Session objectives - *M. Burchinder*
10:35 > Why do we need more techniques? - Clinical and anatomical challenges - *A. Vahanian*
10:44 > Discussion and audience interaction
10:49 > Case demonstration
11:29 > Discussion and audience interaction
11:41 > Which devices are available for transcatheter mitral valve repair? - *F. Maisano*
11:51 > Discussion and audience interaction
11:56 > Session evaluation and key learnings - *H. Moellmann*

- 10:00 -

10:30-12:00 ROOM 352A Innovation Hub	<p>New mechanical treatment options for patients with pulmonary embolism <i>Chairperson: M. Velgijn</i> <i>Co-chairperson: P. Wank</i></p> <p>Attend this session if you want:</p> <ul style="list-style-type: none"> > To learn about the antithrombotic options and their limitations in patients with pulmonary embolism > To identify new catheter-based treatment alternatives > To understand the role of extra-corporeal membrane oxygenation in patients with pulmonary embolism presenting cardiogenic shock
10:30 10:35	<ul style="list-style-type: none"> > Session objectives - <i>M. Velgijn</i> > Catheter-based treatment in pulmonary embolism patients: when, in whom and how to judge its efficacy? - <i>E. McFadden</i> > Angiojet technology: state-of-the-art and case examples - <i>D. Antonucci</i> > Discussion and audience interaction > Ultrasound-assisted catheter-based thrombolysis: state-of-the-art and case examples > Discussion and audience interaction > Angiojet technology: state-of-the-art and case examples > Discussion and audience interaction > Use of extra-corporeal membrane oxygenation in patients with pulmonary embolism and refractory cardiogenic shock - <i>M. Roffi</i> > Discussion and audience interaction > Session evaluation and key learnings - <i>P. Wank</i>
10:30-12:00 ROOM 342AB	<p>Timing of coronary angiography and PCI in comatose survivors of out-of-hospital cardiac arrest <i>Chairperson: M. Noc</i> <i>Co-chairperson: J.F. Lassen</i></p> <p>Attend this session if you want:</p> <ul style="list-style-type: none"> > To learn in which comatose survivors of out-of-hospital cardiac arrest immediate coronary angiography should be performed > To select an optimal PCI strategy after defining the coronary anatomy > To learn about adjunctive antiplatelet treatment in comatose patients undergoing PCI
10:30 10:35 10:40 10:45 10:50 11:00 11:05 11:10 11:15 11:20 11:25 11:30 11:35	<ul style="list-style-type: none"> > Session objectives - <i>M. Noc</i> > Immediate coronary angiography/PCI in comatose survivors of out-of-hospital cardiac arrest - What does the EAP/CSF consensus say? - <i>G. Olivero</i> > Discussion and audience interaction > To go or not to go for immediate coronary angiography: case example - <i>C. Spaulding</i> > Discussion and audience interaction > How to select an optimal PCI strategy: case example - <i>M. Noc</i> > Discussion and audience interaction > Post-PCI antiplatelet therapy when tablets cannot be swallowed? - <i>G. Covic</i> > Discussion and audience interaction > Session evaluation and key learnings - <i>J.F. Lassen</i>
10:30-12:00 ROOM 351	<p>CUT@EuroPCR - Integrated physiology and imaging use for strategy change and decision-making in complex PCI <i>With the collaboration of Japanese Association of Cardiovascular Intervention and Therapeutics</i> <i>Chairpersons: M. Nakamura, W. Wijffels</i></p> <p>Attend this session if you want:</p> <ul style="list-style-type: none"> > To demonstrate the importance of coronary imaging for understanding pathophysiology in vivo > To demonstrate ongoing progression of disease by physiology and imaging > To emphasise the usefulness of integrated physiology and imaging use for the guidance of PCI
10:30 10:35 10:40 10:45 10:50 11:00 11:05 11:10 11:15 11:20 11:25 11:30 11:35	<ul style="list-style-type: none"> > Session objectives - <i>M. Nakamura</i> > Physiology and imaging for procedural planning > Discussion and audience interaction > ACS with apparently normal coronary angiography > Evidence for impact of imaging on outcomes > Discussion and audience interaction > Coronary angiography revealed true culprit lesion causing very late stent thrombosis 5 years after stent implantation > Discussion and audience interaction > Session evaluation and key learnings - <i>W. Wijffels</i>
10:30-12:00 ROOM 352A How should I treat?	<p>Latvia and Russia (Siberia) share their most educational cases <i>With the collaboration of the Working Group on Interventional Cardiology of the Latvian Society of Cardiology and the Siberian Association of Interventional Cardiologists</i> <i>Chairpersons: A. Eglis, V. Ganyukov</i></p> <p>Attend this session if you want:</p> <ul style="list-style-type: none"> > To share the experience of endovascular treatment of complex structural heart disease > To reflect on tips and tricks of no standard procedures for structural heart disease > To understand the feasibility and standards of endovascular interventions for structural heart disease in high-risk patients
10:30 10:35 10:40 10:45 10:50 11:00 11:05 11:10 11:15 11:20 11:25 11:30 11:35	<ul style="list-style-type: none"> > Session objectives - <i>A. Eglis</i> > Case 1 - Simultaneous TAVI and digital subtraction angiography aortic septal defect closure in patient with combined critical aortic stenosis and aortic septal defect > How would I treat? - <i>A. Rudzitis</i> > How did I treat? - <i>A. Rudzitis</i> > Discussion and audience interaction > Consensus - <i>A. Eglis</i> > Case 2 - Staged treatment of adult patient with ventricular failure: stent implantation in the right ventricular outflow tract - <i>R. Tarazov</i> > How would I treat? - <i>A. Rudzitis</i> > How did I treat? - <i>R. Tarazov</i> > Discussion and audience interaction > Consensus - <i>V. Ganyukov</i> > Session evaluation and key learnings - <i>V. Ganyukov</i>

10:30-12:00 ROOM 352B How should I treat?	<p>Germany and Poland share their most educational cases <i>With the collaboration of the Association on Cardiovascular Intervention of the Polish Cardiac Society (ACVH-ASV) and the Working Group on Cardiovascular Interventions of the German Society of Cardiology (DGCI)</i> <i>Chairpersons: A. Elzasser, A. Ochala</i></p> <p>Attend this session if you want:</p> <ul style="list-style-type: none"> > To reflect on complications during left main interventions > To learn different concepts in managing distal left main bifurcation > To share expertise of specific techniques to avoid complications during left main interventions
10:30 10:35 10:40 10:45 10:50 11:00 11:05 11:10 11:15 11:20 11:25 11:30 11:35	<ul style="list-style-type: none"> > Session objectives - <i>A. Elzasser</i> > Case 1 - Lost stent during left main intervention - <i>T. Schmitz</i> > How would I treat? - <i>A. Wilkowiak</i> > How did I treat? - <i>H. Neff</i> > Discussion and audience interaction > Consensus - <i>A. Elzasser</i> > Case 2 - Elective PCI of the distal left main bifurcation with severe calcification > How would I treat? - <i>H. Neff</i> > How did I treat? - <i>A. Wilkowiak</i> > Discussion and audience interaction > Consensus - <i>A. Ochala</i> > Session evaluation and key learnings - <i>A. Ochala</i>
10:30-12:00 ROOM 352A LEARNING	<p>Learning OCT <i>Facilitators: K.T. Chan, G. Guagliumi, T. Johnson</i></p> <p>Attend this session if you want:</p> <ul style="list-style-type: none"> > To be able to understand and recognise the most common OCT patterns > To learn about the most commonly accepted OCT definitions and how to react to the findings > To appreciate when OCT may be useful prior to - and after - stent or scaffold implantation
10:30 11:00 11:25	<ul style="list-style-type: none"> > Discussion and audience interaction > Consensus - <i>A. Ochala</i> > Session evaluation and key learnings - <i>A. Ochala</i>
12:30-14:30 THEATRE BONDEAUX Tools & Techniques (TM)	<p>The Evolut R operator experience: valve performance and deliverability <i>With an unrestricted educational grant from MEDTRONIC</i> <i>Chairperson: E. Grube</i> <i>Co-chairperson: J. Webb</i> <i>Panelists: N. Morat, C. Tamburino</i></p> <p>Attend this session if you want:</p> <ul style="list-style-type: none"> > To understand the key performance features of the new self-expanding Evolut R valve system > To learn tips and tricks on the Evolut R system through LIVE and recorded LIVE learning cases > To appreciate how a 14 Fr delivery profile improves clinical outcome
12:30 12:35 12:40 12:45 12:50 13:00 13:10 13:20 13:30 13:35 14:15 14:25	<ul style="list-style-type: none"> > Session objectives - <i>E. Grube</i> > The new CoreValve Evolut R platform: delivering confidence to the TAVI procedure - <i>N. Morat</i> > LIVE demonstration from Bern University Hospital - Bern, Switzerland > Time to React@PCR > How true delivery profile diminution reduces vascular access challenges and complication - <i>C. Tamburino</i> > Case demonstration > Time to React@PCR > Session evaluation and key learnings - <i>J. Webb</i>
12:30-14:30 THEATRE HANAU Tools & Techniques (TM)	<p>FFR, OCT, angiography: the benefits of integration in daily clinical practice <i>With an unrestricted educational grant from ST. JUDE MEDICAL</i> <i>Chairperson: F. Pavi</i> <i>Co-chairperson: J. Hill</i> <i>Panelists: J. Escaned, G. Guagliumi</i></p> <p>Attend this session if you want:</p> <ul style="list-style-type: none"> > To discover the benefits of FFR and OCT integrated in the cath lab ready and available to assess and treat ischemic lesions > To learn about the benefits of OCT-angiography co-registration to define the right PCI strategy > To gain knowledge on the decision-making process to implant bioresorbable scaffolds under OCT guidance
12:30 12:35 12:40 12:45 12:50 13:00 13:10 13:20 13:30 13:40 14:15 14:25	<ul style="list-style-type: none"> > Session objectives - <i>F. Pavi</i> > LIVE demonstration from Thoraxcenter - Rotterdam, The Netherlands > Time to React@PCR > OCT co-registered with angiography: procedural advantages and a new decision-making process - <i>G. Guagliumi</i> > KCS: the importance of FFR and OCT in culprit and non-culprit lesions - <i>J. Escaned</i> > Case demonstration > Time to React@PCR > Session evaluation and key learnings - <i>J. Hill</i>

- 12:00 -

13:30-14:00 ■ The use of fully bioresorbable vascular scaffolds in real-world settings: the latest evidence

With an unrestricted educational grant from ABBOTT VASCULAR

- Chairperson: C.K. Naber
 - Co-chairperson: P. Smith
 - Panelists: A. Sethi, C. Simonon
- Attend this session if you want:
- > To review the latest clinical outcomes with bioresorbable vascular scaffolds
 - > To discuss which patients can be treated successfully with bioresorbable vascular scaffolds

- 12:30 Session objectives - C.K. Naber
- 12:35 > Ghost EU: update - P. Caporazono
- 12:47 > Discussion and audience interaction
- 12:45 > ABSORB Extend one-year results in moderately complex lesions - A. Alabdidi
- 12:52 > Discussion and audience interaction
- 12:55 > GABIR: acute performance from German-Austrian real-world experience - C. Hamm
- 12:02 > Discussion and audience interaction
- 12:05 > REPAIR: acute performance from Iberian real-world experience - F. Hernandez
- 12:12 > Discussion and audience interaction
- 12:15 > ABSORB First: worldwide all-comer one-year outcomes
- 12:22 > E. Fechtner
- 12:25 > Discussion and audience interaction
- 12:32 > ASSURE: two-year registry outcomes - C.K. Naber
- 12:35 > Discussion and audience interaction
- 12:35 > Panel discussion
- 12:35 > Session evaluation and key learnings - P. Smith

12:30-13:30 ■ The COMBO dual therapy stent - Can true vessel healing facilitate short-term DAPT

With an unrestricted educational grant from ORBISCH

- Chairperson: M. Haude
 - Co-chairperson: R. Virmont
- Attend this session if you want:
- > To learn how to assess true vessel healing under OCT after stenting
 - > To learn about the latest clinical developments of the dual therapy stent with active endothelial progenitor cell capture
 - > To learn why COMBO is an important technology in the DAPT duration controversy

- 12:30 Session objectives - R. Virmont
- 12:35 > Correlation of tissue coverage and true vessel healing under OCT imaging - M. Joner
- 12:46 > Discussion and audience interaction
- 12:53 > Long-term validation of the dual therapy stent for everyday use - R. Mehran
- 13:00 > Discussion and audience interaction
- 13:11 > Can DAPT duration be shortened safely with the dual therapy stent? - R. De Winter
- 13:21 > Discussion and audience interaction
- 13:26 > Session evaluation and key learnings - M. Haude

12:30-13:30 ■ MitraClip procedure: simplifying the complex

With an unrestricted educational grant from ABBOTT VASCULAR

- Chairperson: A. Vahanian
 - Co-chairperson: F. Maisano
 - Panelists: S. Baldus, F. Ruzschatzka, S. von Bardeleben
- Attend this session if you want:
- > To learn about the new developments and data in mitral space
 - > To learn about tips and tricks on treating complex anatomy with MitraClip
 - > To view the reinforcing of the importance of engagement of heart failure specialist in the multidisciplinary team and MitraClip therapy

- 12:30 Session objectives - F. Maisano
- 12:35 > What's hot in mitral regurgitation interventions? - F. Maisano
- 12:45 > How far can you go with MitraClip?
- 12:45 > Case 1 - S. Baldus
- 12:55 > Case 2 - S. von Bardeleben
- 13:05 > Case 3 - A. Vahanian
- 13:15 > How do you bring heart failure into the team? - F. Ruzschatzka
- 13:25 > Session evaluation and key learnings - A. Vahanian

12:30-13:30 ■ All you need to know about critical limb ischaemia

Chairperson: A. Sanguet

Co-chairperson: T. Zeller

- Attend this session if you want:
- > To review a comprehensive and clinically relevant update on this field
- > To identify the current evidence base and existing guidelines
- > To recognise the open questions that need addressing in the near future
- 12:30 Session objectives - T. Zeller
- 12:35 > Background and clinical data - A. Sanguet
- 12:45 > Technical aspects - Issues in clinical practice - R. Temarel
- 12:55 > Guidelines and recommendations - Y. Goufflet
- 13:05 > Unresolved issues and outlook - T. Zeller
- 13:15 > Questions and answers
- 13:25 > Session evaluation and key learnings - A. Sanguet

12:30-14:00 ■ Absorbable polymer and polymer-free technologies: viable solutions for unmet needs in PCI

With an unrestricted educational grant from ALIUMEDICA MEDICAL TECHNOLOGIES

- Chairperson: A. Colombo
 - Co-chairperson: H. Mehlmann
- Attend this session if you want:
- > To share clinical experiences in the use of absorbable polymer and polymer-free stents in real practice
 - > To demonstrate how polymer-free DES may increase safety in patients undergoing PCI requiring short DAPT
 - > To understand why the absorbable polymer and polymer-free technologies may be more efficacious in specific complex PCI subsets

- 12:30 Session objectives - H. Mehlmann
- 12:35 > PCI in a patient with DAPT constraints: procedure and clinical outcome - P. Sella
- 12:45 > Discussion and audience interaction
- 12:55 > PCI in a patient with diabetes: procedure and clinical outcome - R. Romaguera
- 12:05 > Discussion and audience interaction
- 12:15 > PCI in a patient with a complex coronary CTO: procedure and clinical outcome - R. Gorbio
- 12:25 > Discussion and audience interaction
- 12:35 > PCI in a patient with a complex coronary anatomy: procedure and clinical outcome - R. Tigen
- 12:45 > Discussion and audience interaction
- 12:55 > Session evaluation and key learnings - A. Colombo

12:30-13:30 ■ Combined Factor Xa and platelet inhibition to prevent recurrent events after ACS: the story so far

With an unrestricted educational grant from BAYER HEALTHCARE PHARMACEUTICALS

- Chairperson: R.G. Sieg
 - Panelists: A. Kastrup, G. Montalescot, M. Roffi
- Attend this session if you want:
- > To understand the dual-pathway strategy for secondary prevention after ACS
 - > To learn about the value of adding rivaroxaban in addition to dual antiplatelet for secondary prevention after ACS
 - > To gain insight into the increasing breadth of oral anticoagulant use in cardiology: the rivaroxaban profile

- 12:30 Session objectives - R.G. Sieg
- 12:35 > The dual pathway strategy for ACS secondary prevention: what is the rationale? - M. Roffi
- 12:47 > Discussion and audience interaction
- 12:52 > The added value of Factor Xa inhibition in practice: optimising management of complex ACS cases - A. Kastrup
- 13:04 > Discussion and audience interaction
- 13:09 > The rivaroxaban clinical trial programme: proven experience and new directions in cardiology - G. Montalescot
- 13:21 > Discussion and audience interaction
- 13:26 > Session evaluation and key learnings - R.G. Sieg

12:30-14:00 ■ Learning alcohol septal ablation for hypertrophic obstructive cardiomyopathy

Facilitators: S. Cook, T. Guleset, T. Lefevre

Panelist: R. Siegenfeld

- Attend this session if you want:
- > To share tips and tricks to make septal ablation easy and successful
- > To discuss how to prevent and manage potential complications
- > To discuss how to integrate available evidence into daily practice

- 13:00 -

13:35-14:35 ■ Mitralign: a platform for mitral and tricuspid valve repair

With an unrestricted educational grant from MITRALIGN

- Chairperson: A. Latib
 - Co-chairperson: T. Feldman
- Attend this session if you want:
- > To understand how to perform mitral repair in patients with functional mitral regurgitation
 - > To understand how to perform tricuspid repair in patients with functional tricuspid regurgitation
 - > To learn more about case examples of the Mitralign procedure

- 13:35 Session objectives - T. Feldman
- 13:40 > Mitralign CE: mitral 6 months primary endpoint - G. McKern
- 13:52 > Discussion and audience interaction
- 13:57 > Tricuspid repair with the Mitralign annuloplasty system
- 14:09 > Discussion and audience interaction
- 14:14 > Case review and examples - R. Hamm
- 14:26 > Discussion and audience interaction
- 14:31 > Session evaluation and key learnings - A. Latib

13:35-14:35 ■ Treatment of secondary mitral regurgitation via percutaneous annuloplasty

With an unrestricted educational grant from CARDIAC DIMENSIONS

- Attend this session if you want:
- > To appreciate useful tips for procedural technique
- > To learn about the latest efficacy data for percutaneous annuloplasty
- > To discuss the role of percutaneous annuloplasty for treatment of functional mitral regurgitation

- 13:35 Session objectives
- 13:40 > Overview of the catheter mitral contour device and clinical data - C. Spaulding
- 13:52 > Discussion and audience interaction
- 13:57 > Case demonstration
- 14:09 > Discussion and audience interaction
- 14:14 > Cathion as a part of the heart failure treatment plan
- 14:26 > Discussion and audience interaction
- 14:31 > Session evaluation and key learnings

13:35-14:35 ■ Left atrial appendage closure: which patients benefit most?

With an unrestricted educational grant from BOSTON SCIENTIFIC

- Chairperson: D. Holmes
 - Co-chairperson: A. Vahanian
- Attend this session if you want:
- > To learn which patients may benefit from left atrial appendage closure
 - > To understand how to best balance the risk of stroke and bleeding in specific patient groups
 - > To know the latest clinical evidence, guidelines and expert consensus recommendations on left atrial appendage closure

- 13:35 Session objectives - D. Holmes
- 13:40 > Why patient had a stroke and cannot take oral anticoagulation long-term? - M.W. Beggs
- 13:47 > Discussion and audience interaction
- 13:57 > Why patient has severe renal failure and a high CHADS2-VASc score? - M. Price
- 14:09 > Discussion and audience interaction
- 14:14 > Why patient has a stent and a high stroke risk? - H. Stewart
- 14:23 > Discussion and audience interaction
- 14:31 > Session evaluation and key learnings - A. Vahanian

13:35-14:35	DE5: bare metal or bioactive stent: which stent to use to treat ACS patients? OPTIMAX the third way (third generation bioactive stent)
Room 331	
Symposium	With an unrestricted educational grant from HEXACATH
	<i>Chairperson: B. De Bruyne</i>
	<i>Co-chairperson: P. Kojouhar</i>
	Attend this session if you want:
	> To evaluate the clinical results of the third titanium-nitride-oxide bioactive stent than Optimax in ACS patients
	> To appreciate the current clinical programme of bioactive stents compared with the best performing DES in ACS patients
	> To understand the impact of the new ESC Guidelines on DAPT treatment and on the choice of stents types in ACS patients
13:35	> Session objectives - <i>B. De Bruyne</i>
13:39	> TDC-ACS trial: randomised comparison of a new generation bioactive stent versus a new generation DES in ACS patients - <i>J. von Der Heyden</i>
13:46	> Discussion and audience interaction
13:52	> How to combine early healing and short term DAPT The Optimax first-in-man and OCT trial - <i>P. Kojouhar</i>
14:01	> Discussion and audience interaction
14:05	> Are all stents equal for ACS patients? The new ESC recommendations position - <i>M. Angel</i>
14:16	> Discussion and audience interaction
14:18	> The TITAN-AMI multicentre registry: final result at 12-month follow-up - <i>J.A. Gomez-Hospital</i>
14:27	> Discussion and audience interaction
14:31	> Session evaluation and key learnings - <i>B. De Bruyne</i>

- 14:00 -

14:40-17:00	Complex cardiovascular interventions and new techniques: LIVE demonstrations from Clinique Pasteur - Toulouse, France and from Thoraxcenter - Rotterdam, The Netherlands
MAIN ARENA	

14:40-16:40	How to successfully perform PCI for complex bifurcation lesions?
THEATRE BLEU	
	<i>Chairperson: I. Al Rashidan</i>
	<i>Co-chairperson: R. Mohd Ali</i>
	<i>Panelists: M. Lesiak, S.T. Lim</i>
	Attend this session if you want:
	> To discuss proper selection of patients and lesions for different bifurcation techniques
	> To learn practical tips and tricks for optimal bifurcation treatment
14:40	> Session objectives - <i>R. Mohd Ali</i>
14:45	> How to select the appropriate bifurcation technique for a specific lesion and patient - <i>M. Behon</i>
14:55	> Time to React@PCR
15:10	> Key tips and tricks for bifurcation interventions
15:20	> Time to React@PCR
15:35	LIVE demonstration from Clinique Pasteur - Toulouse, France
16:30	> Time to React@PCR
16:35	> Session evaluation and key learnings - <i>I. Al Rashidan</i>

14:40-16:40	Device closure of left atrial appendage
THEATRE	
BONDEAUX	
	<i>Chairperson: E. Eckhout</i>
	<i>Co-chairperson: M.W. Begnum</i>
	Attend this session if you want:
	> To be apprised on the latest evidence of left atrial appendage closure
	> To learn how to accurately select patients who will benefit
	> To learn how to match each device to your patient's anatomy
14:40	> Session objectives - <i>E. Eckhout</i>
14:44	> Current evidence - <i>C. Grossi</i>
14:52	> Time to React@PCR
14:58	LIVE demonstration from Bern University Hospital - Bern, Switzerland
15:39	> Time to React@PCR
15:54	> Imaging to guide left atrial appendage closure - <i>A. Zakos</i>
16:02	> Time to React@PCR
16:08	> Device selection - <i>F. Helwig</i>
16:16	> Time to React@PCR
16:22	> Optimal antithrombotic therapy after left atrial appendage closure - <i>D. Hickey-Smith</i>
16:30	> Time to React@PCR
16:35	> Session evaluation and key learnings - <i>M.W. Begnum</i>

14:40-16:40	Below-the-knee revascularisation: from simple to complex
THEATRE	
MAVANE	
	<i>Chairperson: R. Fenezi</i>
	<i>Co-chairperson: T. Gouellic</i>
	<i>Panelists: M. Boulet, A. Souquet, J. Ton, T. Zeller</i>
	Attend this session if you want:
	> To assess techniques that are relevant to your clinical practice
	> To recognise the open questions and unmet needs
14:40	With continuous LIVE demonstration from Anna Cecilia Hospital - Gellipolia, Italy
14:45	With continuous time to React@PCR
14:50	> Session objectives - <i>R. Fenezi</i>
14:55	> Technical aspects for a successful below-the-knee revascularisation - <i>A. Souquet</i>
15:00	> Lessons learned, unresolved issues and future perspectives
15:10	> Session evaluation and key learnings - <i>T. Gouellic</i>

14:40-16:10	The essentials: how to treat a STEMI and multivessel disease
ROOM 241	
The experts' table	
	With the collaboration of the EAPCI New Initiative For Young Interventionalists Committee
	<i>Senior advisor: M.C. Morice</i>
	<i>Facilitators: R. Dilek, G. Toth</i>
	Attend this session if you want:
	> To understand how to identify the culprit lesion in cases with multivessel presentation
	> To learn how to investigate ischaemia in non-culprit vessels
	> To discuss the best management strategy for non-infarct related arteries in STEMI
14:40	> Session objectives - <i>R. Dilek</i>
14:45	> How to select the appropriate bifurcation technique for a specific lesion and patient - <i>M. Behon</i>
14:55	> Time to React@PCR
15:10	> Key tips and tricks for bifurcation interventions
15:20	> Time to React@PCR
15:35	LIVE demonstration from Clinique Pasteur - Toulouse, France
16:30	> Time to React@PCR
16:35	> Session evaluation and key learnings - <i>I. Al Rashidan</i>

14:40-16:40	Device-based left ventricular cavity reduction in heart failure
ROOM 245A	
	<i>Chairperson: H. Sievert</i>
	<i>Panelists: J. Bortunek, F. Casselman, H. Moellmann, C. Tamburino</i>
	Attend this session if you want:
	> To become familiar with the potential of device-based interventions targeting ventricular reshaping and cavity reduction in heart failure management
	> To discuss patient selection and procedural aspects for ventricular partitioning and cavity reduction
	> To review the available evidence and outcome of device-based approaches in ischaemic heart failure
14:40	> Session objectives - <i>H. Sievert</i>
14:45	> Left ventricular cavity reconstruction and reshaping in heart failure: surgical approach - <i>F. Casselman</i>
14:50	> Discussion and audience interaction
14:55	> Left ventricular cavity reconstruction and reshaping in heart failure: device-based approach - <i>J. Bortunek</i>
15:00	> Discussion and audience interaction
15:05	> Case demonstration: percutaneous left ventricular remodeling using Panchute
15:10	> Discussion and audience interaction
15:15	> Case demonstration: percutaneous left ventricular remodeling using Revivent device
15:20	> Discussion and audience interaction
15:25	> Session evaluation and key learnings

14:40-16:40	Italy, South Africa and Turkey share their most educational cases
ROOM 243	
How should I treat?	
	With the collaboration of the Italian Vascular and Endovascular Surgery Society, the Vascular Society of Southern Africa and the Turkish Society for Vascular and Endovascular Surgery
	<i>Chairpersons: E. Bozkurt, F. Pehnetli</i>
	Attend this session if you want:
	> To optimise both strategy and technique in treating patients with thoraco-abdominal aneurysm
	> To understand how to deal with challenging cases using appropriate dedicated devices
	> To appreciate the value of surgical, endovascular and hybrid approach for complex patients
14:40	> Session objectives - <i>F. Pehnetli</i>
14:45	> Case 1 - Rescue procedure after failed chimney graft for the treatment of an aortic aneurysm involving the origin of the celiac trunk - <i>X. Tzombou</i>
14:50	> How would I treat?
14:55	> How would I treat? - <i>A. Foytje</i>
15:00	> Discussion and audience interaction
15:05	> Case 2 - Ruptured aneurysm
15:10	> How would I treat? - <i>A. Foytje</i>
15:15	> How would I treat?
15:20	> How would I treat?
15:25	> How would I treat? - <i>S. Ibbot</i>
15:30	> Discussion and audience interaction
15:35	> Session evaluation and key learnings - <i>E. Bozkurt</i>

14:40-16:40	Tips and tricks in the management of complex PCI procedures
ROOM 251	
	<i>Chairperson: S. Gargio</i>
	<i>Co-chairperson: H. Falcot</i>
	<i>Facilitator: S. Carson</i>
	Attend this session if you want:
	> To understand the importance of a holistic preparation of a patient for a complex procedure
	> To understand the skills required to participate in complex angioplasty
	> To better understand how advanced imaging is required to support complex procedures
14:40	> Session objectives - <i>H. Falcot</i>
14:45	> Patient preparation - <i>R. Babin</i>
14:50	> Discussion and audience interaction
15:00	> How to prepare the team - <i>S. Pesot</i>
15:10	> Discussion and audience interaction
15:17	> How to plan a coronary CTO: clinical case - <i>I. Cobbaut</i>
15:22	> Discussion and audience interaction
15:28	> Coronary bifurcation: the new side branch - <i>L. Bender</i>
15:38	> Discussion and audience interaction
15:48	> Left main - How essential is intracoronary imaging - <i>R. Esteves</i>
15:54	> Discussion and audience interaction
16:00	> Radiation exposure: How to reduce it for every procedure
16:05	> Session evaluation and key learnings - <i>S. Gargio</i>

14:40-16:40	Percutaneous treatment of mitral regurgitation: edge-to-edge repair
ROOM 342A	
	<i>Co-chairperson: O. Franzen</i>
	Attend this session if you want:
	> To understand the impact of anatomy on the success of mitral repair
	> To learn how to select good candidates for MitraClip
	> To learn how to improve outcomes
14:40	> Session objectives - <i>O. Franzen</i>
14:45	> Which patients are suitable for MitraClip in 2015?
14:50	> Discussion and audience interaction
14:52	> Case demonstration
15:02	> Discussion and audience interaction
15:07	> What is the role of MitraClip today compared to surgical valve replacement/repair? - <i>R. Corfi</i>
15:12	> Discussion and audience interaction
15:18	> How to make it easy: tips and tricks - <i>H. Ince</i>
15:24	> Discussion and audience interaction
15:30	> Session evaluation and key learnings

14:40-15:40	All you need to know about coronary physiology: FFR, iFR, IMR
ROOM 351	
THEATRE MAVANE	
	<i>Chairperson: J. Escaned</i>
	<i>Co-chairperson: P. McCarthy</i>
	Attend this session if you want:
	> To review a comprehensive and clinically relevant update on this field
	> To identify the current evidence base and existing guidelines
	> To recognise the open questions that need addressing in the near future
14:40	> Session objectives - <i>J. Escaned</i>
14:45	> Background and clinical data: FFR - <i>P. McCarthy</i>
14:55	> Technical and clinical issues: FFR and IMR - <i>P. Ullmer</i>
15:05	> Guidelines - <i>F. Barbato</i>
15:15	> Unresolved issues and outlook - <i>J. Escaned</i>
15:25	> Questions and answers
15:35	> Session evaluation and key learnings - <i>P. McCarthy</i>

14:40-16:40	Device-based left ventricular cavity reduction in heart failure
ROOM 245A	
	<i>Chairperson: H. Sievert</i>
	<i>Panelists: J. Bortunek, F. Casselman, H. Moellmann, C. Tamburino</i>
	Attend this session if you want:
	> To become familiar with the potential of device-based interventions targeting ventricular reshaping and cavity reduction in heart failure management
	> To discuss patient selection and procedural aspects for ventricular partitioning and cavity reduction
	> To review the available evidence and outcome of device-based approaches in ischaemic heart failure
14:40	> Session objectives - <i>H. Sievert</i>
14:45	> Left ventricular cavity reconstruction and reshaping in heart failure: surgical approach - <i>F. Casselman</i>
14:50	> Discussion and audience interaction
14:55	> Left ventricular cavity reconstruction and reshaping in heart failure: device-based approach - <i>J. Bortunek</i>
15:00	> Discussion and audience interaction
15:05	> Case demonstration: percutaneous left ventricular remodeling using Panchute
15:10	> Discussion and audience interaction
15:15	> Case demonstration: percutaneous left ventricular remodeling using Revivent device
15:20	> Discussion and audience interaction
15:25	> Session evaluation and key learnings

14:40-16:40	Italy, South Africa and Turkey share their most educational cases
ROOM 243	
How should I treat?	
	With the collaboration of the Italian Vascular and Endovascular Surgery Society, the Vascular Society of Southern Africa and the Turkish Society for Vascular and Endovascular Surgery
	<i>Chairpersons: E. Bozkurt, F. Pehnetli</i>
	Attend this session if you want:
	> To optimise both strategy and technique in treating patients with thoraco-abdominal aneurysm
	> To understand how to deal with challenging cases using appropriate dedicated devices
	> To appreciate the value of surgical, endovascular and hybrid approach for complex patients
14:40	> Session objectives - <i>F. Pehnetli</i>
14:45	> Case 1 - Rescue procedure after failed chimney graft for the treatment of an aortic aneurysm involving the origin of the celiac trunk - <i>X. Tzombou</i>
14:50	> How would I treat?
14:55	> How would I treat? - <i>A. Foytje</i>
15:00	> Discussion and audience interaction
15:05	> Case 2 - Ruptured aneurysm
15:10	> How would I treat? - <i>A. Foytje</i>
15:15	> How would I treat?
15:20	> How would I treat?
15:25	> How would I treat? - <i>S. Ibbot</i>
15:30	> Discussion and audience interaction
15:35	> Session evaluation and key learnings - <i>E. Bozkurt</i>

14:40-16:40	Tips and tricks in the management of complex PCI procedures
ROOM 251	
	<i>Chairperson: S. Gargio</i>
	<i>Co-chairperson: H. Falcot</i>
	<i>Facilitator: S. Carson</i>
	Attend this session if you want:
	> To understand the importance of a holistic preparation of a patient for a complex procedure
	> To understand the skills required to participate in complex angioplasty
	> To better understand how advanced imaging is required to support complex procedures
14:40	> Session objectives - <i>H. Falcot</i>
14:45	> Patient preparation - <i>R. Babin</i>
14:50	> Discussion and audience interaction
15:00	> How to prepare the team - <i>S. Pesot</i>
15:10	> Discussion and audience interaction
15:17	> How to plan a coronary CTO: clinical case - <i>I. Cobbaut</i>
15:22	> Discussion and audience interaction
15:28	> Coronary bifurcation: the new side branch - <i>L. Bender</i>
15:38	> Discussion and audience interaction
15:48	> Left main - How essential is intracoronary imaging - <i>R. Esteves</i>
15:54	> Discussion and audience interaction
16:00	> Radiation exposure: How to reduce it for every procedure
16:05	> Session evaluation and key learnings - <i>S. Gargio</i>

14:40-16:40	Percutaneous treatment of mitral regurgitation: edge-to-edge repair
ROOM 342A	
	<i>Co-chairperson: O. Franzen</i>
	Attend this session if you want:
	> To understand the impact of anatomy on the success of mitral repair
	> To learn how to select good candidates for MitraClip
	> To learn how to improve outcomes
14:40	> Session objectives - <i>O. Franzen</i>
14:45	> Which patients are suitable for MitraClip in 2015?
14:50	> Discussion and audience interaction
14:52	> Case demonstration
15:02	> Discussion and audience interaction
15:07	> What is the role of MitraClip today compared to surgical valve replacement/repair? - <i>R. Corfi</i>
15:12	> Discussion and audience interaction
15:18	> How to make it easy: tips and tricks - <i>H. Ince</i>
15:24	> Discussion and audience interaction
15:30	> Session evaluation and key learnings

14:40-15:40	All you need to know about coronary physiology: FFR, iFR, IMR
ROOM 351	
THEATRE MAVANE	
	<i>Chairperson: J. Escaned</i>
	<i>Co-chairperson: P. McCarthy</i>
	Attend this session if you want:
	> To review a comprehensive and clinically relevant update on this field
	> To identify the current evidence base and existing guidelines
	> To recognise the open questions that need addressing in the near future
14:40	> Session objectives - <i>J. Escaned</i>
14:45	> Background and clinical data: FFR - <i>P. McCarthy</i>
14:55	> Technical and clinical issues: FFR and IMR - <i>P. Ullmer</i>
15:05	> Guidelines - <i>F. Barbato</i>
15:15	> Unresolved issues and outlook - <i>J. Escaned</i>
15:25	> Questions and answers
15:35	> Session evaluation and key learnings - <i>P. McCarthy</i>

14:00-15:40 ■ Bosnia & Herzegovina and Serbia share their most educational cases
ROOM 352A
Competition

With the collaboration of the Working Group for Cardiac Catheterisation and Percutaneous Coronary Interventions of the Cardiology Society of Serbia and the Working Group on Interventional Cardiology of the Association of Cardiologists of Bosnia and Herzegovina
Chairpersons: M.A. Nedeljkovic, I. Terzić

Attend this session if you want:
 > To understand the causes, mechanisms, clinical course, and bailout strategies of most feared complications in the catheterisation laboratory
 > To reflect on preventive measures that could minimise the chance for particular complication
 > To share experience with colleagues on most important technical details and strategies that operators performed

14:40 > Session objectives - I. Terzić
 14:42 > Case 1 - Left main dissection during diagnostic angiography followed by successful PCI
 14:46 > Discussion and audience interaction
 15:02 > Case 2 - Right (coronary artery) and wrong (chain of events) - A. Delic
 15:10 > Discussion and audience interaction
 15:16 > Case 3 - Iatrogenic left main dissection during recatheterisation of occluded circumflex artery - N. Bozinovic
 15:24 > Discussion and audience interaction
 15:30 > Case 4 - Left anterior descending artery dissection during stent implantation in circumflex artery - I. Terzić
 15:38 > Discussion and audience interaction
 > Session evaluation and key learnings - M.A. Nedeljkovic

14:00-16:40 ■ Cyprus, Moldova and Romania share their most educational cases
ROOM 352B
Competition

With the collaboration of the Cyprus Interventional Cardiology Working Group, the Moldovan Working Group of Interventional Cardiology and the Romanian Working Group of Interventional Cardiology
Chairpersons: S. Constantinides, S.D. Moa, I. Popovici

Attend this session if you want:
 > To reflect on acute and mid-term complications of true ostial left anterior descending lesions
 > To recognise and evaluate the different options in addressing procedural complications
 > To share expertise in avoiding complications of left main PCI

14:40 > Session objectives - S. Constantinides
 14:44 > Case 1 - Primary PCI for ostial left anterior descending occlusion: to stent or not to stent the left main?
 14:49 > How would I treat? - C. Eltychou
 14:54 > How would I treat? - C. Eltychou
 15:00 > Discussion and audience interaction
 15:06 > Consensus - S. Constantinides
 15:16 > Case 2 - Restenosis after successful primary PCI in ostial left anterior descending artery followed by acute thrombosis of left main
 15:25 > How would I treat? - C. Eltychou
 15:30 > How would I treat? - I. Nedeljkovic
 15:32 > How did I treat?
 15:35 > Discussion and audience interaction
 15:42 > Consensus
 15:50 > Case 3 - Restenosis in ostial circumflex and ramus intermedius after successful primary PCI in the ostial left anterior descending
 16:01 > How would I treat? - I. Nedeljkovic
 16:11 > How would I treat?
 16:18 > Discussion and audience interaction
 16:24 > Consensus - S.D. Moa
 16:32 > Session evaluation and key learnings - S.D. Moa

14:40-16:40 ■ Learning transseptal technique for left atrial appendage closure
ROOM 352A
LEARNING

Facilitators: A. Vahanian, O. Wolf
Attend this session if you want:

> To understand how anatomical landmarks and imaging can guide transseptal puncture
 > To share tips and tricks for safe procedural technique
 > To review in depth how optimal transseptal access for left atrial appendage closure differs from other indications

15:45-16:45 ■ Integrating coronary anatomy and physiology: advances in co-registration techniques
ROOM 252A
Innovation Hub

Co-Chairperson: R. Komowski
Chairperson: P. Lillier

Attend this session if you want:
 > To review advances in image-based integration of coronary anatomy and physiology
 > To recognise innovations in co-registration of two- and three- dimensional coronary angiography with IVUS or OCT
 > To understand the potential value and pitfalls of imaging-based functional computation

15:45 > Session objectives - R. Komowski
 15:47 > Virtual FFR computation from multislice computed tomography
 15:57 > Discussion and audience interaction
 16:01 > Virtual FFR computation from invasive angiography
 16:11 > Discussion and audience interaction
 16:15 > Co-registration of coronary angiography with IVUS
 16:20 > E. Regier
 16:29 > Discussion and audience interaction
 16:39 > Co-registration of coronary angiography with OCT
 16:41 > G. Goudounil
 16:50 > Discussion and audience interaction
 16:52 > Session evaluation and key learnings - P. Lillier

15:45-16:45 ■ Kazakhstan and Slovakia share their most educational cases
ROOM 352A
Competition

With the collaboration of the Society of Interventional Cardiology of Kazakhstan and the Working Group on Interventional Cardiology of the Slovak Society of Cardiology
Chairpersons: V. Fridrich, O. Sedkov

Attend this session if you want:
 > To learn about optimal PCI strategy for patients with STEMI and multivessel disease and how potential life-threatening complication during primary PCI should be managed
 > To reflect on the role of PIVAMI study in the formation of new treatment strategy for STEMI patients
 > To share similar experience between peers

15:45 > Session objectives - O. Sedkov
 15:47 > Case 1 - Management of critical left main stenosis and CTO of right coronary artery in patient with cardiogenic shock - M. Drogala
 15:52 > Discussion and audience interaction
 16:01 > Case 2 - Primary PCI and cardiogenic shock: what stenosis should be treated first?
 16:07 > Discussion and audience interaction
 16:15 > Case 3 - Coronary artery rupture during primary PCI
 16:21 > Discussion and audience interaction
 16:29 > Case 4 - The late corner with STEMI and primary PCI
 16:35 > Discussion and audience interaction
 16:43 > Session evaluation and key learnings - V. Fridrich

- 16:00 -

16:50-18:20 ■ Radial access in challenging situations
THEATRE BLEU
Chairperson: J. Monségu

Attend this session if you want:
 > To improve patient selection for vascular access
 > To learn practical tips and tricks to make radial access easier
 > To share experience for prevention and management of complications

16:50 > Session objectives
 16:54 > LIVE demonstration from Clinique Pasteur - Toulouse, France
 17:04 > Time to React@PCR
 17:06 > How to overcome difficulties - H. Benamer
 17:12 > Time to React@PCR
 17:14 > Practical tips and tricks to prevent and solve complications? - S.P. Semko
 17:16 > Time to React@PCR
 17:18 > Session evaluation and key learnings - J. Monségu

16:50-18:20 ■ Left atrial appendage closure systems: implantation techniques
THEATRE BORDEAUX
Attend this session if you want:

> To review currently used devices and procedural techniques
 > To learn how to tackle challenging anatomies with the different devices
 > To avoid complications during implantation

16:50 > Session objectives
 16:55 > Watchman Flex step-by-step case-based discussion
 17:07 > Time to React@PCR
 17:12 > ACRYAmulet: step-by-step case-based discussion
 17:24 > Time to React@PCR
 17:29 > Catheter device step-by-step case-based discussion
 18:01 > Time to React@PCR
 18:15 > Session evaluation and key learnings

16:50-18:20 ■ Glimpses into the future: streamlining peripheral interventions
THEATRE HAVANE
Chairperson: A. Cernomoni
Co-Chairperson: T. Zeller
Panelists: Z. Kojanec, S.T. Lim, A. Sauguet, H. Sievert

Attend this session if you want:
 > To step into a new horizon in the peripheral field
 > To discuss the potential role of upcoming technologies in peripheral interventions
 > To understand how technology advancements could help you in your daily practice

16:50 > With continuous LIVE demonstration from Maria Cecilia Hospital - Cortigö, Italy
 16:54 > With continuous time to React@PCR
 16:58 > Session objectives - T. Zeller
 17:04 > Advanced imaging - A. Cernomoni
 17:10 > Beyond the limits of drug-coated techniques - A. Sauguet
 17:12 > Hydrodynamic dissection: a novel re-entry technique for subintimal approach in below-the-knee vessel - R. Frenzel
 17:14 > Session evaluation and key learnings - A. Cernomoni

16:50-18:20 ■ Innovation in cardiovascular pharmacology for the interventional cardiologist
ROOM WALLLOT
Innovation Hub
Chairperson: R. Komowski
Co-Chairperson: P.G. Sieg

Attend this session if you want:
 > To be updated on emerging cardiovascular pharmacotherapy
 > To recognise new drugs and medications undergoing late-phase clinical trials
 > To appreciate interactions between current and future pharmacologic interventions

16:50 > Session objectives - P.G. Sieg
 16:54 > Injectable antithrombotics - R. Storey
 17:02 > Oral antithrombotics - P. Wancick
 17:10 > Discussion and audience interaction
 17:22 > Anti-inflammation agents - P. Lillier
 17:30 > Post-conditioning pharmacology - M. Ouzie
 17:38 > Discussion and audience interaction
 17:50 > Lipid modifying agents: LDL reducers and HDL augmenters - P.G. Sieg
 18:16 > Discussion and audience interaction
 > Session evaluation and key learnings - R. Komowski

16:50-18:20 ■ The essentials: how to manage cardiogenic shock in a patient with ACS
ROOM 241
The experts

With the collaboration of the ESCC New Initiatives For Young Interventionalists Committee
Seminarians: S.B. King III
Facilitators: A. Elgarnani, G. Tait
Attend this session if you want:
 > To be able to rapidly identify the signs of haemodynamic deterioration
 > To discuss about the utility of intra-aortic balloon pump, left ventricular assist devices and extra-corporeal membrane oxygenation

16:50-18:20 ■ Alternatives to catheter-based renal sympathetic denervation in hypertension
ROOM 242A
Competition
With the collaboration of the EHCTHD 2015
Chairperson: T.F. Lüscher
Co-Chairperson: M. Lobo
Panelists: S. Berovic, J. Deemen, E. Lew, D. Schenker

Attend this session if you want:
 > To appreciate device-based alternatives to renal denervation
 > To understand how to modulate blood pressure
 > To be exposed to a critical appraisal about these devices

16:50 > Session objectives - T.F. Lüscher
 16:55 > Why do we need interventional approaches to treat hypertension in 2015? - K. Touboul
 17:05 > Discussion and audience interaction
 17:15 > Arteriovenous coupler - The RoX system - M. Lobo
 17:23 > Discussion and audience interaction
 17:30 > Carotid bulb restoration - The CardioKinetics system
 17:38 > J. Van De Heyden
 17:45 > Discussion and audience interaction
 17:55 > Baroreflex stimulation - CRR system - R. Wechter
 17:57 > Discussion and audience interaction
 18:00 > Aortic stimulation - Empase device
 18:08 > Discussion and audience interaction
 18:15 > Session evaluation and key learnings - M. Lobo

16:00-18:20 ■ New heart failure devices

F. JOM 352A
Chairperson: J. Bartunek
Co-chairperson: D. Burkhoff

Attend this session if you want:

- > To understand the role of device-based interventions in the current multidisciplinary management of heart failure
- > To discuss new devices aiming at heart failure monitoring
- > To understand the principles and potential of novel therapeutic devices for heart failure interventional treatment



16:50-18:20 ■ Stent for Life initiative in perspective

ROOM 352A
With the collaboration of Stent for Life
Chairperson: P. Kala
Co-chairperson: Z. Kaliszczko

Attend this session if you want:

- > To share with the audience the best therapeutic approach in patients at highest clinical risk, i.e. high-risk NSTEMI, out-of-hospital cardiac arrest and acute stroke
- > To discuss the need for precise data management
- > To learn and agree on the need of high-quality STEMI network

- 16:50 > Session objectives
- 16:55 > Percutaneous device for left atrial pressure monitoring
- 17:03 > Discussion and audience interaction
- 17:15 > Magneta device for renal decompression
- 17:22 > Discussion and audience interaction
- 17:35 > Endopace: stimulating third chamber
- 17:43 > Discussion and audience interaction
- 17:55 > V-Wave device for unidirectional left-to-right atrium decompression
- 18:03 > Discussion and audience interaction
- 18:15 > Session evaluation and key learnings

- 16:50 > Session objectives - P. Kala
- 16:55 > STEMI Registry data: validation and quality improvement
- 17:03 > F. Wedinger
- 17:15 > Discussion and audience interaction
- 17:22 > High-risk NSTEMI population as our next target - H. Pereira
- 17:35 > Discussion and audience interaction
- 17:43 > STEMIlike network for acute stroke management
- 17:55 > P. Widimsky
- 18:03 > Discussion and audience interaction
- 18:15 > Indication for coronary angiography / PCI in patients with out-of-hospital cardiac arrest - M. Noc
- 18:30 > Discussion and audience interaction
- 18:45 > Session evaluation and key learnings - Z. Kaliszczko

16:50-18:20 ■ TAMI: how to optimise patients' outcomes in challenging situations?

ROOM 342AB
With the collaboration of the EAPC Women Committee
Chairperson: J. Mehilli
Co-chairperson: A.S. Petronio

Attend this session if you want:

- > To identify the anatomical pitfalls of TAMI
- > To learn about decision-making in patients with challenging anatomy
- > To learn procedural tips and tricks to overcome challenging anatomy

- 16:50 > Session objectives - J. Mehilli
- 16:55 > Clinical case: small anulus - D. Mylotte
- 17:03 > Discussion and audience interaction
- 17:15 > Clinical case: bicuspid valve - R. Etchicimoff
- 17:23 > Discussion and audience interaction
- 17:35 > Clinical case: paradoxical low-flow low-gradient C. Ojalliani
- 17:43 > Discussion and audience interaction
- 17:55 > Clinical case: outflow obstruction
- 18:03 > Lecture: gender and TAMI outcomes - M. Gilard
- 18:15 > Session evaluation and key learnings - A.S. Petronio

17:50-18:20 ■ Percutaneous coronary interventions in Asia-Pacific

ROOM 351
With the collaboration of the Asian Interventional Cardiovascular Therapeutics
Chairpersons: A. Sethi, H.C. Tan
Pannelists: K.H. Sim, W. Udojochidem

Attend this session if you want:

- > To learn about the practice of PCI in the Asia-Pacific region
- > To discuss interesting and complex cases performed by experts in Asia

- 17:50 > EuroPCR welcomes ACT
- 16:55 > Session objectives - H.C. Tan
- 17:03 > How has FFR changed my PCI practice - S.J. Park
- 17:15 > Discussion and audience interaction
- 17:23 > A complex CTO: how I did it? - H.L. Koo
- 17:35 > Discussion and audience interaction
- 17:43 > Transradial coronary intervention: how 'Slender' can we go?
- 17:55 > Discussion and audience interaction
- 18:03 > My most memorable bifurcation case
- 18:15 > Discussion and audience interaction
- 18:30 > Session evaluation and key learnings - A. Sethi

16:50-18:20 ■ Iran and United Kingdom share their most educational cases

ROOM 352B
With the collaboration of the Iranian Society of Interventional Cardiology (ISOC) and the British Cardiovascular Intervention Society (BCIS)
Chairpersons: M. Hashemian, S. Redwood

Attend this session if you want:

- > To understand the importance of the multidisciplinary team approach to patient care
- > To learn percutaneous options for aortic trauma
- > To appreciate difficult management decisions regarding concomitant valve disease in presence of aortic stenosis

- 16:50 > Session objectives - M. Hashemian
- 16:55 > Case 1 - Traumatic thoracic aortic transection - S. Toplevi
- 17:03 > How would I treat? - R.H. Stobbs
- 17:15 > How would I treat? - S. Toplevi
- 17:23 > How did I treat? - S. Toplevi
- 17:35 > Discussion and audience interaction
- 17:43 > Consensus - M. Hashemian
- 17:55 > Case 2 - Aortic stenosis with concomitant mitral disease: a difficult management dilemma - D. Muir
- 17:03 > How would I treat?
- 17:15 > How would I treat? - R.H. Stobbs
- 17:23 > How did I treat? - D. Muir
- 17:35 > Discussion and audience interaction
- 17:43 > Consensus - S. Redwood
- 17:55 > Session evaluation and key learnings - S. Redwood

16:50-18:20 ■ Re-learning femoral access for structural interventions

ROOM LEARNING
Facilitators: T. LeRève, F. Ribichini, E. Stabile

Attend this session if you want:

- > To identify the appropriate candidate for femoral access
- > To discuss the pros and cons of available closure devices
- > To share ways to prevent and treat access site complications

16:50-18:20 ■ Strategies for successful medical writing

ROOM TERNES 1
With the collaboration of Eurointervention and Asahiintervention
Chairpersons: P. De Feyter, U. Kaul, P.W. Serruys, Y. Zhang

Attend this session if you want:

- > To appraise the various types of research methodology
- > To simplify your research writing process
- > To advance your scientific career

- 16:50 > Session objectives
- 16:55 > Research methodology: randomised clinical trials versus observational studies - Pros and cons of meta-analysis, large registries
- 17:03 > Discussion and audience interaction
- 17:08 > How to make it easier for journal editors to select your research
- 17:14 > Discussion and audience interaction
- 17:21 > How to respond to peer-review comments
- 17:27 > Discussion and audience interaction
- 17:34 > Boost your scientific career - High impact and tools for the smart researcher
- 17:40 > Discussion and audience interaction
- 17:47 > Session evaluation and key learnings

- 09:00 -

09:00-12:40 ■ Complex cardiovascular interventions and new techniques: LIVE demonstrations from Golden Jubilee National Hospital, West of Scotland Heart & Lung Centre - Glasgow, United Kingdom and from Städtische Kliniken Neuss, Lukaskrankenhaus - Neuss, Germany

MAIN ARENA

09:00-10:30 ■ How and when should we perform PCI in a patient after CABG - Native vessel or saphenous vein graft PCI?
Chairperson: F. Heilig
Co-Chairperson: P. Lillier

09:00-10:30 ■ How and when should we perform PCI in a patient after CABG - Native vessel or saphenous vein graft PCI?
Chairperson: F. Heilig
Co-Chairperson: P. Lillier

THEATRE BLEU

Attend this session if you want:

- > To discuss the pros and cons for saphenous vein graft PCI versus native vessel PCI
- > To reflect on the key points when planning a saphenous vein graft PCI
- > To exchange about the treatment of no reflow or slow flow after saphenous vein graft PCI

09:10 ■ Session objectives - P. Lillier
09:01 ■ Key points to successfully treat a lesion in a degenerated saphenous vein graft - S. Kiedey
09:16 ■ LIVE demonstration from Thoraxcenter - Rotterdam, The Netherlands
09:59 ■ Time to React@PCR
10:11 ■ How to successfully prevent and treat slow flow or no reflow after saphenous vein graft PCI - J. Mehlili
10:20 ■ Time to React@PCR
10:26 ■ Session evaluation and key learnings - F. Heilig

09:00-10:30 ■ Treating coronary artery disease in the TAVI patient - Why, when and how?
Chairperson: S. Windecker
Co-Chairperson: T. Lefèvre

THEATRE BORDEAUX

Attend this session if you want:

- > To learn the current evidence of the impact of coronary artery disease on survival post TAVI
- > To develop clinical strategies to safely manage coronary artery disease in the TAVI patient
- > To refine your case selection according to the latest evidence

09:50 ■ Session objectives - S. Windecker
09:04 ■ Why do PCI? Which patient and which lesion should we treat? - B. De Bruyne
09:12 ■ Time to React@PCR
09:20 ■ LIVE demonstration from Städtische Kliniken Neuss, Lukaskrankenhaus - Neuss, Germany
10:00 ■ Time to React@PCR
10:10 ■ When and how to do do PCI? - A. Colombo
10:18 ■ Time to React@PCR
10:26 ■ Session evaluation and key learnings - T. Lefèvre

09:00-10:30 ■ Controversies in management of STEMI with cardiogenic shock

THEATRE HAVANE

Chairperson: C.K. Naber
Co-Chairperson: D. Dudek
Panelists: D. Mylotte

Attend this session if you want:

- > To learn how to individualise patient management
- > To discuss the scientific evidence for management of high-risk patients
- > To learn practical tips and tricks to prevent and solve complications

09:50 ■ Session objectives - D. Dudek
09:15 ■ Intra-aortic balloon pump: evidence versus practice S. Redwood
09:13 ■ Discussion and audience interaction
09:25 ■ Role of other left ventricular assist devices for management of STEMI with cardiogenic shock? - H. Thiele

09:32 ■ Discussion and audience interaction
09:45 ■ Complete revascularisation as gold standard?
09:53 ■ Discussion and audience interaction
10:05 ■ Specific antithrombotic strategies in STEMI patients with cardiogenic shock - M. Noc
10:13 ■ Discussion and audience interaction
10:25 ■ Session evaluation and key learnings - C.K. Naber

09:00-10:30 ■ New tools and techniques in coronary CTO

ROOM MALLOT

Innovation Hub

Attend this session if you want:

- > To remain updated on new micro-catheters and wires designed for CTO procedures
- > To acquire new tools and techniques that appear useful for CTO recanalisation
- > To discuss the role of novel intracoronary imaging during CTO recanalisation

09:00 ■ Session objectives - A. Serra
09:04 ■ New catheters to enhance the proximal cap penetration S. Wöhr
09:14 ■ Questions and answers
09:17 ■ New guide-wires to improve propagation and crossability M. Yonane

09:27 ■ Questions and answers
09:30 ■ New applications of catheter-based imaging - C. Di Mario
09:40 ■ Questions and answers
09:43 ■ Discussion and audience interaction
09:51 ■ Tools and techniques to optimise retrograde recanalisation M. Odier

10:01 ■ Questions and answers
10:04 ■ Bioreabsorbable scaffolds in coronary CTO: lessons from initial experiences and follow-up - M. Lesiak
10:14 ■ Questions and answers
10:17 ■ Discussion and audience interaction
10:25 ■ Session evaluation and key learnings

09:00-10:30 ■ The essentials: how to prevent and manage PCI complications
With the collaboration of the EAPCI New Initiatives For Young Interventionalists Committee
Senior advisor: E. Guibe
Facilitators: C.T. Chin, O. Gampert, A. Wolf

ROOM X41


The essentials

Attend this session if you want:

- > To discuss how to prevent the most common PCI complications
- > To know how to manage PCI complications
- > To share your complication with your peers

■ euro
PCR

Scientific programme

Friday 22nd May, 2015Valid as of 19th March, 2015

Only Faculty who confirmed their attendance are listed in this programme.
 For real-time updates, please consult the interactive programme.



00-10:30 ■ Controversy in antithrombotic management in patients undergoing coronary interventions

With the collaboration of *Acute Cardiovascular Care Association (ACCA)*

Chairperson: R. Storey

Co-chairperson: J. Morais

Attend this session if you want:

> To learn how to use P2Y12 inhibitors prior to angiography in NSTEMI

> To know how long you should use DAPT following coronary stenting

> To understand how to manage triple therapy after coronary stenting

> Session objectives - *R. Storey*

> Pre-treatment in ACS - *L. Bolognese*

> Discussion and audience interaction

> DAPT duration after coronary stenting: 1, 3, 6 or 12 months - *R. Byrne*

> Discussion and audience interaction

> Triple therapy after coronary stenting for how long?

> Discussion and audience interaction

> Antithrombotic therapy after 1 year if oral anticoagulation is mandatory: why and for whom? - *J.R. Geller*

> Discussion and audience interaction

> Session evaluation and key learnings - *J. Morais*

10:13

10:25

10:30-10:30 ■ Croatia and Czech Republic share their most educational cases

With the collaboration of the *Working Group on Interventional Cardiology of the Croatian Society of Cardiology and the Working Group on Interventional Cardiology of the Czech Society of Cardiology*

Chairpersons: A. Ernst, J. Stasek

Attend this session if you want:

> To reflect on concept of physiology-guided revascularisation in complex multivessel disease

> To discuss revascularisation strategy in a patient after previous CABG

> To learn some technical aspects and priorities in multivessel coronary artery interventions

> Session objectives - *A. Ernst*

> Case 1 - Revascularisation of a patient with ACS and three-vessel disease

> How would I treat? - *H. Pirovic*

> How would I treat? - *H. Pirovic*

> How did I treat? - *H. Pirovic*

> Discussion and audience interaction

> Consensus - *A. Ernst*

> Case 2 - FFR-guided complex multivessel PCI in a patient after CABG - *M. Mares*

> How would I treat? - *H. Pirovic*

> How would I treat?

> How did I treat? - *M. Mares*

> Discussion and audience interaction

> Consensus - *J. Stasek*

> Session evaluation and key learnings - *J. Stasek*

09:50

09:55

09:10

09:15

09:30

09:35

09:40

10:00

10:20

10:25

10:30

10:30-10:30 ■ Learning rotablator

Facilitators: *A. Ong, F. Sharif*

Attend this session if you want:

> To review the basic principles, patient and lesion selection

> To understand how to safely and successfully use rotational atherectomy

> To find out how to overcome or manage the most frequent issues

> Session objectives - *A. Ong, F. Sharif*

> Case 1 - Rotablation of a patient with ACS and three-vessel disease

> How would I treat?

> How would I treat? - *H. Pirovic*

> How did I treat? - *H. Pirovic*

> Discussion and audience interaction

> Consensus - *A. Ernst*

> Case 2 - FFR-guided complex multivessel PCI in a patient after CABG - *M. Mares*

> How would I treat? - *H. Pirovic*

> How would I treat?

> How did I treat? - *M. Mares*

> Discussion and audience interaction

> Consensus - *J. Stasek*

> Session evaluation and key learnings - *J. Stasek*

09:50

09:55

09:10

09:15

09:30

09:35

09:40

10:00

10:20

10:25

10:30

10:30-10:30 ■ Learning rotablator

Facilitators: *A. Ong, F. Sharif*

Attend this session if you want:

> To review the basic principles, patient and lesion selection

> To understand how to safely and successfully use rotational atherectomy

> To find out how to overcome or manage the most frequent issues

> Session objectives - *A. Ong, F. Sharif*

> Case 1 - Rotablation of a patient with ACS and three-vessel disease

> How would I treat?

> How would I treat? - *H. Pirovic*

> How did I treat? - *H. Pirovic*

> Discussion and audience interaction

> Consensus - *A. Ernst*

> Case 2 - FFR-guided complex multivessel PCI in a patient after CABG - *M. Mares*

> How would I treat? - *H. Pirovic*

> How would I treat?

> How did I treat? - *M. Mares*

> Discussion and audience interaction

> Consensus - *J. Stasek*

> Session evaluation and key learnings - *J. Stasek*

09:50

09:55

09:10

09:15

09:30

09:35

09:40

10:00

10:20

10:25

10:30

10:30-10:30 ■ Learning rotablator

Facilitators: *A. Ong, F. Sharif*

Attend this session if you want:

> To review the basic principles, patient and lesion selection

> To understand how to safely and successfully use rotational atherectomy

> To find out how to overcome or manage the most frequent issues

> Session objectives - *A. Ong, F. Sharif*

> Case 1 - Rotablation of a patient with ACS and three-vessel disease

> How would I treat?

> How would I treat? - *H. Pirovic*

> How did I treat? - *H. Pirovic*

> Discussion and audience interaction

> Consensus - *A. Ernst*

> Case 2 - FFR-guided complex multivessel PCI in a patient after CABG - *M. Mares*

> How would I treat? - *H. Pirovic*

> How would I treat?

> How did I treat? - *M. Mares*

> Discussion and audience interaction

> Consensus - *J. Stasek*

> Session evaluation and key learnings - *J. Stasek*

09:50

09:55

09:10

09:15

09:30

09:35

09:40

10:00

10:20

10:25

10:30

10:30-10:30 ■ Learning rotablator

Facilitators: *A. Ong, F. Sharif*

Attend this session if you want:

> To review the basic principles, patient and lesion selection

> To understand how to safely and successfully use rotational atherectomy

> To find out how to overcome or manage the most frequent issues

> Session objectives - *A. Ong, F. Sharif*

> Case 1 - Rotablation of a patient with ACS and three-vessel disease

> How would I treat?

> How would I treat? - *H. Pirovic*

> How did I treat? - *H. Pirovic*

> Discussion and audience interaction

> Consensus - *A. Ernst*

> Case 2 - FFR-guided complex multivessel PCI in a patient after CABG - *M. Mares*

> How would I treat? - *H. Pirovic*

> How would I treat?

> How did I treat? - *M. Mares*

> Discussion and audience interaction

> Consensus - *J. Stasek*

> Session evaluation and key learnings - *J. Stasek*

09:50

09:55

09:10

09:15

09:30

09:35

09:40

10:00

10:20

10:25

10:30

10:30-10:30 ■ Learning rotablator

Facilitators: *A. Ong, F. Sharif*

Attend this session if you want:

> To review the basic principles, patient and lesion selection

> To understand how to safely and successfully use rotational atherectomy

> To find out how to overcome or manage the most frequent issues

> Session objectives - *A. Ong, F. Sharif*

> Case 1 - Rotablation of a patient with ACS and three-vessel disease

> How would I treat?

> How would I treat? - *H. Pirovic*

> How did I treat? - *H. Pirovic*

> Discussion and audience interaction

> Consensus - *A. Ernst*

> Case 2 - FFR-guided complex multivessel PCI in a patient after CABG - *M. Mares*

> How would I treat? - *H. Pirovic*

> How would I treat?

> How did I treat? - *M. Mares*

> Discussion and audience interaction

> Consensus - *J. Stasek*

> Session evaluation and key learnings - *J. Stasek*

09:50

09:55

09:10

09:15

09:30

09:35

09:40

10:00

10:20

10:25

10:30

10:30-10:30 ■ Learning rotablator

Facilitators: *A. Ong, F. Sharif*

Attend this session if you want:

> To review the basic principles, patient and lesion selection

> To understand how to safely and successfully use rotational atherectomy

> To find out how to overcome or manage the most frequent issues

> Session objectives - *A. Ong, F. Sharif*

> Case 1 - Rotablation of a patient with ACS and three-vessel disease

> How would I treat?

> How would I treat? - *H. Pirovic*

> How did I treat? - *H. Pirovic*

> Discussion and audience interaction

> Consensus - *A. Ernst*

> Case 2 - FFR-guided complex multivessel PCI in a patient after CABG - *M. Mares*

> How would I treat? - *H. Pirovic*

> How would I treat?

> How did I treat? - *M. Mares*

> Discussion and audience interaction

> Consensus - *J. Stasek*

> Session evaluation and key learnings - *J. Stasek*

09:50

09:55

09:10

09:15

09:30

09:35

09:40

10:00

10:20

10:25

10:30

10:30-10:30 ■ Learning rotablator

Facilitators: *A. Ong, F. Sharif*

Attend this session if you want:

> To review the basic principles, patient and lesion selection

> To understand how to safely and successfully use rotational atherectomy

> To find out how to overcome or manage the most frequent issues

> Session objectives - *A. Ong, F. Sharif*

> Case 1 - Rotablation of a patient with ACS and three-vessel disease

> How would I treat?

> How would I treat? - *H. Pirovic*

> How did I treat? - *H. Pirovic*

> Discussion and audience interaction

> Consensus - *A. Ernst*

> Case 2 - FFR-guided complex multivessel PCI in a patient after CABG - *M. Mares*

> How would I treat? - *H. Pirovic*

> How would I treat?

> How did I treat? - *M. Mares*

> Discussion and audience interaction

> Consensus - *J. Stasek*

> Session evaluation and key learnings - *J. Stasek*

09:50

09:55

09:10

09:15

09:30

09:35

09:40

10:00

10:20

10:25

10:30

10:30-10:30 ■ Learning rotablator

Facilitators: *A. Ong, F. Sharif*

Attend this session if you want:

> To review the basic principles, patient and lesion selection

> To understand how to safely and successfully use rotational atherectomy

> To find out how to overcome or manage the most frequent issues

> Session objectives - *A. Ong, F. Sharif*

> Case 1 - Rotablation of a patient with ACS and three-vessel disease

> How would I treat?